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ABSTRACT

The medicinal values of marijuana have often been overshadowed due to the
psychotropic, “recreational” effects it brings about in a user. For hundreds of years the
therapeutic uses of cannabis sativa were appreciated, but the inability to control the
dosage of the main constituent, and therefore the psychotropic effects, rendered the drug
a liability. The elucidation of the structure of this main psychoactive constituent, ∆9tetrahydrocannabinol (∆9-THC) by Gaoni and Mechoulam in 1964 opened the door to the
discovery of a vast array of knowledge about cannabinoids. From the multiple classes of
cannabinoids and the ways these compounds interact with the body to the design and
synthesis of new cannabinoids based on structure-activity relationships (SAR), the
scientific studies into the medicinal effects of marijuana have flourished. There are two
main goals of the research presented in this dissertation: To design new cannabinoids that
have the potential to become pharmaceutical products with therapeutic effects parallel to
∆9-THC while minimizing the psychoactive effects and to better understand the
interactions that these cannabimimetic analogs have with the cannabinoid receptors. This
dissertation pursues these goals through the syntheses of two series of cannabimimetic
indoles possessing electron-withdrawing substituents and one series of indoles possessing
an electron-donating substituent.
Halogenated compounds were the primary focus of the series of indoles
possessing electron-withdrawing substituents. These compounds were designed to be
selective for the CB2 receptor while also maintaining an affinity for the receptor. Series
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of both N-alkyl-3-(4-halo-1-naphthoyl)indoles and N-alkyl-3-(8-halo-1-naphthoyl)indoles
have been synthesized. These compounds show good affinities for the CB2 receptor and
some also have selectivity for CB2.
Huffman, et.al. had previously synthesized four series of N-alkyl-3-(methoxy-1naphthoyl)indoles which showed either affinity or selectivity for the CB2 receptor
depending on the location of the alkoxy group on the naphthoyl ring. A series of N-alkyl3-(6-methoxy-2-naphthoyl)indoles was synthesized and found to lack any substantial
affinity or selectivity for the receptors.
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CHAPTER ONE
INTRODUCTION

The initial usage of marijuana, or Cannabis Sativa L., named by Carl Linnaeus in
1753, dates back possibly 10,000 years to ancient Chinese culture. To these people,
cannabis was a necessity, not as a psychoactive substance, but rather as a source of fiber.
The thick stalks of the plant were turned into fabric, or hemp, and used for making such
items as clothing, rope, baskets and fishing nets. It is believed that not until the twentyeighth century BC that the medicinal properties of the cannabis plant were introduced to
the people by the emperor Shen-Nung. While this early culture was not unaware of the
psychedelic effects of cannabis, they looked upon them as a negative influence until the
first century AD when Taoism, and its interest in magic and alchemy, was at its height.1
Until the 19th century, when cannabis began receiving serious attention as a result
of its medicinal properties, the main uses of the plant remained both as a source of
recreation and a source of fiber. When the Irish physician William Brooke
O’Shaughnessy returned to England from a professorship at the Medical College of
Calcutta in India, he introduced the western world to the medicinal uses of marijuana.
The news of his findings spread to America, where up until that time the American
settlers primary use of this crop was the fabrication of hemp. In 1854 the U.S.
Dispensatory listed cannabis among the nation’s medicines. 1,2
In the 1920’s and 1930’s the use of marijuana as a recreational drug began to rise
among migrant workers and members of lower socioeconomic groups. Following in the

1

footsteps of anti-opium laws, which were directed at Chinese immigrants, and
prohibition, which was an attack upon the unsupported theory that the working class was
becoming lazy from demon rum, the regulation and eventual outlawing of cannabis was
aimed at the rising Mexican population. The media successfully encouraged this “reefer
racism” among the public and it ultimately ended with the passage of the Marijuana Tax
Law of 1937. This law still permitted the use of cannabis stalks for hemp and the seeds
for bird feed but outlawed the recreational possession of marijuana and put heavy
regulations on the medicinal use, study and prescription of the drug.1 Marijuana has since
been cited in many additional narcotic laws and is today classified as a Schedule I
Controlled Substance under the Comprehensive Drug Abuse Prevention and Control Act
of 1970. A Schedule I substance is defined as having a high abuse potential, no medical
use in the United States, and lacks accepted safety data for use under medical
supervision. 3
The elucidation of the structure of ∆9-tetrahydrocannabinol (∆9-THC, 1, Figure 1),
the main psychoactive component of marijuana, by Gaoni and Mechoulum in 1964, was
instrumental in the development of the therapeutic uses of medicinal marijuana and other
cannabinoids that are employed today.4 The medicinal attributes of THC, which is found
in the flowering buds and upper leaves of the female plant, include, but are not limited to,
analgesic, anti-convulsive, anti-inflammatory, antipyretic, antiematic and appetite
stimulant effects. Patients who suffer from multiple sclerosis, cancer patients undergoing
chemotherapy, those who suffer from glaucoma, and people who have succumbed to
anorexia nervosa due to HIV/AIDS are amongst those experiencing the relief of
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symptoms by using marijuana.5 However, the drawback of using cannabis as a medicinal
agent is the psychotropic effects. These effects include feelings of euphoria, or the “high”
that recreational users experience, a distorted perception of time, a decrease in attention
as well as short term memory problems.6
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Figure 1. Structure of ∆9-THC and the IUPAC dibenzopyran numbering system.4

Since the structure of ∆9-THC was resolved, thousands of cannabinoids have been
synthesized and investigated. However there are currently only four cannabinoids
commercially available on the global market. Of these, two have been sanctioned for use
in the United States by the Food and Drug Administration (FDA). The first cannabinoid
endorsed for medical use was dronabinol (1). Approved in 1992, dronabinol is synthetic
∆9-THC, marketed under the name Marinol® , as an antiematic for cancer patients as well
as an appetite stimulant for those who suffer from anorexia associated with HIV and
AIDS.7 Nabilone (2, Figure 2), the racemate is marketed as Cesamet®, was approved in
2006 for use as an antiematic for cancer patients undergoing chemotherapy.8 The
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oromucosal spray Sativex®, available for prescription in Canada and the United
Kingdom, is a mixture of ∆9-THC (1) and cannabidiol (3, Figure 2) which is prescribed to
alleviate neuropathic pain associated with multiple sclerosis.9 The European Union
approved the marketing of the cannabinoid receptor antagonist rimonabant (4, Figure 2),
or Acomplia®, in 2006 as an anti-obesity drug.10
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Figure 2. Structures of pharmaceutical cannabinoids.

Over the decades following the structure elucidation of ∆9-THC many advances
were made in the area of medicinal marijuana. It was found that over 60 types of
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cannabinoids are naturally occurring in cannabis, a cannabinoid being classically defined
as any terpenophenol classified as a C21 compound typical of and present in Cannabis
sativa L., their carboxylic acids, analogs and transformation products. Of the over 60
naturally occurring cannabinoids found in marijuana, ∆9-THC and cannabinol (CBN, 5,
Figure 3) are the most abundant. Other cannabinoids found in cannabis sativa include,
but are not limited to, ∆8-THC (6, Figure 3), cannabidiol (CBD, 3) and cannabigerol
(CBG, 7, Figure 3). Many of the naturally occurring cannabinoids, including CBN, CBD
and CBG, do not have psychotropic effects.11 Today, the term cannabinoid refers to any
compound that interacts with either cannabinoid receptor, exhibiting pharmacology
similar to that of ∆9-THC.
To date thousands of cannabinoids have been synthesized, but they are all placed
into

one

of

five

general

classes

of

cannabinoids:

classical,

non-classical,

aminoalkylindoles, endocannabinoids, or diaryl pyrazoles. Once the structure of ∆9-THC
was identified there was debate over whether the numbering should be based on the
monoterpenoid substructure or the IUPAC recommendation based on the ABC
dibenzopyran system (ABC - 1).12 Use of the former was popular in Europe, which led to
some confusion since THC was ∆1-THC under the terpenoid numbering system, but ∆9THC using the IUPAC system.
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OH

HO
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Figure 3. Naturally occurring cannabinoids.

Today classical cannabinoids are those compounds closely structurally related to
the native plant constituents through the ABC tricyclic substructure and are numbered
based on the IUPAC numbering system. There is not a structural feature of ∆9-THC that
has not been altered to better understand the reactivity of cannabinoids. Studies showed
that the three locations of greatest interest were the C-1 phenolic hydroxyl, the C-3 alkyl
side chain and the moieties surrounding the C-9 carbon. First, it was determined that the
C-3 side chain retained activity when it consisted of between three to eight carbons and
that addition of either 1,1- or 1,2-dimethyl groups on the chain increased potency.
Stereochemistry of the 1,2-dimethyl substituents in this position did not seem to change
the binding affinities.13 The lengthening and branching of the chain to 1,1-dimethylheptyl
(DMH) seemed to increase the receptor affinity of many cannabinoids.13 The C-1
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hydroxyl group of the A-ring was believed to be necessary for CB1 binding due to
interaction through hydrogen bonding with the receptor. Substitution of this phenolic
moiety has shown that phenol ethers have less binding affinity than ∆9-THC while phenol
esters are active in vivo. Replacement of the hydroxyl with either an amine or thiol has
given mixed results.5 The dimethyl groups on C-6 of the B-ring have been altered but
have been found to have a less pronounced effect than altering the C-3 side chain. It has
been found that the methyl functionality at C-9 is not a requirement for activity.
Synthesis of 11-OH-THC (8, Figure 4), HU 210 (9, Figure 4), and other analogs having
alternative substitutions at this position, have been found to display a high affinity for the
receptor. It is also known that the olefin of the ∆9 or ∆8 position is not a necessity,
stemming from the synthesis of HHC (10, Figure 4).5
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Figure 4. Some synthetic classical cannabinoids.

The altering of these various substituents on ∆9-THC has led to the suggestion
that a three point interaction of the ligand with the receptor is essential for cannabinoid
selectivity. This hypothesis was based on structure-activity relationship (SAR) studies,
which have been verified through the synthesis of a number of additional traditional
cannabinoids. The three features found necessary for biological activity include the C-1
phenol group, which is essential for hydrogen bonding interactions with the receptor, the
C-3 side chain of the A-ring because of its hydrophobic interactions with the receptor and
the placement of a moiety on the C-9 carbon atom of the C-ring (Figure 5).14
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Figure 5. Three Points of Receptor Recognition as determined by SAR studies.

Compounds that exhibit structural features required for analgesia and lack the Bring of the tricyclic benzopyran nucleus of classical cannabinoids are referred to as
nonclassical cannabinoids. The development of these AC bicyclic terpenoids by Pfizer in
the mid-1980s as a series of non-opioid analgesics was based on the observation that the
pyran nucleus and its geminal dimethyl groups on the C-6 carbon were not necessary for
activity.5 Altering the A-ring C-3 side chain, addition of a side chain at C-4 of the C-ring
and synthesizing a series with the C-ring ranging from cyclopentyl to cyclooctyl led to
the optimization of this series with the discovery of CP 55,940 (11, Figure 6). The
synthesis of a variety of the nonclassical cannabinoids, the most common derivations
being an AC or an AB bicyclic ring system, supports the hypothesis of three sites for
receptor recognition.15,16
In 1991, a group at Sterling-Winthrop found that pravadoline, an indole based
nonsteroidal anti-inflammatory drug (NSAID), showed cannabimimetic activity. This
discovery ultimately led to the development of a series of cannabimimetic indoles
classified as aminoalkylindoles (AAI’s). These AAIs are in general characterized by the
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presence of an aroyl moiety at C-3 of the indole nucleus and an alkyl side chain on the
indole nitrogen. (12, Figure 6). While many hypotheses have been made regarding a
correlation of the SAR for classical and nonclassical cannabinoids with AAIs, it has been
found that this class interacts with the receptors in a different manner than classical and
nonclassical cannabinoids.17
A class of endogenous cannabinoids, which occur naturally in mammalian tissue,
was discovered by Mechoulam and co-workers in 1992. These endocannabinoids are
derivatives of arachinodonic acid and are characterized by their long chain,
polyunsaturated fatty acid structure. The first two major endocannabinoids, isolated from
porcine brain, are arachinodoylethanolamide, or anandamide (AEA), so named because
the term ananda comes from the Sanskrit word for inner bliss, and 2-arachidonylglycerol
(13, Figure 6). Since their discovery, many endocannabinoids have been synthesized or
isolated. SAR of endocannabinoids have led to the conclusions that typically they contain
18 to 22 carbon atoms and that 3 to 4 double bonds are required for CB1 binding to
occur.18,19
In 1994, the Sanofi group reported the discovery of diaryl pyrazole cannabinoid
antagonists. The most notable of these antagonists is SR141716A (Rimonabant, 13,
Figure 6). These compounds have affinity for the cannabinoid receptors but do not
activate the intracellular signaling system typically initiated upon binding of G-protein
coupled receptors. Note that Acomplia® is prescribed to overcome obesity when typically
one associates marijuana with appetite stimulation. 11, 20
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Figure 6. Examples of non-traditional (11), AAI (12), endogenous (13), and
diarylpyrazole (14) cannabinoid ligands.

In 1988, the first cannabinoid receptor, CB1, was structurally identified by Devane
and co-workers and the nature of the structure-activity relationships (SAR) of
cannabinoids could begin to be understood. This receptor is primarily located in the
central nervous system and parts of the brain that affect such activities as body
movement, coordination and short term memory.21 In 1993, the discovery of a second
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cannabinoid receptor, CB2, located in the spleen and affecting the immunological, or
peripheral system, aroused more questions about receptor-ligand interactions.22
Cannabinoid receptors are known to be members of the family of G-protein
coupled receptors (GPCR). The commonly shared structural characteristics of GPCR’s
are an extracellular N- terminus and an intracellular C-terminus connected through seven
transmembrane (TM) α-helical loops, which are made up of amino acids. Hydrophilic
amino acids face the interior of the protein while hydrophobic amino acids face the
exterior. The CB1 receptor was isolated in mouse brain in 1990 and then finally in human
brain by Gerard and co-workers in 1991.23-24 The structure of GPCR’s is based upon the
structure of rhodopsin. These G proteins exist in a heterotrimer form (αβγ) and possess
tightly bound guanosine diphosphate (GDP) in the inactive state. Guanosine diphosphate
(GDP) is the product of dephosphorylation of GTP (guanosine-5’-triphospahte) through
GTPase. Upon interaction with a receptor agonist, a conformational change of the
receptor confers sufficient energy to the system such that GDP dissociates. In the absence
of the guanine nucleotides, the receptor-hormone-G protein intermediate complex
exhibits a relatively high affinity for the agonist. The receptor is activated upon binding
of GTP to this complex. The affinity of the agonist ligand for the receptor is then
decreased, and the G-protein dissociates from the receptor and separates into α and βγ
subunits. The GTP bound α subunit now interacts with adenylate cyclase and inhibits its
enzymatic activity, causing a decrease in the conversion of ATP to cyclic AMP (cAMP).
The activated protein also interacts with target ion channels by opening potassium
channels and closing calcium channels.25 Dissociation of the ligand from the receptor
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along with hydrolysis of the GTP on the α subunit allows the system to perpetually
respond to altered concentrations of hormone21 (Figure 7).

Figure 7. Interaction of a G-protein coupled receptor (GPCR).

Since the mapping of the CB1 receptor (Figure 8), many breakthroughs have been
made in the determination of key points of ligand-receptor interaction. Cannabinoid
ligands interact with intracellular G-proteins to inhibit adenylate cyclase. The inhibition
of this secondary messenger leads to a decrease in cyclic AMP production resulting in the
CNS effects that cannabinoids produce in humans and animals.14 Transmutagenic studies
have been carried out on the CB1 receptor in order to identify possible sites of interaction.
The binding of a cannabinoid changes the conformation of transmembrane helix-7
(TM7), which in turn is believed to alter residues in the C-terminus. It is believed that the
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altering of the C-terminus initiates G-protein activation. It has also been found through
chimera studies that in some way Asp163 on TM2 as well as peptides on the third
intracellular loop (C3) play a role in G-protein activation. Another factor showing
involvement of the C3 loop on G-protein activation are interactions between TM3 and
TM6. TM6 has a pro-kink allowing for the possibility that movement in that helix could
be facilitated by a ligand binding. Both Barnett-Norris and Shim and colleagues proposed
that the hydrophobic alkyl side chains of cannabinoid agonists act as triggers to move
TM6. This motion alters the conformation of the C-terminal side of the C3 loop.27 It has
also been found in studies performed using CP-55,940 that Lys192 on TM3 may be a
hydrogen bonding donor to the phenolic oxygen in traditional and non-traditional
cannabinoids.28
To date the detailed structure of the CB2 receptor remains elusive. It is known that
the CB2 receptor has 44% sequence identity with the CB1 receptor and 68% identity in
the TM regions associated with ligand-receptor recognition.22 Chimeric data on Lys192,
known to be involved in CB1 binding, indicates that AAI’s, which have a binding
preference for CB2, do not bind to CB1 in the same manner as other classes of
cannabinoids.28 Ligands found to show an affinity for the CB2 receptor include AAI’s and
structures lacking the A-ring phenolic hydroxyl or possessing hydroxymethyl groups at
that position. Huffman and co-workers have found evidence based on AAIs that aromatic
stacking may be involved in receptor bonding with CB2.29
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Figure 8. 2-D structure of the CB1 receptor in humans.26

Interactions with the CB1 and CB2 receptors can be measured both in vivo and in
vitro. It can be determined if there is possible cannabimimetic activity based on animal
behavioral studies. These tests focus on the prediction of cannabis-like activity through
drug discrimination and other in vivo procedures.

Data from in vivo bioassays is

quantified and reported as an ED50 value. An ED50 value is the dose that produces a
response equal to half of the maximum response. These are determined by plotting the
dose-response relationship, a simple X-Y graph, of the logarithm of the dose versus the
intensity of the response. This results in a sigmoidal curve indicating the threshold dose
along with the dose necessary for maximal response.30,31 These behavioral results have
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been correlated with CB1 receptor affinity. In vitro affinity (Ki) has been plotted against
in vivo potency (ED50) using linear-regression analysis of log-log data. It has been shown
that compounds displaying a high receptor affinity also display behavioral results in
mice.32 The two common bioassays for in vivo measurement are drug discrimination and
a series of tests referred to as the mouse tetrad.
In the drug discrimination test, an animal is put into a cage and taught that it must
press a lever to receive a food reward. Once this is accomplished, the mouse is injected
with ∆9-THC and learns that only one lever will release food. The mouse is then injected
with a vehicle drug and the opposing lever gives the food reward. Finally, the possible
cannabinoid ligand is injected and physiological effects can be noted by observing which
lever the mouse associates with the food reward.33 This model has been indicative of
compounds that would produce cannabimimetic psychoactivity in humans.34
More commonly used for in vivo studies is the mouse tetrad bioassay. Developed
in the mid-1980s by Billy Martin and colleagues, this methodology is preferred because
of the nominal expenses and short time duration that this series of four tests requires. The
series of four behavioral tests, that when put together are capable of determining
cannabis-like activity, include the measurement of spontaneous activity (SA), analgesia
by means of tail flick (TF), hypothermia via rectal temperature (RT) and catalepsy using
ring immobility (RI). Carried out in one group of mice, these tests are performed at 5, 20,
60 and 90 minutes, respectively, after initial injection of the cannabinoid.31
In vitro assays, which quantify CB1 and CB2 activity through radiolabelled
ligands, include [35S]GTPγS binding and competitive binding assays. Also,
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autoradiography, using the radiolabelled ligand [35S]GTPγS (Figure 9) has provided an
effective method for exploring the brain regional distribution of CB1 receptor activated
G-proteins.32 These receptors are now known to reside mainly in the basal ganglia,
cerebellum, hippocampus and cerebral cortex, which explains the psychological and
physiological effects cannabinoids have on the CNS. It is also known that agonist
promoted binding of [35S]GTPγS evaluates the interactions between G-proteins and
GPCR’s. Unlike its GTP analog, [35S]GTPγS is poorly hydrolyzed due to the
phosphorothioate group. When present, this radioligand competes with GTP for the GαGTP binding site and forms the quasi-irreversible Gα- GTPγS complex, whose half-life is
prolonged (Figure 10). From this, the agonist rates of GDP and [35S]GTPγS exchange can
be compared and the degree of G protein activation is determined. The amount of
[35S]GTPγS displaced provides a quantitative measure of the affinity and the efficacy of a
compound. These qualities are then used to determine if a cannabinoid is an agonist,
antagonist or partial agonist. The efficacy, which is the ability of a drug to induce a
biological response in a receptor, should not be confused with the affinity of a drug to
bind to a receptor. Generally an agonist has a high affinity as well as a high efficacy and
an antagonist has affinity but lacks efficacy. An agonist can also have a high efficacy,
producing maximal response, while having low affinity for the receptor. Alternatively, an
agonist of low efficacy, which cannot activate the receptor to the same degree, may
occupy a large part of the receptor, or have a high affinity. A drug categorized as a partial
agonist falls into the latter category.35,36
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Figure 9. Structure of [35S]GTPγS showing the phosphorothiote group.

Figure 10. Interaction of [35S]GTPγS with a G Protein.

A second method for determining cannabimimetic activity in vitro employs the
use of competitive binding assays. These bioassays measure the displacement of [3H]CP55,940 or [3H]WIN-55, 212-2, as described by Compton and co-workers.32 Comparison
of these in vitro values with findings from previous in vivo studies reinforced the validity
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of this procedure. This assay employs either rat brain membrane preparations for
determining CB1 activity or chinese hamster ovary (CHO) transfected cell lines if
determining CB2 activity.37 The appropriate cells are added to solutions containing a
known quantity of radioligand followed by varying concentrations of the cannabinoid
analog. The amount of radioactivity present is quantified using liquid scintillation
spectrometry.32 The amount of displacement, or IC50 value, is obtained by non-linear
regression of the log of the concentration-percent displacement data. This value is used to
determine the Ki value, or inhibition constant, through the application of the ChengPrusoff equation (Figure 11).38 This equation applies the concentration of radioligand,
[3L], the known dissociation constant of the radioligand from the receptor, Kd, and the
IC50 value, or the concentration of the cannabinoid analog that displaces fifty-percent of
the radioligand, as obtained from the binding assay. All studies are performed in triplicate
and reported results are representative of the combined data of three to six independent
experiments.

Ki =

IC50
1+

[ 3 L]
Kd

Figure 11. Cheng-Prusoff Equation.38

The affinity of a cannabinoid for either the CB1 or CB2 receptors is reported as a
Ki value. A high affinity ligand will have a low Ki value for one or both of these
receptors. When one receptor has a much higher affinity than the other, this cannabinoid
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is said to selective for that receptor. This selectivity helps in understanding the SAR of
certain compounds with the receptors and assists in the design of future cannabinoids.
The Ki values for some aforementioned cannabinoids are shown in Table 1, along with
the CB1 and/or CB2 selectivity of each.

Table 1. Ki values of common cannabinoids.
compound
∆9-THC (1)
∆8-THC (6)
Cannabinol, CBN (5)
Cannabidiol, CBD (3)
HU-210 (9)
SR141716A (14)
CP-55,940 (11)
AEA (13)
WIN-55,212-2 (12)
a

Ki CB1 (nM)
40.7 ± 2.0a
47.6 ± 2.4 b
308 ± 40 a
4350 ± 390 a
0.73 ± 0.11 a
12.3 ± 3.1 a
0.58 ± 0.07 a
89 ± 10 a
1.9 ± 0.1 a

Ki CB2 (nM)
36.4 ± 10 a
39.3 ± 2.0 b
96.3 ± 14.4 a
2860 ± 1230 a
0.22 ± 0.18 a
702 ± 62 a
0.69 ± 0.02 a
371 ± 102 a
0.28 ± 0.16 a

CB1 selectivity
0.9
0.8
0.3
0.7
0.3
57
1.2
4.2
0.1

CB2 selectivity
1.1
1.2
3.2
1.5
3.3
0.01
0.8
0.2
6.8
B

Ref. 37. b Ref. 39.

The focus of this dissertation is the synthesis of CB2 selective ligands. This
research is derived from investigations into the SAR of aminoalkylindoles (AAIs).
Modification and distribution of various substituents on the indole and naphthoyl
moieties of AAIs has led to the design of many new CB2 selective ligands.
Studies into AAIs began in 1991 when Sterling-Winthrop was designing a new
series of nonsteroidal anti-inflammatory drugs (NSAIDs). Of these NSAIDs, Pravadoline
(15, Figure 12) was found to inhibit contractions of mouse vas deferens. The inhibition of
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mouse vas deferens (MVD) is known to be due to effects caused by CB1 receptor
interactions.17, 40 The inhibition of MVD activity has been associated with the inhibition
of adenylate cyclase as well as the inhibition of prostaglandin synthetase activity.41 The
finding that this drug had cannabimimetic activity led to the design of a series of indole
based cannabinoids, the most potent of which is WIN-55,212-2 (12). These AAIs display
a higher affinity for the CB2 receptor, thus making them the focus of many new
investigations. Huffman and co-workers initiated studies using the program PCModel to
describe a common pharmacophore between ∆9-THC and this new class of
cannabinoids.42 It was found that the aroyl moiety of the AAIs align with the ∆9 olefin of
∆9-THC, the carbonyl of AAIs align with the phenolic C-1 hydroxyl and the
aminoalkylindole on the indole nitrogen align with the C-3 side chain of classical
cannabinoids (Figure 13).

OCH3

O

N

15
N
O

Figure 12. Structure of the NSAID pravadoline.
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Figure 13. PCModel comparison of ∆9-THC and WIN-55,212-2.

In addition to the alignment predicted above, it was believed by Eissenstat that a
small substituent, or none, was required at the C-2 of the indole.43 Based on this
pharmacophore, a series of 2-methyl-N-alkyl-3-(1-naphthoyl)indoles was designed.42 The
replacement of the morpholino group emanated from the assumption that since the C-3
alkyl side chain of ∆9-THC aligned with this group, the replacement of the amine
substituent with an alkyl chain would retain its cannabimimetic activity. The synthesis of
a series of 2-methyl-N-alkyl-3-(1-naphthoyl)indoles (16, Figure 14) with the alkyl chain
ranging from one to seven carbons was initiated and the results can be seen in Table 2.
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Figure 14. General structure of 2-methyl-N-alkyl-3-(1-naphthoyl)indole.

Table 2. Effects of replacing the aminoalkyl side chain with an alkyl chain.

compound
JWH-042
JWH-043
JWH-015
JWH-016
JWH-007
JWH-004
JWH-009
c

R
methyl
ethyl
n
propyl
n
butyl
n
pentyl
n
hexyl
n
heptyl

Ki , CB1 (nM)
>10,000 c
1180 ± 44.0 c
336 ± 36.0 c
22.0 ± 1.5 c
9.5 ± 4.5 c
48.0 ± 13.0 c
311 ± 106 c

Ki , CB2 (nM)
5050 ± 192 c
964 ± 242 c
13.8 ± 4.6 c
4.3 ± 1.6 c
2.9 ± 2.6 c
4.0 ± 1.5 c
141 ± 14.5 c

CB2 selectivity
1.2
24
5.1
3.3
12
2.2
B

Ref. 44.

The Ki values for the N-alkyl-2-methyl-3-(1-naphthoyl)indole series shown above
show that an alkyl chain ranging from three to six carbons have affinity for the
cannabinoid receptors.44 It should be noted however that it is the propyl and pentyl chains
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that display affinity as well as a selectivity for the CB2 receptor. The affinities of chain
lengths below propyl and above hexyl are greatly attenuated.
Since affinity for the receptors was maintained by replacement of the aminoalkyl
chain with an alkyl chain, studies began into the altering of other sites of these N-alkyl-3(1-naphthoyl)indoles. Analysis of the 2-methyl substituent of the indole resulted the
findings that while the removal of the methyl group maintained and in some cases
accentuated receptor binding, elongation of the methyl substituent reduced or terminated
all affinity.17, 40, 45
The aromatic functionality of the AAI pharmacophore is typically a naphthyl ring,
a phenyl or substituted phenyl substituent usually attenuates receptor affinity. The aroyl
moiety was proven to be essential for activity; when it was replaced with an acyl
substituent the compounds had virtually no affinity. This supported the hypothesis that
aromaticity was playing a vital role in receptor interactions.42
The remaining piece of the predicted pharmacophore to be altered was the
carbonyl. The alignment of the carbonyl with the phenolic hydroxyl of traditional
cannabinoids implied that this site was involved in hydrogen bonding interactions with
the receptors. Reduction of the carbonyl group to a methylene gave compounds that
retain receptor affinity, thus reinforcing the conclusion that AAIs do not interact via
hydrogen bonding while supporting the aromatic stacking hypothesis.46
The details of the interaction of AAIs with the CB1 and CB2 receptors remain
enigmatic. Showalter performed initial approaches to establishing SAR for the peripheral
receptor by determining and compiling CB2 Ki data for known AAIs.37 It was found that
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these cannabinoids had selectivity for this receptor. Mutation studies done on the CB1
receptor have verified that this class of cannabinoids does not interact in the same manner
as classical, nonclassical and endogenous cannabinoids. The replacement on CB1 of
Lys192 with an alanine by Song and Bonner corroborated the previously stated finding.28
This mutation attenuated the affinity of classical and nonclassical cannabinoids while
only slightly affecting the potency of WIN-55,212-2. It has been hypothesized that AAIs
may interact with the receptors via aromatic stacking.28 Both Reggio47 and Huffman29
have done studies, which show that hydrogen bonding is not a factor in AAI ligandreceptor interactions. This was accomplished through the synthesis of series of
compounds incapable of hydrogen bonding. While these naphthylideneindenes (17,
Figure 15) and the indolylnaphthylmethane JWH-175 (18, Figure 15) showed affinity for
the CB1 receptor there was still speculation that hydrogen bonding could occur involving
the indole nitrogen. To eliminate any doubt, Huffman synthesized the indene JWH-176
(19, Figure 15), a hydrocarbon, and found that it too retained an affinity for the CB1
receptor, thus providing compelling evidence against a ligand-receptor hydrogen bonding
interaction (Table 3). Studies supporting aromatic stacking have also been reported by
Reggio and colleagues.47 There are two transmembrane regions of the CB1 receptor that
contain clusters of aromatic amino acids. Docking studies that the Reggio group
performed showed that on TM5 there is a tryptophan that may interact with the indole
ring system, a phenylalanine that possibly interacts with one ring of the naphthoyl system
and a tyrosine on TM3 believed to interact with the second naphthoyl ring. This evidence
is further supported by the decreased potency of the pyrrole derivatives, having one less
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aromatic ring than their indole analogs.46,47 A series of 3-(1-naphthoyl)-N-pentylpyrroles
with aromatic substituents placed at the C-2 of the pyrrole nucleus showed moderate to
high affinities for the receptors.48 The findings from this series, which increased possible
aromatic interactions by the addition of another aromatic moiety, reinforced the theory of
aromatic stacking between the ligand and the receptor.

N
C5H11

C5H11

N
17

18

19

O

Figure 15. AAIs synthesized to disprove H-bonding with cannabinoid receptors.

Table 3. Ki values for AAIs lacking the carbonyl moiety.

Ki , CB1 (nM)
22 ± 2.0 d
26 ± 4.0 d

compound
JWH-175 (18)
JWH-176 (19)
d

Ref. 29.
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When Reggio developed indene 17 it was not only to study the effects of the
carbonyl group, but to study the bioactive conformations of these AAIs. The E and Z
indene isomers serve as good rigid analogs of the S-cis and S-trans AAI conformations.
Ultimately, it was determined that when the C-2 position of the indole is unsubstituted,
the principal conformation is the S-trans, in which the C-3 aryl is proximate to C-2
(Figure 16). However, when there is a methyl group at the C-2 position, the preferred
conformation is S-cis, which places the C-3 aryl near C-4 of the indole nucleus (Figure
17). It is believed that the reason for these preferred conformations is to avoid steric bulk
in the plane of the indole ring system so allowing the cannabinoids to interact with the
receptors via aromatic stacking.47
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Figure 16. Conformations of N-alkyl-3-(1-naphthoyl)indoles.
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Figure 17. Conformations of 2-methyl- N-alkyl-3-(1-naphthoyl)indoles.
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Many AAIs have been synthesized with various substituents on the naphthoyl
ring. To summarize, addition of these groups reveals that frequently the placement of
alkyl and alkoxy substituents on the two, four, six, and seven positions of the naphthoyl
ring has shown increased CB2 affinity relative to their unsubstituted analogs.44,49,50
Based on the significant receptor affinities and the observed CB2 selectivity of
aminoalkylindoles such as WIN-55,212-2 (12, Figure 6, Table 1) and JWH-015 (Figure
14, Table 2), and the increased affinities of the naphthalene substituted analogs, the
synthesis of a series of halogen substituted compounds was proposed. The research in this
dissertation focuses on the synthesis and pharmacology of these 4’-halo and 8’-halonaphthoylindoles.
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CHAPTER TWO
RESULTS AND DISCUSSIONS

Cannabimimetic Indoles

Many N-alkyl-3-(1-naphthoyl)indoles have been synthesized with electrondonating substituents, namely alkyl and alkoxy groups, on the naphthoyl ring. These
compounds show increased CB2 affinity relative to their unsubstituted analogs. However,
no compounds have been previously synthesized in this series which have electronwithdrawing substituents. For this reason it was decided to design a series of N-alkyl-3(halo-naphthoyl)indoles. The primary focus of the research in this dissertation has been in
the area of cannabimimetic indoles possessing halogen substituents on a 3-(1-naphthoyl)
substituent. An initial retrosynthetic pathway to N-alkyl-3-(4-halo-1-naphthoyl)indoles
and their 2-methyl analogs was designed (Figure 18). This synthesis involved the
coupling of a naphthoyl halide with an alkyl indole via the Okauchi modification of the
Friedel-Crafts reaction.51 The required starting materials for this pathway were not
commercially available, therefore the first priority was to synthesize the precursor
compounds.
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R

O

R'
N
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+

R
X

X = Br, Cl, I, F
R = n-C3H7
= n-C5H11
R' = H, CH3

Figure 18. Retrosynthetic pathway to N-alkyl-3-(4-halo-1-naphthoyl)indoles and the 2methyl analogs.

Alkyl Indoles

Alkylation of indole and its 2-methyl analog was performed using KOH and
DMSO along with the appropriate alkyl halide (Figure 19). This SN2 reaction involves
deprotonation of the indole followed by nucleophilic attack on the primary alkyl halide,
displacing the halide leaving group. This reaction gave yields of 88-98%, the by-product
being the 1,3-dialkyl indole. Purification of the indoles was performed by one of two
methods: vacuum distillation at 200 °C using a Kugelrohr or column chromatography.
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RX, KOH/DMSO
R'

R'
N

N

80 °C, 1.5 h
88-98%

H

R

R' = H, CH3
RX = n-C3H7I
= n-C5H11Br

Figure 19. Preparation of alkyl indoles.

Table 4. Yields of alkyl indoles.
Compound no.
20
21
22
23

R
n-C5H11
n-C5H11
n-C3H7
n-C3H7

R’
H
CH3
H
CH3

Yield (%)
98
97
90
88

4-halo-1-naphthoic acids

All 4-halo-1-naphthoic acids, with the exception of 4-fluoro-1-naphthoic acid
which is commercially available, were to be synthesized from the corresponding 1halonaphthalenes. Initially, the proposed synthetic pathway involved electrophilic
aromatic substitution of the 1-halonaphthalene using N,N-diphenylcarbamyl chloride and
aluminum chloride to produce the 4-halo-1-naphthalamide.52 Base hydrolysis of the

32

amide using KOH and diethylene glycol would subsequently yield the 4-halo-1-naphthoic
acid (Figure 20).

X

X
(Ph)2NCOCl, AlCl3
DCE
reflux, 6 h
O

N

Ph

Ph
X
KOH/(HOCH2CH2)2O
180 °C, 19 h
O

X = Br, Cl, I

OH

Figure 20. Initially proposed synthetic pathway for 4-halo-1-naphthoic acids.

The first attempts at this synthesis were carried out using 1-bromonaphthalene.
Acylation was acheived using N,N-diphenylcarbamyl chloride and anhydrous aluminum
chloride in 1,2-dichloroethane (DCE), successfully resulting in 4-bromo-1-naphthalamide
in 40% yield. The N,N-diphenylamide functionality is very stable and sterically hindered,
so the conditions employed by Cason and co-workers were believed necessary.53 Several
attempts to obtain the desired carboxylic acid using KOH and diethylene glycol were
unsuccessful. Spectral data indicated that starting material was recovered, so an
alternative route was sought and the overall scheme is shown in Figure 21.
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2. NaOH/H2O
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OH
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X
KOH/H2O
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O

OH

Figure 21. Second proposed synthesis of 4-halo-1-naphthoic acids.

The first step in the alternate route (Figure 21) employed the Friedel-Crafts
acylation of the 1-halonaphthalenes using anhydrous aluminum chloride and acetyl
chloride. The solvents and reaction times differed for each halide (Figure 22), but the
same chemistry was behind the product formation.54-56 While some 2-acylation product
was observed, acylation occurred primarily in the 4- position and provided the desired
product, 4-acetyl-1-halonaphthalene in 55-84% yield, after purification by column
chromatography.
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Br

Br
AlCl3, CH3COCl/CS2
0 °C, 2 d
r.t. 3 d
62%
O

24

CH3

Cl

Cl
AlCl3, CH3COCl/DCM
40 °C, 30 min
84%
O

25
I

CH3

I
AlCl3, CH3COCl/DCM
0 °C, 2 d
r.t. 3 d
55%
O

CH3
26

Figure 22. Friedel-Crafts conditions and yields for each halide.
Oxidation of 4-acetyl-1-halonaphthalene to the corresponding carboxylic acid was
achieved through the pyridinium salt via application of the King modification of the
Haloform reaction,57 followed by hydrolysis using NaOH. Since the purification of
carboxylic acids can be difficult and can result in a significant loss of yield, purification
was effected by refluxing the crude acid in methanol and sulfuric acid. This gave the
corresponding methyl 4-halo-1-naphthoate. After purification of the methyl ester, base
hydrolysis was carried out in KOH and water to provide the 4-halo-1-naphthoic acids in
acceptable yields.
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Table 5. Yields for 4-acetyl-1-halonaphthoates.
X

O

Compound no.
27
28
29

OCH3

X
Br
Cl
I

Yield (%)
58
63
56

Table 6. Yields for 4-halo-1-naphthoic acids.
X

O

Compound no.
30
31
32

X
Br
Cl
I
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OH

Yield (%)
73
88
86

N-alkyl-3-(4-halo-1-naphthoyl)indoles

The proposed subsequent steps for the target compounds were to prepare the
naphthoyl chloride from the carboxylic acid, then activate the C-3 of the indole ring using
the conditions described by Okauchi and co-workers to achieve acylation at the C-3
position.51 The mild Lewis acid dimethylaluminum chloride was to be used to achieve
this (Figure 23).

X

X
SOCl2
reflux, 2 h

O

OH

O

Cl

4-halo-1-naphthoyl chloride

R'

Me2AlCl, DCM
0 °C, 1 h

X

O

N
R

4-halo-1-naphthoyl
chloride r.t. 4 h

R'
N
R

R = n-C3H7
= n-C5H11
R' = H, CH3
X = Br, Cl, I, F

Figure 23. Okauchi modification of the Friedel-Crafts reaction.
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4-Bromo-1-naphthoic acid (30) was refluxed with thionyl chloride to provide the
corresponding acyl chloride. Subsequent treatment of the indole 20 in dimethylaluminum
chloride and dichloromethane with the acid chloride was expected to afford the desired
product 39. Unfortunately this reaction proceeded only to give back starting materials.
Subsequent attempts employing the use of various Lewis acids including ethylaluminum
dichloride and diethylaluminum chloride were performed. These efforts proved futile in
initial trials using both 4-bromo-1-naphthoic acid (30) and 4-chloro-1-naphthoic acid
(31). Again, an alternative route was explored for successful coupling to arrive at the
desired compounds.
A previously used method by former Huffman group member Dong Dai was
employed.42 This procedure involved treating indole or 2-methylindole with
methylmagnesium bromide in anhydrous diethyl ether. Treatment of the indolyl anion
with the appropriate naphthoyl chloride ideally would provide the corresponding 3-(4halo-1-naphthoyl)indoles. N-Alkylation of the indole was to be carried out as previously
discussed and would yield the target compound (Figure 24). Unfortunately, this
procedure was known to give low yields and the intermediate 3-naphthoylindoles are
difficult to purify.
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r.t. 4 h

H
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MeMgBr, dry ether
0 °C, 1 h

R'
N
H

RX, KOH/DMSO

X

O

80 °C, 1.5 h
R'
N
R' = H, CH3
R = n-C3H7
= n-C5H11
X = Br, Cl
RX = n-C3H7I
= n-C5H11Br

R

Figure 24. Alternative coupling using the Grignard Reagent MeMgBr.

Accordingly, indole was stirred at 0 °C in anhydrous diethyl ether followed by
addition of methymagnesium bromide. A temperature of 0 °C was maintained throughout
the addition of the 4-bromo-1-naphthoyl chloride and was kept at that temperature for
four hours thereafter. Successful coupling resulted in a 76% yield of 3-(4-bromo-1naphthoyl)indole. The target compounds were acquired following N-alkylation in KOH
and DMSO. Target compounds 37-40 were prepared in this manner. This procedure also
proved successful for the synthesis of the N-alkyl-3-(4-chloro-1-naphthoyl)indole series
and the 2-methyl analogs (41-44).
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Table 7. Yields of 3-(4-halo-naphthoyl)indoles and the 2-methyl analogs.

O
X

N

R'

H

Compound no.
33
34
35
36

X
Br
Br
Cl
Cl

R’
H
CH3
H
CH3

Yield (%)
76
44
35
36

Repeatedly low yields of the intermediates 34-36 were burdensome and reversion
to the Okauchi procedure was attempted for the acylation using 4-iodo-1-naphthoic acid
and 4-fluoro-1-naphthoic acid. Attempts to synthesize target compounds 45-48 and 49-52
proved successful and the desired products were formed in yields of 7-52%
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Table 8. Yields of N-alkyl-3-(4-halo-1-naphthoyl)indoles and the 2-methyl
analogs synthesized via Figure 24.

O
X

N

R'

R

Compound no.
37
38
39
40
41
42
43
44

X
Br
Br
Br
Br
Cl
Cl
Cl
Cl

R
n-C3H7
n-C3H7
n-C5H11
n-C5H11
n-C3H7
n-C3H7
n-C5H11
n-C5H11

a

R’
H
CH3
H
CH3
H
CH3
H
CH3

Yield (%)a
12
50
18
10
15
46
48
31

Yields are unoptimized and are representative of the one time alkylation of 3-(4-halo-1naphthoyl)indoles.
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Table 9. Yields of N-alkyl-3-(4-halo-1-naphthoyl)indoles and the 2-methyl
analogs synthesized via the Okauchi Method (Figure 23).

O
X

N

R'

R

Compound no.
45
46
47
48
49
50
51
52

X
I
I
I
I
F
F
F
F

R
n-C3H7
n-C3H7
n-C5H11
n-C5H11
n-C3H7
n-C3H7
n-C5H11
n-C5H11

a

R’
H
CH3
H
CH3
H
CH3
H
CH3

Yields (%)a
7
13
15
27
52
56
10
15

Yields are unoptimized and are representative of a one time Okauchi coupling.

42

Table 10. Pharmacology results for N-alkyl-3-(4-bromo-1-naphthoyl)indole series and
the 2-methyl analogs.

O
Br

N

R'

R

Compound no.

R

R’

JWH-386 (37)
JWH-395 (38)
JWH-387 (39)
JWH-394 (40)

n-C3H7
n-C3H7
n-C5H11
n-C5H11

H
CH3
H
CH3

Kia/CB1b
(nM)
161 ± 16
373 ± 43
1.19 ± 0.06
14 ± 0.2

Kia/CB2c
(nM)
27 ± 1.6
31 ± 2
1.10 ± 0.13
2.8 ± 0.2

CB2
selectivity
6
12
1
5

Ki data was aquired by Dr. Billy Martin and Dr. Jenny Wiley of Virginia Commonwealth
University.
a
Data from displacement of [3H]CP-55,940 in at least three independent experiments run
in duplicate and expressed as the mean of three values with standard error of mean.
b
Receptor affinity determined using rat brain homogenate.
c
Receptor affinity determined using membranes from CHO-K1 cells transfected with the
human CB2 cannabinoid receptor.
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Table 11. Pharmacology and GTPγS results for N-alkyl-3-(4-chloro-1-naphthoyl)indole
series and the 2-methyl analogs.

O
Cl

N

R'

R

Compound no.

R

R’

JWH-400 (41)
JWH-399 (42)
JWH-398 (43)
JWH-397 (44)

n-C3H7
n-C3H7
n-C5H11
n-C5H11

H
CH3
H
CH3

Kia/CB1b
(nM)
93 ± 8
187 ± 16
2.3 ± 0.1
8.9 ± 0.3

Ki/CB2c
(nM)
44 ± 0.4
22 ± 1
2.8 ± 0.2
2.3 ± 0.02

CB2
selectivity
2
9
0.8
4

Ki and GTPγS data were aquired by Dr. Billy Martin and Dr. Jenny Wiley of Virginia
Commonwealth University.
a
Data from displacement of [3H]CP-55,940 in at least three independent experiments run
in duplicate and expressed as the mean of three values with standard error of mean.
b
Receptor affinity determined using rat brain homogenate.
c
Receptor affinity determined using membranes from CHO-K1 cells transfected with the
human CB2 cannabinoid receptor.

Compound no.
JWH-397 (44)
JWH-399 (42)
JWH-400 (41)

EC50 (nM)
0.74 ± 0.01
6.58 ± 0.11
9.46 ± 2.94

GTPγS CB2c
Emax (%)
63.2 ± 4.1
97.8 ± 35.6
100.3 ± 2.7
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Emax vs CP-55,940
0.51 ± 0.03
0.79 ± 0.28
0.81 ± 0.02

Table 12. Pharmacology results for N-alkyl-3-(4-iodo-1-naphthoyl)indole series and the
2-methyl analogs

O
I

N

R'

R

Compound no.

R

R’

JWH-423 (45)
JWH-422 (46)
JWH-421 (47)
JWH-420 (48)

n-C3H7
n-C3H7
n-C5H11
n-C5H11

H
CH3
H
CH3

Kia/CB1b
(nM)
140 ± 10
501 ± 48
2.5 ± 0.2
14 ± 1

Kia/CB2c
(nM)
6.6 ± 0.2
20 ± 0.4
1.3 ± 0.02
2.1 ± 0.1

CB2
selectivity
21
25
2
7

Ki data was aquired by Dr. Billy Martin and Dr. Jenny Wiley of Virginia Commonwealth
University.
a
Data from displacement of [3H]CP-55,940 in at least three independent experiments run
in duplicate and expressed as the mean of three values with standard error of mean.
b
Receptor affinity determined using rat brain homogenate.
c
Receptor affinity determined using membranes from CHO-K1 cells transfected with the
human CB2 cannabinoid receptor.
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Table 13. Pharmacology results for N-alkyl-3-(4-fluoro-1-naphthoyl)indole series and the
2-methyl analogs

O
F

N

R'

R

Ki data was aquired by Dr. Billy Martin and Dr. Jenny Wiley of Virginia Commonwealth
University.
a
Data from displacement of [3H]CP-55,940 in at least three independent experiments run
in duplicate and expressed as the mean of three values with standard error of mean.
b
Receptor affinity determined using rat brain homogenate.
c
Receptor affinity determined using membranes from CHO-K1 cells transfected with the
Compound no.

R

R’

JWH-414 (49)
n-C3H7
H
JWH-415 (50)
n-C3H7
CH3
JWH-412 (51) n-C5H11
H
JWH-413 (52) n-C5H11
CH3
human CB2 cannabinoid receptor.

Kia/CB1b
(nM)
240 ± 7
530 ± 37
7.2 ± 0.5
14 ± 0.7
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Kia/CB2c
(nM)
33 ± 2
38 ± 1
3.2 ± 0.5
2.2 ± 0.2

CB2
selectivity
7
14
2
6

The CB1 and CB2 receptor affinities of the 4-bromo, 4-chloro-, 4-iodo and 4fluoro indole derivatives 37-40, 41-44, 45-48 and 49-52 are presented in Table 10, 11, 12
and 13, respectively. Table 11 also provides CB2 GTPγS binding data for three of the
B

four 4-chloro analogs.
Data for the N-alkyl-3-(4-bromo-1-naphthoyl)indole series and the 2-methyl
analogs (37-40) provided some interesting findings. While all compounds exhibited from
good to high affinity for the CB2 receptor, both 37 and 38, the 2H- and C-2 methyl propyl
derivatives, displayed 6- and 12-fold selectivity for CB2. The pentyl analogs 39 and 40
have very high affinity for the CB2 receptor as well as the CB1 receptor. Even though this
B

high affinity (Ki = 1.2 nM/ CB1 and Ki = 1.1 nM/ CB2 for 39; Ki = 14 nM/ CB1 and Ki = 3
nM/ CB2 for 40) is desirable, when the affinity is high for both receptors the compound is
considered ineffective. The propyl analogs have decent affinity for the CB2 receptor,
although not as high their pentyl analogs, but they are better CB2 selective ligands.
In the N-alkyl-3-(4-chloro-1-naphthoyl)indole series, and their 2-methyl analogs,
(41-44) the propyl compounds are again the more CB2 selective of the group. The 2methyl propyl compound 42 has 9-fold selectivity for the CB2 receptor with Ki values of
187 nM and 22 nM at CB1 and CB2, respectively. The 2H- pentyl derivative 43 actually
displays a slight preference for the CB1 receptor but overall both pentyl derivatives have
high affinity for both cannabinoid receptors.
GTPγS data was determined for the 4-chloro compounds (41, 42 and 44). The
EC50 and Emax values determine the potency and efficacy of a compound. Each of these
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compounds was found to initiate a response in the CB2 G-coupled protein receptor
(GPCR) at low nanomolar concentrations, indicating that they are agonists.
The propyl derivatives of the N-alkyl-3-(4-iodo-1-naphthoyl)indole series and its
2-methyl analogs (45-48) show the highest CB2 selectivity of the entire 4-halo series. Ki
values for 45, the 2H- analog, are 140 nM for CB1 and 6.6 nM for CB2 while the 2-methyl
analog has Ki values of 501 nM at CB1 and 20 nM at CB2. These equate to 21- and 25fold selectivities for CB2 as well as having good CB2 affinities. The pentyl derivatives
display high affinity for both receptors with 48, the C-2 substituted compound, having
selectivity for CB2.
Compounds 49-52, the N-alkyl-3-(4-fluoro-1-naphthoyl)indole series and its 2methyl analogs, continue the trends seen in the previously discussed series. The propyl
analogs 49 and 50 display high selectivities for the CB2 receptor. It was determined that
the pentyl compounds continue to have a very high affinity for both CB1 and CB2,
ultimately rendering them devoid of any pertinent cannabimimetic interest.
In general, the N-alkyl-3-(4-halo-1-naphthoyl)indole series of cannabinoids
display high affinity as well as some selectivity for the CB2 receptor. The propyl analogs
have CB2 selectivities of up to 25-fold and maintain an affinity for CB2 ranging from 2040 nM, except for 45 which has the highest affinity, 6.6 nM, of all the propyl compounds.
It is also observed that within the propyl compounds, the C-2 substituted analogs display
higher selectivities than the pentyl analogs. In the pentyl series, all 2H- derivatives have
very high affinity for both CB1 and CB2 receptors, and therefore have no selectivity. The
2-methyl analogs, while having very high affinities for both receptors, do show
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selectivity for the CB2 receptor over their 2H- analogs. The N-propyl 4-iodo series stands
apart from the other halogens, displaying high CB2 selectivity of 21- and 25-fold as well
as high CB2 affinity.

N-alkyl-3-(8-halo-1-naphthoyl)indoles

Based on the pharmacology data for the 4-halo series of cannabimimetic indoles
that indicated several examples of compounds with selectivity for the CB2 receptor it was
B

decided to synthesize another series of halo indoles. A literature search provided
procedures for the synthesis of 8-bromo-1-naphthoic acid and 8-iodo-1-naphthoic acid.
As reported by Bailey and co-workers these carboxylic acids could be produced through
a simple two step pathway in relatively high yields.58
The selective mercury-mediated decarboxylation of an aromatic anhydride,
specifically 1,8-naphthalic anhydride, to give the mono-acid and carbon dioxide is known
as the Pesci reaction.59 Numerous studies on the mechanism of this reaction have been
carried out, however the exact mechanism remains unclear.60-65 The naphthalic anhydride
is hydrolyzed to the dicarboxylate anion followed by treatment with mercury (II) oxide
(HgO) in acetic acid and water, to give in situ generation of mercuric acetate [Hg(OAc)2].
The mercury species subsequently displaces one of the carboxylate groups, releasing
CO2. This results in formation of the 8-hydroxymercuri-1-naphthoic anhydride
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intermediate. Acidic hydrolysis then releases mercury as a salt yielding the arene monoacid (Figure 25).66

O

O

O
i) NaOH, H2O

Hg

O

O

O

OH

conc. HCl

ii) HgO,
AcOH/H2O (3:1)

Figure 25. The Pesci reaction.

Treatment of 1,8-naphthalic anhydride with NaOH followed by mercuric acetate
in acetic acid and water prompted mercury-mediated decarboxylation of the anhydride.
Two days at reflux in acetic acid resulted in formation of the highly stable 8hydroxymercuri-1-naphthoic anhydride (53, Figure 26) in 96% yield. Halogenation of
this organo-mercurio intermediate, as shown in Figure 26, was carried out and provided a
series of 8-halo-1-naphthoic acids.
Intermediate 53 was stirred at 0 °C in aqueous acetic acid followed by addition of
bromine and aqueous sodium bromide. Bromination was initiated via the tribromide
anion, Br3-.67-69 Nucleophilic attack of 8-hydroxymercuri-1-naphthoic anhydride (53) by
bromide resulted in a bromo-mercuri intermediate. This intermediate underwent
nucleophilic substitution by bromine leading to the desired 8-bromo-1-naphthoic acid
(54) in 87% yield with no further purification necessary along with mercury (II) bromide.
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8-Iodo-1-naphthoic acid was synthesized in a similar manner after 15 hours of
reflux following the addition of iodine and aqueous potassium iodide to 53. Iodine is
poorly soluble in water, however, in the presence of iodide salts solubility is increased by
the formation of tri-iodide anion, I3-, which promotes iodination in the same way as the
tribromide anion.67,70,71 The solution was filtered and to the filtrate was added sodium
thiosulfate and water, which reduces any remaining iodine to iodide. The filtrate was
acidified and acid 55 was filtered out of the solution in 52% yield (Figure 26).

O

O

O

NaOH/H2O
reflux

Hg

Hg(OAc)2, AcOH/H2O
reflux, 48 h
96%

O

O

53

Br

O

OH

AcOH/H2O, 0 °C

Hg

O

O

NaBr(aq), Br2
0 °C to 100 °C
87%
I2, KI(aq)
reflux, 12 h

54

I

O

OH

53
Na2S2O3, H3O+
52%

55

Figure 26. Synthesis of 8-halo-1-naphthoic acids.
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A procedure for making 8-chloro-1-naphthoic acid was described by Whitmire
and co-workers 72 (Figure 27). However, this procedure employed the use of chlorine gas
and alternate routes of chlorination were investigated. Initial attempts to synthesize the
desired carboxylic acid involved generation of Cl2(g) in situ using 6M HCl and dilute
sodium hypochlorite (Figure 28).73 A vial containing bleach was placed into a 60mL
syringe and the 6M HCl was drawn through the needle. Upon shaking the syringe, the
solution reacted and a yellow gas was immediately formed. This gas was then injected
into the organo-mercurio solution at 0 °C and then slowly heated to 100 °C. Confirmation
of the addition of chlorine to the aromatic system was difficult due to the crude
spectroscopic data, so purification through the methyl ester was initiated. The identity of
the methyl ester, once purified, could then be verified by NMR spectroscopy and GC/MS.
Compounds containing chlorine have a distinct mass spectrometry signature. An M+2
peak is observed with an intensity ratio of M:M+2 of 3:1.74 Esterification was attempted
using methanol and sulfuric acid. The methyl ester was isolated and the spectroscopic
data indicated that the chlorination reaction had failed. The resulting product was the
unsubstituted methyl-1-naphthoate.

Hg

O

O
NaOH(aq), NaCl(aq),HCl
reflux

Cl

O

OH

Cl2(g), AcOH
r.t to 100 °C

Figure 27. Whitmire synthesis of 8-chloro-1-naphthoic acid.
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NaOCl(aq) + 2HCl(aq)

Cl2(g) + NaCl(aq) + H2O

Figure 28. Generation of chlorine gas in situ.

Modifications of Whitmire’s procedure were attempted and a second chlorinating
agent, N-chlorosuccinimide (56, Figure 29, NCS), was employed. The strength of the
nitrogen-chlorine bond in NCS makes it difficult to break, thus this is the ratedetermining step, or a first order reaction.75 It is also reported that in aqueous acidic
solutions in the presence of chloride ion, NCS produces a steady but small concentration
of Cl2(g) along with succinimide.76 Unlike elemental halogens where only half of the
halogen is consumed, NCS allows for consumption of all of the halogen species.77 Ring
chlorination of aromatic compounds with NCS proceeds by electrophilic substitution.77,78
Unfortunately this reagent also proved to be unsuccessful and 1-naphthoic acid was
obtained along with recovered organo-mercurio starting material.

O

Cl

CH3

Cl

H3C

N
O

O

N
O
N
Cl

56

57

Figure 29. Chlorinating agents used.
Using NCS in an alternate synthetic pathway was the next approach. The
procedure previously employed by Rule and co-workers79 was combined with the above
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procedure designed by Bailey58 for the formation of 54. Reagents were adjusted and an
aqueous solution of sodium chloride and NCS were used in place of aqueous sodium
bromide and molecular bromine. Attempts to methylate the crude acid using methanol
and sulfuric acid proved unsuccessful. A new esterification method involving refluxing
the carboxylic acid in thionyl chloride followed by removal of the thionyl chloride in
vacuo and treatment of the remaining gum with anhydrous methanol was performed.80
Although only yields of 2-3% were obtained, enough of the methyl ester was formed to
show by GC/MS that the addition of chlorine was not successful.
A 1:1 ratio of chlorinating agent to 53 was being used. Since this was a first-order
reaction and NCS allows for use of all the available chlorine, it is known that raising the
equivalents of NCS would have no effect on the rate of the reaction. Therefore, an
alternate chlorinating agent was pursued. Chlorination employing the use of 1,3-dichloro5,5-dimethyl hydantoin (57, Figure 29, DCDMH) proceeds in the same manner as NCS.77
During the Pesci reaction, the addition of the HgO solution to the hydrolyzed
dicarboxylate salt results in a dense white precipitate. It was believed that inefficient
stirring of this solution may have been hindering efficient mixing of the reagents and the
substrate. The following approach incorporated the use of a stir plate with sufficient
power to maintain constant stirring of the dense solution.
DCDMH was used in the Bailey58 procedure, with vigorous stirring, followed by
dissolution of the mercuri-chloro intermediate in 12M NaOH. Filtration of the undesired
mercury salts and acidification of the filtrate using concentrated HCl resulted in the
formation of a white precipitate. This precipitate, which is soluble in water, is believed to
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be 5,5-dimethylhydantoin (DMH). Extraction of the filtrate with dichloromethane gave
the desired 8-chloro-1-naphthoic acid (58, Figure 30). To verify this, the methyl ester was
to be synthesized. It was found however that esterification of 1-naphthoic acid derivatives
with substituents in the C-8 position would not undergo esterification using methanol and
sulfuric acid.81 The addition of a substituent in the C-8 position caused steric hindrance of
the carboxyl moiety. The lone reported methylating agent to esterify one of these
carboxyl derivatives was diazomethane.81 The hazards associated with the preparation of
diazomethane led to the safer solution of using trimethylsilyl diazomethane (TMSD).82
The methylation of 58 was successfully performed in a medium of TMSD and methanol,
the mechanism of which can be seen in Figure 31. The addition of the chlorine was
supported by the spectral data. Proton nuclear magnetic resonance (1H NMR) indicated
six rather than seven aromatic hydrogens as well as splitting patterns associated with
substitution in the 1 and 8 positions and GC/MS showed an M peak at 220 as well as an
M+2 peak at 222 in a 3:1 ratio.
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Hg

O

O

1) AcOH/H2O
0 °C, 15 m
NaCl(aq), N,N-dichloro-5,5-dimethylhydantoin
0 °C to 100 °C

Cl

2) 12M NaOH,
conc. HCl
30%

53

O

OH

58

Cl

O

OCH3

2.0M TMSD, MeOH
58
reflux, 1.5 h
40%

59

Figure 30. Successful synthesis and esterification of 8-chloro-1-naphthoic acid.
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Figure 31. Mechanism of esterification using TMSD.

Carboxylic acids 54, 55 and 58 were converted to their corresponding acid
chlorides using thionyl chloride and then coupled with the appropriate N-alkylindoles via
the previously employed Okauchi method of acylation using dimethylaluminum chloride.
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Yields of 11-64% of the corresponding N-alkyl-3-(8-halo-1-naphthoyl)indoles (60-67)
were achieved after column chromatography.

X

O

O

OH

X

Cl

SOCl2
reflux, 2 h
8-halo-1-naphthoyl chloride

X
R'
N
R

Me2AlCl, DCM
0 °C, 1 h

8-halo-1-naphthoyl chloride
r.t. 4 h

O

R'
N
R

R = n-C3H7
= n-C5H11
R' = H, CH3
X = Br, I

Figure 32. Okauchi coupling of N-alkyl-3-(8-halo-1-naphthoyl)indoles and the 2methyl analogs
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Table 14. Yields of N-alkyl-3-(8-halo-1-naphthoyl)indoles and the 2-methyl
analogs.
Compound no.
60
61
62
63
64
65
66
67

X
Br
Br
Br
Br
I
I
I
I

R
n-C3H7
n-C3H7
n-C5H11
n-C5H11
n-C3H7
n-C3H7
n-C5H11
n-C5H11

a

R’
H
CH3
H
CH3
H
CH3
H
CH3

Yields (%)a
48
16
78
15
21
35
11
64

Yields are unoptimized and are representative of a one time Okauchi coupling.
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Table 15. Pharmacology results for N-alkyl-3-(8-bromo-1-naphthoyl)indole series
and the 2-methyl analogs

Br
O

R'
N
R

Compound no.

R

R’

JWH-428 (60)
JWH-429 (61)
JWH-424 (62)
JWH-425 (63)

n-C3H7
n-C3H7
n-C5H11
n-C5H11

H
CH3
H
CH3

Kia/CB1b
(nM)
>10,000
>10,000
21 ± 3.4
54 ± 11

Kia/CB2c
(nM)
192 ± 14
278 ± 69
5.4 ± 0.2
9.97 ± 0.4

CB2
selectivity
>52
>36
4
5.5

Ki data was aquired by Dr. Billy Martin and Dr. Jenny Wiley of Virginia Commonwealth
University.
a
Data from displacement of [3H]CP-55,940 in at least three independent experiments run
in duplicate and expressed as the mean of three values with standard error of mean.
b
Receptor affinity determined using rat brain homogenate.
c
Receptor affinity determined using membranes from CHO-K1 cells transfected with the
human CB2 cannabinoid receptor
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Table 16. Pharmacology results for N-alkyl-3-(8-iodo-1
-naphthoyl)indole series and the 2-methyl analogs

I
O

R'
N
R

Compound no.

R

R’

JWH-419 (64)
JWH-418 (65)
JWH-416 (66)
JWH-417 (67)

n-C3H7
n-C3H7
n-C5H11
n-C5H11

H
CH3
H
CH3

Kia/CB1b
(nM)
2960 ± 240
4290 ± 440
73 ± 10
522 ± 58

Kia/CB2c
(nM)
152 ± 33
536 ± 66
3.3 ± 0.1
13 ± 0.2

CB2
selectivity
19
8
22
40

Ki data was aquired by Dr. Billy Martin and Dr. Jenny Wiley of Virginia Commonwealth
University.
a
Data from displacement of [3H]CP-55,940 in at least three independent experiments run
in duplicate and expressed as the mean of three values with standard error of mean.
b
Receptor affinity determined using rat brain homogenate.
c
Receptor affinity determined using membranes from CHO-K1 cells transfected with the
human CB2 cannabinoid receptor
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The CB1 and CB2 receptor affinities of the 8-bromo and 8-iodo indole derivatives
60-63 and 64-67 are presented in Tables 15 and 16, respectively. Both the N-alkyl-3-(8halo-1-naphthoyl)indole series and their 2-methyl analogs provided some intriguing
findings.
N-propyl-3-(8-bromo-1-naphthoyl)indole and the 2-methyl analog displayed no
affinity for the CB1 receptor. They did however have very modest affinities for the CB2
receptor (Ki = 192 nM for 60 and Ki = 278 nM for 61). This moderate affinity for CB2,
combined with total lack of affinity for CB1, ultimately gives a 52- and 36-fold selectivity
for the CB2 receptor. The pentyl analogs 62 and 63 have selectivity for the CB2 receptor,
however, the high affinities that the 2H- and C-2 methyl derivatives display for both
receptors provides an undesirable combination.
The N-alkyl-3-(8-iodo-1-naphthoyl)indoles and their 2-methyl analogs provided
some unexpected results. All compounds in this series have high selectivity for CB2. The
propyl series, like the 8-bromo series, has little affinity for the CB1 receptor. The 2Hanalog displays 19-fold selectivity for the CB2 receptor, while the 2-methyl analog has
lower affinity resulting in an 8-fold preference for CB2. The pentyl series, on the other
hand, exhibits not only high affinity for the CB2 receptor, but high selectivity. The 2Hderivative (66) was found to have Ki at CB1 of 73 nM and Ki at CB2 of 3.3 nM. The 2methyl derivative, 67, has Ki at the CB1 receptor of 522 nM and Ki at CB2 of 13 nM. This
equates to 22- and 40-fold selectivity for the pentyl analogs, respectively. Note that the 8iodo series reverses the trends previously seen in the 4-and 8-halo compounds.
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In summary, placement of a halogen in the C-8 position of the naphthoyl ring
leads to an increase in CB2 selectivity as well as to a decrease in CB1 affinity. In the
propyl derivatives, it is now the unsubstituted C-2 analog that displays higher CB2
selctivity relative to its 2-methyl analog. The N-pentyl-3-(8-bromo-1-naphthoyl)indoles
continue to show higher selectivity for the 2-methyl substituted derivative over its
unsubstituted analog. However, the N-pentyl-3-(8-iodo-1-naphthoyl)indoles display a
much higher selectivity than their propyl counterparts while maintaining the trend
previously seen with the 2-methyl cannabinoid having higher selectivity than its 2Hderivative. It is worth mentioning that the iodo substituted compounds (45-48 and 64-67)
demonstrate CB2 affinity and selectivity that is much greater than the other halogen
substituted cannabimimetic indoles, particularly JWH-417 (67).

N-alkyl-3-(6-methoxy-2-naphthoyl)indoles

Over the years, many derivatives of the N-alkyl-3-(1-naphthoyl)indole series have
been synthesized. The addition of alkyl and alkoxy substituents to various positions of the
naphthoyl ring has been investigated.49 A wide range of affinities for the CB1 receptor
and affinity along with selectivity for CB2 has been observed. This is true particularly in
the methoxy series of analogs. Receptor affinities have been determined for four different
methoxy series, in which the group has been located on the C-2, C-4, C-6 and C-7
positions of the naphthoyl ring. It was found that in the 7-methoxy series and the 4-
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methoxy series, no selectivity was observed, but both had an affinity for each
receptor.29,46 The 2-methoxy derivatives display CB2 selectivity ranging from 22 to 53fold while compounds in the 6-methoxy series have selectivities of 17, 23 and 333-fold as
well as high affinity for the CB2 receptor. In the N-alkyl-3-(6-methoxy-1naphthoyl)indole series the pentyl compounds have high affinities for the CB1 receptor as
well as selectivity for the CB2 receptor. The propyl compounds also display high
selectivity for the CB2 receptor over the CB1 receptor. While the 2H indole with an Npropyl substituent has 17-fold selectivity for the CB2 receptor, the 2-methyl analog has
not only a high affinity for the CB2 receptor but has 333-fold selectivity.47 Based upon
the selectivity of the 3-(6-methoxy-1-naphthoyl)indoles the synthesis of a series of Nalkyl-3-(6-methoxy-2-naphthoyl)indoles was initiated. The proposed synthetic approach
is outlined in Figure 33.
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Figure 33. Synthetic pathway for N-alkyl-3-(6-methoxy-2-naphthoyl)indoles

Table 17. Yields of N-alkyl-3-(6-methoxy-2-naphthoyl)indoles
Compound no.
69
70
71
72

R
n-C3H7
n-C3H7
n-C5H11
n-C5H11

R’
H
CH3
H
CH3

Yield (%)a
4
37
59
11

. aYields are unoptimized and are representative of a one time Okauchi coupling.

6-Methoxy-2-naphthoic acid is commercially available and the synthesis of this
series of cannabimimetic indoles employed the Okauchi method previously discussed.
The use of dimethylaluminum chloride to activate the C-3 of the indole ring coupled with
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the 6-methoxy-2-naphthoyl chloride (68) resulted in the target N-alkyl-3-(6-methoxy-2naphthoyl)indole compounds.
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Table 18. Pharmacology results for N-alkyl-3-(6-methoxy-2-naphthoyl)indole
series and the 2-methyl analogs

OCH3
O

R'
N
R

Compound no.

R

R’

JWH-411 (69)
JWH-410 (70)
JWH-408 (71)
JWH-409 (72)

n-C3H7
n-C3H7
n-C5H11
n-C5H11

H
CH3
H
CH3

Kia/CB1b
(nM)
2036 ± 203
2682 ± 397
190 ± 12
746 ± 77

Kia/CB2c
(nM)
561 ± 54
322 ± 46
91 ± 3.4
232 ± 21

CB2
selectivity
4
8
2
3

Ki data was aquired by Dr. Billy Martin and Dr. Jenny Wiley of Virginia Commonwealth
University.
a
Data from displacement of [3H]CP-55,940 in at least three independent experiments run
in duplicate and expressed as the mean of three values with standard error of mean.
b
Receptor affinity determined using rat brain homogenate.
c
Receptor affinity determined using membranes from CHO-K1 cells transfected with the
human CB2 cannabinoid receptor.
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Pharmacological data for the N-alkyl-3-(6-methoxy-2-naphthoyl)indoles were
considerably different from those of the corresponding 1-naphthoyl analogs. Unlike the
6-methoxy-1-naphthoyl derivatives, this series displayed no significant affinity for either
the CB1 or CB2 receptor nor was there selectivity for either receptor. The 2H- and 2methyl-N-propyl compounds 69 and 70, display 4- and 8-fold selectivity for the CB2
receptor but exhibit little affinity (Ki = 561 nM for 69 and Ki = 322 nM for 70). The
pentyl series displays moderate CB2 affinity but lacks any significant selectivity for the
B

receptor.

Electron-withdrawing nitro substituents

The studies presented in this dissertation of electron-withdrawing halogen
substituents on N-alkyl-3-(1-naphthoyl)indoles and their affinity for the cannabinoid
receptors has shown that relative to their unsubstituted analogs, either significant affinity
or selectivity for the CB2 receptor is observed. These findings led to an inquiry into how
other electron-withdrawing substituents would affect receptor interactions. For this
reason it was determined that a series of cannabimimetic naphthoylindoles possessing a
nitro substituent should be synthesized.
Previous studies conducted by Hongfeng Deng of the Makriyannis group showed
that addition of a nitro group to N-alkyl-3-(1-benzoyl)indole derivatives showed
increased affinity for CB2 relative to unsubstituted analogs.83
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Initially the study by Deng involved nitration of AM679 (73) to AM1202 (74).
These compounds can be seen in Figure 34, nitration being achieved using fuming nitric
acid and concentrated sulfuric acid. While AM679 had selectivity for CB1, the addition of
the nitro substituent led to a more than 15-fold increase for the CB2 receptor in AM1202
(Table 19). Based on this observation, another series of nitro analogs was designed.
Pharmacology for some of the series can be seen in Table 20.

I

I
O

O

NO2

Nitration
N

N
C5H11

C5H11

73

74

Figure 34. N-pentyl-3-(2-iodo-1-benzoyl)indole, AM 679 and its nitro analog, AM1202.

Table 19. Pharmacology for AM679 (73) and AM1202 (74).83
Compound
AM679 (73)
AM1202 (74)

Kia/CB1b (nM)
13.5
98.9

Kia/CB2c (nM)
49.5
22.9

a

CB2 selectivity
0.3
4

Data from displacement of [3H]CP-55,940 in at least three independent experiments run
in duplicate and expressed as the mean of three values with standard error of mean.
b
Receptor affinity determined using rat brain homogenate.
c
Receptor affinity determined using membranes from CHO-K1 cells transfected with the
human CB2 cannabinoid receptor.
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No nitro compounds were synthesized that were devoid of a halogen substituent.
Reasoning for this is that the Makriyannis group is interested in developing covalent
affinity radioprobes, which are used to label the cannabinoid receptors, allowing studies
of receptor-ligand interactions. The iodo compound AM661 (Table 20) displayed high
affinity for both CB1 and CB2 receptors. Also, the iodo substituent allowed the compound
to be radioactively labeled. Therefore, it was decided that this compound would be a
good lead structure for the synthesis of additional cannabimimetic indoles. The
replacement of the N-pentyl chain on the indole with an (N-methyl-2-piperidinyl)methyl
group creates a chiral center on the cannabinoid. This is of interest because it has been
found that when the enantiomers are separated, one racemate has a higher binding affinity
than the other, thus affecting the selectivity profile. Proposed research to be carried out in
the Huffman laboratory has interest in the investigation of cannabimimetic indoles with
one electron-withdrawing substituent on the naphthoyl ring, in this case a nitro group.
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Table 20. Ki values for 1-(N-methyl-2-piperidinyl)methyl-3-(2-iodobenzoyl)indole
derivatives with nitro substituents.83
I
O
R5
R2
N

R6

N

Deng
Compounds
AM2233
AM1241
AM661
1
2

R5

R2

R6

H
NO2
H
NO2
H

H
H
CH3
CH3
CH3

H
H
H
H
NO2

Ki/CB1
(nM)
3.4
548.4
33.6
2133
40

Ki/CB2
(nM)
7.6
1.6
33.9
41.8
80

CB2 selectivity
0.4
343
1
51
0.5

Over the course of this study three nitro-naphthoic acids were synthesized. Initial
attempts were focused on the formation of 4-nitro-1-naphthoic acid. The retrosynthetic
pathway can be seen in Figure 35.
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Figure 35. Retrosynthetic pathway for the synthesis of 4-nitro-1-naphthoic acid

5-nitroacenaphthene (75) was synthesized by the nitration of acenaphthene. The
substrate was dissolved in acetic acid, which was followed by the slow addition of nitric
acid. When the addition was finished, the solution was immediately poured over ice and a
yellow precipitate (75) was filtered out in 88% yield.84 Oxidation of 75 was carried out
using potassium dichromate in acetic acid at 100 °C for 3.5 h.85 The reaction mixture was
then poured over ice and 4-nitro-1,8-naphthalic anhydride (76) precipitated as an orange
solid in yields of up to 63% (Figure 36). Comparison of the synthetic 4-nitro-1,8naphthalic anhydride (76) with commercially available 4-nitro-1,8-naphthalic anhydride
revealed that they are identical.
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75
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Figure 36. Nitration and oxidation of acenaphthene.

Transformation of 76 to 4-nitro-1-naphthoic acid (78) was to proceed via the
Pesci reaction (Figure 25), just as in the syntheses of the 8-halo-1-naphthoic acids,
however difficulties were encountered. The overall procedure of mercury mediated
decarboxylation again involved stirring 4-nitro-1,8-naphthalic anhydride (76) in a sodium
hydroxide solution, followed by neutralization of the excess base with acetic acid.
Mercuric acetate in water was then added and the solution was refluxed for 50 h.
Filtering this solution led to anhydro-4-nitro-8-hydroxymercuri-1-naphthoic acid (77), a
highly stable, insoluble mercury intermediate. This compound was then refluxed in 1 M
HCl for 2 h.66. Ideally, 4-nitro-1-naphthoic acid (78) would be the product of this
reaction. However, it was determined by infrared spectroscopy that no acid was formed.
Only trace amounts of product were soluble in organic solvents indicating that the
organo-mercuri intermediate had not been recovered. This procedure was repeated using
0.58 M, 0.65 M, and 2.5 M solutions of sodium hydroxide. Following the mercuration,
reflux was carried out in 1 M HCl. 58, 60, 62 Occasionally a water soluble salt was formed,
however attempts to further acidify this salt, which was formed in an acidic medium, did
not result in the precipitation of product. Overall, these reactions resulted in no
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identifiable product, let alone the desired acid. Since an insoluble intermediate was being
formed, the concentration of HCl used in the acid hydroysis of 77 was altered.
Concentrations of 0.65 M, 1.0 M, 2.0 M, and concentrated HCl were employed under the
conditions of each of the previous synthetic attempts. Again, no formation of the desired
product was observed.
Rather than using mercuric acetate, a solution of mercury (II) oxide in acetic acid
and water was utilized to create the mercuric acetate in situ. Attempts were made using
both red and yellow mercury (II) oxide, for which no chemical difference has been
reported in the literature. Ultimately, this procedure did not produce the desired 4-nitro-1naphthoic acid.
An additional aspect of the reaction that may have been the problem was the
solubility of various salts in this reaction medium. Rather than using sodium hydroxide,
potassium hydroxide was used to initiate decarboxylation. This was followed by addition
of yellow mercury oxide in acetic acid and water. After 96 h at reflux, the solid was
filtered, and dried. This reaction is thermally driven and reaction times of 48 to 96 h have
been previously reported, as well as the need for temperatures of up to 200 °C when a
nitro substituent is present.66 The solid was refluxed in concentrated HCl for 6 h, the
suspension filtered and then dried. The crude product was recrystallized from glacial
acetic acid. Spectral data verified that 4-nitro-1-naphthoic acid (78) had been
synthesized.62,

86

The optimized synthetic pathway can be seen in Figure 37. The

formation of 78 was further verified by the synthesis of methyl-4-nitro-1-naphthoate (79)
using methanol and sulfuric acid.
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Figure 37. Synthesis of 4-nitro-1-naphthoic acid (78) from 4-nitro-1,8-naphthalic
anhydride (76).

While the investigation into the formation of 78 was being undertaken, the
synthesis of 8-nitro-1-naphthoic acid and 5-nitro-1-naphthoic acid was accomplished. It
is known that electrophilic attack on naphthalenes with deactivating meta-directing
groups is expected to take place in the 5- and 8-positions of the naphthalene ring.87 This is
because the electron withdrawing substituent is more effective in deactivating the ring on
which it is situated than the adjacent ring. This leads to attack at the two remaining 1positions of the naphthalene. 1-Naphthaldehyde was nitrated using fuming nitric acid,
acetic acid and sulfuric acid.88 This led to the formation of 8- (80) and 5-nitro-1naphthaldehydes (81). Purification of the aldehydes was achieved using column
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chromatography and it was found that these compounds formed in a 2:1 ratio,
respectively. The successful oxidation of 80 and 81 was accomplished using freshly
prepared Jones Reagent and distilled acetone.89 This procedure gave 8-nitro-1-naphthoic
acid (82) and 5-nitro-1-naphthoic acid (83) in about 60% yield. These acids could be used
without further purification. (Figure 38).
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Figure 38. Synthesis of 5- and 8-nitro-1-naphthoic acids.

After the successful synthesis of carboxylic acids 78, 82 and 83, the next step was
to attempt coupling with an alkylindole. Initial attempts using 8-nitro-1-naphthoic acid
(82) employed the Okauchi procedure. The acid chloride was prepared and added to a
stirring solution of N-pentylindole (20) in dichloromethane and dimethylaluminum
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chloride (Me2AlCl). Multiple Okauchi syntheses employing various N-alkylindoles were
attempted with no success for either 82 or 83. The use of different Lewis acids was also
enlisted. Ethylaluminum dichloride (EtAlCl2) and diethylaluminum chloride (Et2AlCl)
did not give the desired product and it was suspected that the aluminum may form a
complex with the nitro substituent. Possible evidence to refute this interaction was due to
the fact that the Makriyannis group was able to successfully couple indoles with
nitrobenzoyl halides employing aluminum chloride (AlCl3). If such an interaction was
indeed playing a role in the inability of the coupling to proceed smoothly, it would be
necessary to employ the use of a metal that would not interact with the substituent. Ottoni
and co-workers90 reported the successful use of tin (IV) chloride (SnCl4) in the activation
of the 3-position of the indole ring, therefore the synthesis was attempted utilizing this
Lewis acid. Ultimately, no coupling of the indole with 8-nitro-1-naphthoyl chloride was
observed. Synthesis was also attempted employing AlCl3. Procedures using this Lewis
acid were performed under both the Okauchi modification of Friedel-Crafts acylation as
well as traditional Friedel-Crafts conditions.91 All efforts to couple both 5-nitro-1naphthoic acid (83) and 8-nitro-1-naphthoic acid (82) proved futile.
The synthesis of 4-nitro-1-naphthoic acid (78) was more efficient than the
synthesis of the 5- (83) and 8-nitro-1-naphthoic acids (82), therefore, after the initial
attempts of Okauchi coupling failed using acid 78 a synthesis of 3-(4-nitro-1naphthoyl)indole was designed (Figure 39). This process involved formation of
indolylmagnesium bromide by stirring indole and methylmagnesium bromide (MeMgBr)
in dichloromethane at 0 °C followed by addition of the 4-nitro-1-naphthoyl chloride (84).
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This coupling has proven difficult but trace amounts of 3-(4-nitro-1-naphthoyl)indole
(85) have been successfully obtained when the reaction was run at 0 °C for 4 h. Minute
amounts of 2-methyl-3-(4-nitro-1-naphthoyl)indole (86) have also been isolated under the
same conditions.
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0 °C, 1 h

NO2

O
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R'
N
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R' = H, 85, 10%
R' = CH3, 86, 7%

Figure 39. Synthesis of 3-(4-nitro-1-naphthoyl)indole and the 2-methyl analog.

Due to the difficulty in producing moderate yields of the unsubstituted 85 and 86
analogs the project was dropped. Further attempts to synthesize the target N-alkyl-3-(4nitro-1-naphthoyl)indoles were not undertaken.
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Reinvestigation of the Friedel-Crafts acylation of N-p-toluenesulfonylpyrrole

Several years ago a series of cannabimimetic N-alkyl-3-(1-naphthoyl)pyrroles was
synthesized by Julia Lainton of the Huffman group.92 These were investigated to further
provide evidence for binding of AAIs to the cannabinoid receptors via aromatic stacking.
Friedel-Crafts acylation conditions were employed for the final coupling of the pyrrole
derivatives and 1-naphthoyl chloride catalyzed by the strong Lewis acid aluminum
chloride (AlCl3). These standard Friedel-Crafts conditions involve the addition of the
substrate to a stirring solution of aluminum chloride and the acyl halide.91
Although it has been known for many years that electrophilic substitution
reactions of pyrrole and its substituted derivatives occur predominantly at the 2-position,
it has also been found that placement of a bulky substituent on the nitrogen provided
mainly acylation in the 3-position under Friedel-Crafts conditions.93-99 This was believed
to be primarily due to steric hindrance at the pyrrole 2-position. However, the
regioselectivity has been found to differ when using weaker Lewis acids. While AlCl3
provides regioselective acylation at the 3-position, Kakushima and co-workers99 found
that

weaker

Lewis

acids

such as

ethylaluminum

dichloride

(EtAlCl2)

and

diethylaluminum chloride (Et2AlCl) regioselectively acylate the 2-position of the pyrrole.
The Huffman group continually uses the modified Okauchi procedure of the
Friedel-Crafts acylation.51 This method has been employed for the synthesis of many 3acylindoles and involves stirring the substrate with the catalyst for approximately 30
minutes prior to addition of the acyl halide. 50, 100 Using this method, Padgett found that
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with Et2AlCl, only the 2-isomer was obtained, but when AlCl3 was used, a 9:1 ratio of the
3-isomer to the 2-isomer was obtained unlike when Lainton had carried out this
procedure finding that under typical Friedel-Crafts conditions with AlCl3, an equal
mixture of the 2- and 3-isomers was obtained.92, 101
Overall, the findings of the Huffman group, using N-p-toluenesulfonylpyrrole (87,
Figure 40, N-Ts-pyrrole) as the substrate, showed that when using more than 1.0
equivalents of AlCl3 under typical Friedel-Crafts conditions, in both dichloromethane
(DCM) and 1,2-dichloroethane (DCE) the predominant product (>88%) was the 3acylated (86, Figure 40) isomer. Reducing the amount of catalyst to 1.0 equivalents and
0.9 equivalents showed an increase to 15-32% of 2-isomer (89, Figure 40) attained,
respectively. 92
Further investigations into the effect of the Lewis acid were performed utilizing
the Okauchi method of acylation. N-Ts-pyrrole (Figure 40) was used in concentrations of
0.075M and 0.221M in both DCM and DCE. The findings are summarized as follows:
When using AlCl3 the 3-isomer was the main product, however when EtAlCl2 was used
as catalyst the ratio of 2- to 3-isomer greatly increased and the 2-isomer became the
predominant product. The use of Et2AlCl led to almost exclusively to the 2-isomer along
with recovered starting material.102
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Figure 40. Structures of N-p-toluenesulfonylpyrrole and its acylated 3- and 2isomers.

The reinvestigation into the effects of the use of AlCl3 in the Okauchi method
involved acylation using 1-naphthoyl chloride, acetyl chloride and acetic anhydride.
Whether 1.0, 1.2, 1.5 or 2.0 equivalents of AlCl3 were used, all led to the 3-isomer as the
major product. When 0.9 equivalents of AlCl3 were used, the ratio of 2- to 3-isomer was
increased, but the 3-isomer was still the predominant product.102, 103
As previously stated, pyrroles normally undergo electrophilic substitution at the
2-position.92 It was originally considered that acylation in the 3-position may occur via
initial substitution at the 2-position followed by rearrangement to the C-3 carbon, as this
has been observed in substituted pyrroles in acidic medium.104-106 However, Kakushima
and co-workers established that this was not a logical mechanism based on the
observation that 2-acetyl-N-benzenesulfonylpyrrole formed a stable complex with AlCl3
and could be recovered unchanged after aqueous work-up.98 Similarly, the Huffman
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group recovered both 2-(1-naphthoyl)-N-p-toluenesulfonylpyrrole and the 3-isomer
unchanged after stirring with AlCl3 in DCM for 2 h.102

p-toluenesulfonyl chloride,
THF, 0 °C
N
H

N
O S O

NaH
r.t., 16 h
80%

87

Figure 41. Synthesis of N-p-toluenesulfonylpyrrole.

In early studies of the acylation of indoles in the 3-position using the Okauchi
method, Paul Szklennik of the Huffman group obtained evidence that the Okauchi
procedure involves an intermediate organoaluminum complex between the indole and the
Lewis acid.100 Ottoni and co-workers had found that organotin intermediates formed
when employing the Okauchi procedure were insoluble in DCM unless nitromethane was
added to the reaction mixture.90 The organoaluminum counterparts however, are found to
be soluble in DCM. 100
Kakushima reported that N-benzenesulfonylpyrrole and AlCl3 in DCE remains
heterogenous and that there is no evidence of complex formation by 1H NMR and UV.99
However, it was found that a mixture of N-Ts-pyrrole and 0.9 equivalents of AlCl3 in
DCE is a homogenous solution and N-benzenesulfonylpyrrole behaved similarly.
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Attempts to acquire a 1H NMR of the homogenous solution run in DCE-d4 proved
difficult so it was found necessary to prepare the sample in a dry, inert atmosphere.102
The 1H NMR spectra that was obtained from the stirring of N-Ts-pyrrole and 0.9
equivalents of AlCl3 in DCE-d4 was not well resolved (Figure 43), but it clearly showed
the loss of signals at δ6.29 and δ7.17 which correspond to the C-3 and C-2 protons of NTs-pyrrole (Figure 42). It was also noted that the doublets assigned to the phenyl ring at
δ7.30 and δ7.74 were no longer present. The most prominent doublets in the spectra
appear at δ7.80 and δ7.83, however the bulk of aromatic protons appear as a wide
multiplet and no reasonable integration was possible. The absence of N-Ts-pyrrole
signals in Figure 43 cannot be attributed to a shift of the spectrum. In addition to the
aromatic methyl peak at δ2.36 there was now a second peak at δ2.46 (Figure 43). A 13C
NMR could not be taken because of the rapid decomposition of the sample. When the NTs-pyrrole and AlCl3 in DCE was quenched with water, starting material was recovered.
Quenching of a solution of N-Ts-pyrrole and AlCl3 with D2O showed deuterium
incorporation at the C-2 and C-3 positions while quenching the reaction in either EtAlCl2
or Et2AlCl with D2O showed no deuterium incorporation by 1H NMR.107
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Figure 42. 1H NMR spectrum of N-p-toluenesulfonylpyrrole (87) in DCE-d4.103
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Figure 43. 1H NMR spectrum of N-p-toluenesulfonylpyrrole (87) and AlCl3 in DCEd4.103
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This evidence indicates that the mechanism of acylation of N-Ts-pyrrole using
AlCl3 differs from that employing the use of weaker Lewis acids. Changes in the 1H
NMR spectrum, the deuterium quenching results and the homogeneity of the reaction
using AlCl3 implies that the mechanism of this reaction is probably similar to that of the
Okauchi and Ottoni acylation procedure.51, 90 A possible mechanism for formation of the
2- and 3-isomers is shown in Figure 43.
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Figure 44. Proposed mechanism of the acylation of N-p-toluenesulfonylpyrrole using
AlCl3.102
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As shown in Figure 43, the reaction of N-Ts-pyrrole with AlCl3 leads reversibly to
a mixture of the 2- and 3-organoaluminum intermediates. This occurs through either
cation 90 or 91. Reaction of species 92 with the aroyl chloride leads to the corresponding
3-aroylpyrrole 88. Similarly, reaction of 93 with an aroyl chloride will lead to the 2aroylpyrrole 89. Although the suggested mechanistic pathway ideally provides both
regioisomers, it is believed that the acylation of the 2-position occurs at a much slower
rate of reaction due to steric effects that are not a problem when acylation occurs at the
unencumbered C-3 position. It is also hypothesized that there is a direct electronic
interaction of the electrophilic aluminum atom of the 2-isomer with an oxygen of the
sulfonyl group, forming a five-membered structure (94). This interaction would stabilize
the organoaluminum intermediate and decrease the rate of reaction with the aroyl
chloride.102
Evidence to support the mechanistic hypotheses put forward in this study has been
established. In the Okauchi procedure, the organoaluminum intermediates 92 and 93 are
formed prior to addition of the acyl halide, therefore when using 0.9 equivalents of AlCl3
there is no competing reaction for the Lewis acid between the aroyl chloride and the
substrate. However, under normal Friedel-Crafts conditions where the acyl halide is
stirred with the Lewis acid prior to addition of the substrate, N-Ts-pyrrole, it is
hypothesized that a reversible complex in which the AlCl3 is coordinated to the carbonyl
oxygen of the acyl halide exists.108-111 The substrate must then either compete with the
aroyl chloride for AlCl3 or the aluminum-oxygen complex itself becomes the Lewis acid,
resulting in compounds 88 and 89.
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Weaker Lewis acids are less regioselective and presumably do not involve an
organometallic pyrrole derivative. It has been found that under typical Friedel-Crafts
conditions, a polarized AlCl3–acyl halide complex is formed with no NMR indication of
an acylium ion.109 Also, the degree of Lewis acid induced polarization of this complex
decreased with the inductively withdrawing effect of the α-halogens of the Lewis acid
and that the rate of acylation decreased when there were electron withdrawing
substituents on the acyl halide.
It has been suggested that aromatic substitution reactions may proceed via a single
transition state; strongly electrophilic reagents providing early transition states
resembling a π-complex, or a reactant-like transition state, while less electrophilic
reagents provide product-like transition states similar to a resonance stabilized σcomplex, or Wheland intermediates.112-115 The application of the Hammond postulate to
these considerations predicts that in the electrophilic substitution reactions of pyrroles
electrophilic species such as AlCl3 will react at the 3-position, having a higher activation
energy, while electrophilic species such as Et2AlCl will attack at the 2-position,
producing the resonance stabilized, energetically favored, 3-carbocation.102 The Merck
group carried out studies, the findings of which supported this theory, using CNDO/2
calculations. These studies found that the 3-cation was significantly more stable than the
2-cation. This conclusion is also supported by classical valence bond theory. 97
Ultimately, the reinvestigation of the mechanism of Friedel-Crafts acylation of Np-toluenesulfonylpyrrole led to the hypothesis that there are two distinct mechanistic
pathways dependent on the order of addition of reactants. The regioselective acylation of
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N-p-toluenesulfonylpyrrole, when stirred with AlCl3 prior to acyl halide addition, is not a
Friedel-Crafts acylation, but the reaction of an organoaluminum intermediate with an acyl
chloride. Acylations employing weaker Lewis acids proceed via a normal Friedel-Crafts
reaction through a polarized complex between the Lewis acid and the acylating agent.
The nature of the acylating agent and the strength of the Lewis acid determine the
electrophilicity of this complex while the regiochemistry is determined by the transition
state leading to the 2- or 3-carbocation.
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CHAPTER THREE
CONCLUSIONS
This dissertation focuses on the syntheses and pharmacology of three series of
cannabimimetic indoles: (4-halonapththoyl)indoles, (8-halonaphthoyl)indoles and (6methoxy-2-naphthoyl)indoles. These compounds were designed to investigate structureactivity relationships at the cannabinoid receptors and possibly to lead to the discovery of
additional selective ligands for the CB2 receptor.
The two series of halogen analogs were designed as possible selective ligands for
the CB2 receptor. The N-alkyl-3-(4-halo-1-napohthoyl)indoles and their 2-methyl analogs
were synthesized in one of two ways: By coupling a 4-halo-1-naphthoyl chloride with
indole or 2-methyl indole followed by N-alkylation of the indole or by a modified
Friedel-Crafts reaction employing the use of dimethylaluminum chloride to form an
organoaluminum N-alkylindole intermediate to be coupled with a 4-halo-1-naphthoyl
chloride. The 4-halo-1-naphthoic acids were prepared by Friedel-Crafts acetylation of the
corresponding 1-halonaphthalenes. The King modification of the haloform reaction
followed by base hydrolysis gave the crude 4-halo-1-naphthoic acids which were purified
through their methyl esters. Saponification of the esters led to the desired 4-halo-1naphthoic acids. None of these halogenated compounds are devoid of CB2 affinity and
some have CB2 selectivity. This is especially true in the 4-iodo series which has high
affinity as well as selectivity for the CB2 receptor.
The analogous N-alkyl-3-(8-halo-1-napohthoyl)indoles and their 2-methyl analogs
were synthesized through a modification of the Pesci reaction. The mercury-mediated
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decarboxylation of 1,8-naphthalic anhydride led to a highly stable organomercurio
intermediate which upon halogenation gave the desired 8-halo-1-naphthoic acids. The
coupling of an 8-halo-1-naphthoic acid via its acid chloride with an N-alkylindole was
successfully carried out using the Okauchi modification of the Friedel-Crafts reaction.
Each halogen series displays affinity for the CB2 receptor and in some cases selectivity is
also displayed. As in the 4-halo series, the 8-iodo compounds have relatively high
selectivity for CB2.
In the realm of studying the effects of the location of the methoxy substituent on
the naphthoyl ring a series of N-alkyl-3-(6-methoxy-2-naphthoyl)indoles was
synthesized. The Okauchi coupling of an N-alkylindole with 6-methoxy-2-naphthoyl
chloride, prepared from the commercially available 6-methoxy-2-naphthoic acid, led to
the desired N-alkyl-3-(6-methoxy-2-naphthoyl)indoles. However, these compounds have
no significant affinity for either receptor.
A reinvestigation into the acylation of N-p-toluenesulfonylpyrrole with AlCl3 led
to the following conclusions. When using AlCl3 the acylation appears to proceed via
reaction of an organoaluminum intermediate with the acyl chloride. Acylations using
weaker Lewis acids proceed by a normal Friedel–Crafts reaction through a polarized
complex formed from the acylating agent and the Lewis acid. The electrophilicity of this
complex is determined by a combination of the nature of the acylating agent and the
strength of the Lewis acid. In these reactions the regiochemistry is determined by the
character of the transition state leading to the intermediate carbocation. With highly
reactive electrophiles, a reactant-like transition state will favor the 3-substituted product,
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while less reactive electrophiles will provide a product-like transition state that resembles
the more stable cation resulting from attack at C-2.
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CHAPTER FOUR
EXPERIMENTAL

All 1H and

13

C NMR spectra were determined on a 300 MHz Bruker Fourier

Transform Spectrometer or a 500 MHz Bruker Fourier Transform Spectrometer. The
solvent was deuterated chloroform (CDCl3) unless otherwise stated. 1H chemical shifts
are reported in parts per million (ppm) relative to tetramethylsilane (TMS, δ = 0.00 ppm)
as an internal standard. 13C chemical shifts are reported in ppm relative to TMS using the
central CDCl3 peak (t, δ = 77.0 ppm) as an internal standard. Coupling constants are
reported in Hertz (Hz).
GC/MS analyses were performed on a Hewlett-Packard 5890A capillary gas
chromatograph/mass spectrometer at 70 eV or a Shimadzu QP2010 capillary gas
chromatograph/mass spectrometer at 1.01 kV. Mass spectra data are reported as
mass/charge, with intensity as a percentage of the base peak.
High-resolution mass spectrometry data were obtained in the Mass Spectrometry
Laboratory, School of Chemical Sciences, University of Illinois.
Melting points were determined using a Fisher-Johns apparatus and are
uncorrected.
Tetrahydrofuran and diethyl ether were distilled over sodium and benzophenone;
dichloromethane and pyridine were distilled from calcium hydride; acetone was distilled
from potassium permanganate and then dried over calcium carbonate.
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Chemicals were used as received from Sigma-Aldrich, Alfa-Aesar, and Fisher
Scientific unless otherwise stated. All new compounds were homogenous to TLC and 13C
NMR.
Column chromatography was carried out on Sorbent Technologies silica gel (32 –
63 μm) using the indicated solvents as eluents. TLC was carried out using the indicated
solvents.
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N

N-pentylindole (20).
To a stirred solution of 5.00 g (42.7 mmol) of indole in 10 mL of DMSO was added 10.8
g (192 mmol) of crushed KOH. Addition of 12.9 g (85.4 mmol) of 1-bromopentane was
followed by stirring at ambient temperature for 1.5 h under N2. The reaction was
quenched with water and the product was extracted with 3 portions of dichloromethane.
The organic layer was dried (MgSO4) and concentrated in vacuo. Kugelrohr distillation at
200 °C under 19 in. Hg gave 8.15 g (98%) of N-pentylindole as a green oil: 1H NMR
(300 MHz, CDCl3) δ 1.08 (t, J = 6 Hz, 3H), 1.44-1.58 (m, 4H), 1.99 (q, J = 6 Hz, 2H),
4.24 (t, J = 6 Hz, 2H), 6.68 (d, J = 3 Hz, 1H), 7.24 (d, J = 3 Hz, 1H), 7.30 (t, J = 6 Hz,
1H), 7.40 (t, J = 6 Hz, 1H), 7.53 (d, J = 9 Hz, 1H), 7.85 (d, J = 9 Hz, 1H); 13C NMR (75.5
MHz, CDCl3) δ 14.2, 22.5, 29.3, 30.1, 46.5, 101.0, 109.6, 119.3, 121.1, 121.5, 128.0,
128.8, 136.1; GC/MS (EI) m/z (rel intensity) 187 (91), 172 (5), 158 (8), 144 (4), 130
(100), 117 (14), 103 (17), 89 (11), 77 (18), 63 (4), 51 (2).
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N

2-Methyl-N-pentylindole (21).
To a stirred solution of 5.00 g (38.1 mmol) of 2-methylindole in 10 mL of DMSO was
added 9.6 g (171.5 mmol) of crushed KOH. Addition of 11.5 g (76.2 mmol) of 1bromopentane was followed by stirring at ambient temperature for 1.5 h under N2. The
reaction was quenched with water and the product was extracted with 3 portions of
dichloromethane. The organic layer was dried (MgSO4) and concentrated in vacuo.
Kugelrohr distillation at 200 °C under 19 in. Hg gave 7.93 g (97%) of 2-methyl-Npentylindole as a brown oil: 1H NMR (300 MHz, CDCl3) δ 1.41 (t, J = 6 Hz, 3H), 1.751.85 (m, 4H), 2.15 (q, J = 6 Hz, 2H), 2.82 (s, 3H), 4.37 (t, J = 7.5 Hz, 2H), 6.74 (s, 1H),
7.60 – 7.68 (m, 2H), 7.73 (d, J = 9 Hz, 1H), 8.87 (d, J = 9 Hz, 1H); 13C NMR (75.5 MHz,
CDCl3) δ 13.1, 14.5, 23.0, 29.6, 30.4, 43.5, 100.4, 109.5, 119.6, 120.1, 120.8, 128.7,
136.6, 137.2; GC/MS (EI) m/z (rel intensity) 201(99), 186 (27), 172 (4), 158 (4), 144
(100), 130 (29), 115 (24), 103 (12), 91 (9), 77 (15), 63 (4), 51 (3).
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N-propylindole (22).
To a stirred solution of 5.00 g (42.7 mmol) of indole in 10 mL of DMSO was added 10.8
g (192 mmol) of crushed KOH. Addition of 14.5 g (85.4 mmol) of 1-iodopropane was
followed by stirring at ambient temperature for 1.5 h under N2. The reaction was
quenched with water and the product was extracted with 3 portions of dichloromethane.
The organic layer was dried (MgSO4) and concentrated in vacuo. Kugelrohr distillation at
200 °C under 19 in. Hg gave 7.54 g (90%) of N-propylindole as a yellow oil: 1H NMR
(300 MHz, CDCl3) δ 1.19 (t, J = 6 Hz, 3H), 2.10 (sextet, J = 6 Hz, 2H), 4.28 (t, J = 6 Hz,
2H), 6.82 (d, J = 3 Hz, 1H), 7.33 (d, J = 3 Hz, 1H), 7.45 (t, J = 6 Hz, 1H), 7.54 (t, J = 6
Hz, 1H), 7.64 (d, J = 6 Hz, 1H), 7.99 (d, J = 9 Hz, 1H); 13C NMR (75.5 MHz, CDCl3) δ
11.8, 23.8, 48.2, 101.1, 109.7, 119.5, 121.3, 121.6, 128.2, 129.0, 136.3; GC/MS (EI) m/z
(rel intensity) 159 (95), 130 (100), 117 (11), 103 (22), 89 (20), 77(24), 63 (8), 51 (4).
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2-Methyl-N-propylindole (23).
To a stirred solution of 5.00 g (38.1 mmol) 2-methylindole in 10 mL of DMSO was
added 9.6 g (171.5 mmol) of crushed KOH. Addition of 12.9 g (76.2 mmol) of 1iodopropane was followed by stirring at ambient temperature for 1.5 h under N2. The
reaction was quenched with water and the product was extracted with 3 portions of
dichloromethane. The organic layer was dried (MgSO4) and concentrated in vacuo.
Kugelrohr distillation at 200 °C under 19 in. Hg gave 7.49 g (88%) 2-methyl-Npropylindole as a red oil: 1H NMR (300 MHz, CDCl3) δ 1.32 (t, J = 6 Hz, 3H), 2.09 –
2.20 (m, 2H), 2.78 (s, 3H), 4.32 (t, J = 6 Hz, 2H), 6.70 (s, 1H), 7.53 – 7.63 (m, 2H) , 7.68
(d, J = 6 Hz, 1H), 8.02 (d, J = 6 Hz, 1H);

13

C NMR (75.5 MHz, CDCl3) δ 11.9, 13.1,

23.8, 45.0, 100.3, 109.5, 119.6, 120.1, 120.7, 128.6, 136.8, 137.2; GC/MS (EI) m/z (rel
intensity) 173 (91), 144 (100), 130 (18), 115 (18), 103 (11), 89 (6), 77 (13), 63 (4), 51
(4).
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O

1-Acetyl-4-bromo-naphthalene (24) (VJS-066).
To a stirred solution of 1.00 g (4.8 mmol) of 1-bromonaphthalene in 15 mL of carbon
disulfide at 0 °C in a flame-dried flask under N2 was added 0.42 g (5.3mmol) of acetyl
chloride. This solution was stirred at 0 °C for 10 min and 0.84 g (6.3mmol) of AlCl3 was
added. The reaction was stirred at 0 °C for 3 days followed by 2 days of stirring at
ambient temperature. The reaction mixture was then poured over ice and concentrated
HCl, extracted with ether and washed with NaHCO3 and brine. After drying (MgSO4) the
solution was concentrated in vacuo and purified by column chromatography (95:5.
petroleum ether: ether) to give 0.75 g (62%) of 1-acetyl-4-bromo-naphthalene as a brown
oil: 1H NMR (300 MHz, CDCl3) δ 2.74 (s, 3H), 7.65-7.69 (m, 2H), 7.74 (d, J = 6 Hz,
1H), 7.83 (d, J = 6 Hz, 1H), 8.32-8.35 (m, 1H), 8.72-8.75 (m, 1H); 13C NMR (75.5 MHz,
CDCl3) δ 30.1, 126.4, 127.5, 127.8, 128.2, 128.4, 128.7, 128.7, 131.2, 132.3, 135.2,
201.0; GC/MS (EI) m/z (rel intensity) 248 (46), 233 (100), 205 (44), 169 (2), 140 (4), 126
(83), 99 (6), 84 (10), 76 (10), 63 (25), 50 (4). The data agree in all respects with those
reported in the literature.116
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Methyl-4-bromo-1-naphthoate (27) (VJS-070).
To a solution of 0.52 g (2.09 mmol) of 1-acetyl-4-bromonaphthalene in 5 mL of freshly
distilled pyridine in a flame-dried round bottom flask under N2 was added 0.58 g (2.29
mmol) of I2 dissolved in 10 mL of freshly distilled pyridine. This mixture was refluxed
for 30 min and allowed to cool to ambient temperature. The solution was diluted with
ether until a brown precipitate formed. The precipitate was filtered off, suspended in 25
mL of 6 M aqueous NaOH and heated at reflux for 2 h. Upon cooling the solution was
acidified with 10% HCl and the crude 4-bromo-1-naphthoic acid was extracted with ether
and washed with brine. After drying (MgSO4) the ethereal solution was concentrated in
vacuo. The product was dissolved in 20 mL of MeOH to which 4 mL of concentrated
H2SO4 was cautiously added. This solution was heated at reflux for 2 h. After cooling to
ambient temperature the crude product was extracted into ether, the ethereal solution was
washed with brine and dried (MgSO4). The solution was concentrated in vacuo and
purified by column chromatography (95:5 petroleum ether: ether) to give 0.55g (57.3%)
of methyl 4-bromo-1-naphthoate as a yellow oil: 1H NMR (500 MHz, CDCl3) δ 4.00 (s,
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3H), 7.63 (p, J = 8.4 Hz, 2H), 7.77 (d, J = 7.5 Hz, 1H), 7.95 (d, J = 7.5 Hz, 1H), 8.30 (d,
J = 8.0 Hz, 1H), 8.96 (d, J = 8.0 Hz, 1H) ; 13C NMR (75.5 MHz, CDCl3) δ 52.3, 126.3,
126.9, 127.6, 127.7, 128.5, 128.8, 128.9, 130.1, 132.1, 132.4, 167.4; GC/MS (EI) m/z (rel
intensity) 264 (65), 249 (2), 233 (98), 295 (35), 170 (4), 153 (2), 126 (100), 99 (6), 87
(4), 74 (12), 63 (21), 50 (6).

Br

O

OH

4-Bromo-1-naphthoic acid (30) (VJS-077).
To a round bottom flask containing 0.50 g (1.9 mmol) of methyl-4-bromo-1-naphthoate
was added 3.5 g (6 0mmol) of crushed KOH in 25 mL of H2O. The solution was refluxed
overnight and acidified by the dropwise addition of concentrated HCl. The mixture acid
was extracted with ether and dried (MgSO4). Concentration in vacuo gave 0.35g (73%) of
4-bromo-1-naphthoic acid as a white solid: m.p. 215-217 °C (lit m.p.117 217-219 °C); 1H
NMR (300 MHz, DMSO-d6) δ 7.74-7.77 (m, 2H), 8.00 (q, J = 9, 12 Hz, 2H), 8.25-8.28
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(m, 1H), 8.90-8.93 (m, 1H), 13.3 (br s, 1H);

13

C NMR (75.5 MHz, DMSO-d6) δ 63.4,

126.7, 127.5, 127.5, 128.6, 129.0, 129.9, 130.5, 131.8, 132.3, 168.6.

Cl

O

1-Acetyl-4-chloro-naphthalene (25) (VJS-083).
To a solution of 0.15 g (1.9 mmol) of acetyl chloride in 8 mL of freshly distilled
dichloromethane in a flame-dried round bottom flask under N2 was added 0.26 g (2.0
mmol) of AlCl3. This mixture was stirred at ambient temperature for 5 m and 0.28 g (1.72
mmol) of 1-chloronaphthalene was added dropwise over 10 min. The mixture was heated
to 40 °C and stirred for 1 h, poured over a mixture of ice and concentrated HCl. The
product was extracted into ether, washed with brine and dried over MgSO4. The solution
was concentrated in vacuo to give 0.56 g (84%) of 1-acetyl-4-chloro-naphthalene as a
yellow oil, which was used without further purification: 1H NMR (300 MHz, CDCl3) δ
2.58 (s, 3 H), 7.33 (d, J = 7.8 Hz, 1 H), 7.48-7.55 (m, 2 H), 7.57 (d, J = 7.8Hz, 1H), 8.16
(d, J = 7.8, 1 H), 8.72 (d, J = 7.2, 1 H);

13

C NMR (75.5 MHz, CDCl3) δ 29.8, 124.5,

124.7, 126.4, 127.4, 128.4, 128.6, 130.9, 131.2, 134.1, 136.6, 200.5; GC/MS (EI) m/z (rel
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intensity) 204 (69), 189 (100), 161 (75), 126 (54), 99 (7), 84 (6), 75 (11), 63 (19), 50 (3).
The data agree in all respects with those reported in the literature.116
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Methyl-4-chloro-1-naphthoate (28) (VJS-084).
To a solution of 2.44 g (11.9 mmol) of 1-acetyl-4-chloronaphthalene in 5 mL of freshly
distilled pyridine in a flame-dried round bottom flask under N2 was added 3.33 g (13.1
mmol) of I2 dissolved in 15 mL of freshly distilled pyridine. This mixture was refluxed
for 40 m and allowed to cool to ambient temperature. The solution was diluted with ether
until a brown precipitate formed. The precipitate was filtered off, suspended in 12 mL of
6M aqueous NaOH and heated at reflux for 2 h. Upon cooling the solution was acidified
with 10% HCl and the crude 4-chloro-1-naphthoic acid was extracted with ether and
washed with brine. After drying (MgSO4) the ethereal solution was concentrated in
vacuo. The product was dissolved in 25 mL of MeOH to which 5 mL of concentrated
H2SO4 was cautiously added. This solution was heated at reflux for 3 h. After cooling to
ambient temperature the crude product was extracted into ether, the ethereal solution was
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washed with brine and dried (MgSO4). The solution was concentrated in vacuo to give
1.66 g (63%) of methyl 4-chloro-1-naphthoate as a brown oil, which was used without
further purification: 1H NMR (300 MHz, CDCl3) δ 3.90 (s, 3 H), 7.38 (d, J = 7.8, 1 H),
7.45-7.56 (m, 2H), 7.87 (d, J = 8.1, 1 H), 8.18 (d, J = 8.4, 1 H), 8.93 (d, J = 8.1, 1 H);
13

C NMR (75.5 MHz, CDCl3) δ 52.1, 124.6, 124.9, 125.8. 126.2, 127.1, 128.3, 129.9,

130.7, 132.3, 137.2, 166.9; GC/MS (EI) m/z (rel intensity) 220 (61), 205 (2), 189 (100),
161 (48), 126 (42), 99 (5), 94 (2), 75 (8), 63 (16), 50 (3).

Cl

O
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4-Chloro-1-naphthoic acid (31) (VJS-086).
A solution of 0.25 g (1.1 mmol) of 4-chloro-1-methylnaphthoate and 2.10 g (37.4 mmol)
of KOH in 20 mL of H2O were refluxed 12 h under N2. The reaction was cooled to
ambient temperature and acidified with concentrated HCl. The product was extracted
with ether and dried (MgSO4). The organic phase was concentrated in vacuo to give
0.267 g (88%) of 4-chloro-1-naphthoic acid as an off-white solid: m.p. 223-224 °C (lit
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m.p.117 220-221 °C); 1H NMR (300 MHz, DMSO-d6) δ 7.74-7.81 (m, 3H), 8.11 (d, J = 6
Hz, 1H), 8.28-8.31 (m, 1H), 8.93-8.97 (m, 1H), 13.8 (br s, 1H);

13

C NMR (75.5 MHz,

DMSO-d6) δ 124.7, 126.1, 126.7, 127.9, 128.3, 129.0, 130.4, 130.6, 132.3, 135.7, 168.5.

I

O

1-Acetyl-4-iodo-1-naphthalene (26) (VJS-248).
To a stirred solution of 2.00 g (15.4 mmol) of AlCl3 in 10 mL of freshly distilled
dichloromethane in a flame-dried flask under Ar at 0 °C was added dropwise 1.0 g (13.0
mmol) of acetyl chloride. This mixture was stirred at 0 °C for 10 min and 3.0 g (11.2
mmol) of 1-iodonaphthalene was added dropwise over 10 min. The reaction was stirred at
0 °C for 3 days followed by stirring at ambient temperature for 2 days. The reaction
mixture was poured over ice and concentrated HCl, extracted into ether and dried
(MgSO4 ). The solvent was removed in vacuo and the crude product was purified using
column chromatography (petroleum ether: ether, 7:3) to give 1.9 g (55%) of 1-acetyl-4iodonaphthalene as a brown oil: 1H NMR (300 MHz, CDCl3) δ 2.71 (s, 3H), 7.49 (d, J =
7.8 Hz, 1H), 7.58-7.64 (m, 2H), 8.08 (d, J = 7.5 Hz, 1H), 8.13-8.17 (m, 1H), 8.63-8.66
(m, 1H); 13C NMR (75.5 MHz, CDCl3) δ 30.2, 106.1, 126.5, 128.2, 128.6, 128.8, 130.4,
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132.8, 134.6, 136.2, 136.3, 201.3; GC/MS (EI) m/z (rel intensity) 296(70), 281 (100), 253
(27), 169 (2), 154 (4), 141 (4), 126 (89), 100 (4), 87 (3), 76 (13), 63 (7), 50 (6).

I

O

O

Methyl-4-iodo-1-naphthoate (29) (VJS-251).
To a solution of 2.0 g (6.75 mmol) of 1-acetyl-4-iodonaphthalene in 15 mL of freshly
distilled pyridine in a flame-dried round bottom flask under N2 was added 1.9g (7.43
mmol) of I2 dissolved in 20 mL of freshly distilled pyridine. This mixture was refluxed
for 40 min and allowed to cool to ambient temperature. The solution was diluted with
ether until a brown precipitate formed. The precipitate was filtered off, suspended in 40
mL of 6 M aqueous NaOH and heated at reflux for 2.5 h. Upon cooling the solution was
acidified with 10% HCl and the crude 4-bromo-1-naphthoic acid was extracted into ether.
The ether extracts were washed with brine, dried (MgSO4) and concentrated in vacuo.
The crude product was dissolved in 60 mL of MeOH to which 12 mL of concentrated
H2SO4 was cautiously added. This solution was heated at reflux for 2 h., cooled to
ambient temperature and extracted with ether. The ethereal solution was washed with
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brine, dried (MgSO4) and concentrated in vacuo. The crude product was purified by
column chromatography (petroleum ether: ether, 7:3) to give 1.2g (56%) of methyl 4iodo-1-naphthoate as a brown oil: 1H NMR (500 MHz, CDCl3) δ 4.03 (s, 3H), 7.63-7.69
(m, 2H), 7.83 (d, J = 7.5 Hz, 1H), 8.17 (d, J = 7.5 Hz, 1H), 8.21 (d, J = 8.0 Hz, 2H); 13C
NMR (125.77 MHz, CDCl3) δ 52.4, 125.8, 126.2, 126.4, 127.8, 128.1, 128.5, 130.3,
133.0, 133.4, 136.5, 167.6; GC/MS (EI) m/z (rel intensity) 312 (100), 281 (84), 253 (22),
170 (8), 153 (5), 126 (76), 99 (4), 87 (3), 76 (9), 63 (7), 50 (4).

I

O

OH

4-Iodo-1-naphthoic acid (32) (VJS-253).
To a round bottom flask containing 1.1 g (3.5 mmol) of methyl-4-iodo-1-naphthoate was
added 2.0 g (35 mmol) of crushed KOH in 50 mL of H2O. The solution was refluxed
overnight and then acidified by the dropwise addition of concentrated HCl. The mixture
was extracted with ether and dried (MgSO4). Concentration in vacuo gave 0.90g (86%) of
4-iodo-1-naphthoic acid as a white solid: m.p. 209 °C (lit. m.p.118 213 °C); 1H NMR (500
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MHz, DMSO-d6) δ 7.72-7.74 (m, 2H), 7.84 (d, J = 8 Hz, 1H), 8.14 (dd, J = 3, 6.5 Hz,
1H), 8.27 (d, J = 7.5 Hz, 1H), 8.84 (dd, J = 3, 6.5 Hz, 1H), 13.35 (br s, 1H); 13C NMR
(125.77 MHz, DMSO-d6) δ 106.1, 126.0, 126.8, 128.8, 128.9, 130.7, 131.5, 132.8, 134.4,
137.2, 168.8.

O

H

Br

N

3-(4-Bromo-1-naphthoyl)indole (33) (VJS-173).
To a solution of 0.54 mL (1.71 mmol) of MeMgBr [3.17 M in diethyl ether] in 1 mL of
dry ether was added, at 0 °C under Ar, a solution of 0.14 g (1.2 mmol) of indole in dry
ether. The mixture was stirred at 0 °C for 1 h. A solution of freshly prepared 4-bromo-1naphthoyl chloride in 3 mL of dry ether was added dropwise via syringe. The acid
chloride was prepared by the addition of 3 mL (41 mmol) of thionyl chloride to 0.27 g
(1.07 mmol) of 4-bromo-1-naphthoic acid under Ar. The mixture was refluxed for 2 h,
cooled to ambient temperature, and the thionyl chloride was removed in vacuo to give the
acid chloride, which was added to the indole mixture without further purification. The
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acid chloride and indole mixture was stirred at ambient temperature for 4 h. After this
time the reaction was quenched with NH4Cl, the organic phase was extracted with ether
and dried (MgSO4). Concentration in vacuo followed by column chromatography
(petroleum ether;ether, 2:1) gave 0.29 g (76%) of 3-(4-bromo-1-naphthoyl)indole as a
brown solid: 1H NMR (300 MHz, DMSO-d6) δ 7.27-7.33 (m ,2H), 7.53-7.57 (m, 1H),
7.59-7.64 (m, 2H), 7.71 (d, J = 8.4 Hz, 1H), 7.75-7.80 (m, 1H), 7.98 (d, J = 7.5 Hz, 1H),
8.07 (d, J = 8.1 Hz, 1H), 8.25 (d, J = 8.4 Hz, 1H), 8.37-8.34 (m, 1H), 12.18 (br, 1H); 13C
NMR (75.5MHz, DMSO-d6) δ 113.0, 117.6, 121.9, 122.8, 123.9, 124.0, 126.2, 126.6
(br), 127.3, 128.2, 128.6, 129.7, 131.8, 131.9, 137.5, 137.7, 139.4.

O

H

Br

N

2-Methyl-3-(4-bromo-1-naphthoyl)indole (34) (VJS-190).
The title compound was prepared using the procedure VJS-173. To a solution of 0.42 mL
(1.27 mmol) of EtMgBr [3.0M in diethyl ether] in 1 mL of dry ether was added, at 0 °C
under Ar, a solution of 0.12 g (0.88 mmol) of 2-methylindole in dry ether. The mixture
was stirred at 0 °C for 45 min. Freshly prepared 4-bromo-1-naphthoyl chloride, from 0.20
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g (0.80 mmol) of 4-bromo-1-naphthoic acid in 3 mL of thionyl chloride, was dissolved in
dry ether and added dropwise via syringe and stirred at ambient temperature for 4 h. After
this time the reaction was quenched with NH4Cl and the organic phase was extracted with
ethyl acetate. After sitting at ambient temperature for 15 min the solid precipitate was
filtered to give 0.13 g (44%) of 2-methyl-3-(4-bromo-1-naphthoyl)indole as a yellow oil:
1

H NMR (500 MHz, DMSO-d6) δ 2.76 (s , 3H), 6.99 (d, J = 8.0 Hz, 2H), 7.38-7.50 (m,

2H), 7.80 (d, J = 8.0 Hz, 2H), 7.84-7.86 (m, 2H), 8.03 (d, J = 8.0 Hz, 1H), 8.36-8.38 (m,
1H), 12.09 (br, 1H); 13C NMR (75.5 MHz, DMSO-d6) δ 15.8, 111.7, 114.0, 120.5, 122.6,
122.8, 125.0, 125.1, 126.0, 126.5, 128.1, 128.5, 129.0, 131.5, 131.7, 132.1, 135.9, 142.4,
148.7, 188.4.

O

H

Cl

N

3-(4-Chloro-1-naphthoyl)indole (35) (VJS- 201).
A solution of 0.48 mL (1.45 mmol) of EtMgBr [3.0M in diethyl ether] was added with
stirring to 3 mL of dry ether at 0 °C under Ar and stirred until it became cloudy white. A
solution of 0.12 g (1.06 mmol) of indole in 2 mL of dry ether was then added and the
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resulting mixture was stirred at 0 °C for 30 min followed by stirring at ambient
temperature for 30 min. A solution of freshly prepared 4-chloro-1-naphthoyl chloride in 3
mL of dry ether was added dropwise via syringe. The acid chloride was prepared by the
addition of 3 mL (41 mmol) of thionyl chloride to 0.20 g (0.97 mmol) of chloro-1naphthoic acid under Ar. The mixture was refluxed for 2 h, cooled to ambient
temperature, and the thionyl chloride was removed in vacuo to give the acid chloride,
which was added to the indole mixture without further purification. The acid chloride and
indole mixture was stirred at ambient temperature for 4 h, quenched with NH4Cl and
extracted with ether. The ethereal solution was allowed to stand at ambient temperature
for 20 min upon which time a precipitate was filtered out to give 0.11 g (38%) of 3-(4chloro-1-naphthoyl)indole as a cream colored solid: 1H NMR (300 MHz, DMSO-d6) δ
7.27-7.31 (m, 2H), 7.52-7.55 (m, 1H), 7.61-7.71 (m, 2H), 7.74-7.76 (m, 2H), 7.80 (d, J =
7.8 Hz, 1H), 8.08 (d, J = 8.1 Hz, 1H), 8.29-8.33 (m, 2H), 12.25 (br s, 1H);

13

C NMR

(75.5 MHz, DMSO-d6) δ 112.9, 117.5, 121.9, 122.8, 123.8, 124.5, 126.0, 126.3, 126.6,
128.2, 128.4, 130.5, 131.8, 132.5, 137.5, 137.7, 138.7, 190.8.
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2-Methyl-3-(4-chloro-1-naphthoyl)indole (36) (VJS-204).
The title compound was prepared using the procedure VJS-201. A solution of 0.29 mL
(0.87 mmol) of EtMgBr [3.0M in diethyl ether] was added with stirring to 3 mL of dry
ether at 0 °C under Ar until it became cloudy white. A solution of 0.08 g (0.64 mmol) of
2-methylindole in 2 mL of dry ether was then added and the resulting mixture was stirred
at 0 °C for 30 min followed by stirring at ambient temperature for 30 min. Freshly
prepared 4-chloro-1-naphthoyl chloride, from 0.12 g (0.58 mmol) of 4-chloro-1naphthoic acid, was dissolved in dry ether and added via syringe. The reaction was stirred
at ambient temperature for 4 h, quenched with NH4Cl and extracted with ether. The
ethereal solution was allowed to stand at ambient temperature for 20 min upon which
time a precipitate was filtered out giving 0.12 g (62%) of 2-methyl-3-(4-chloro-1naphthoyl)indole as a cream colored solid: 1H NMR (300 MHz, DMSO-d6) δ 6.95 (t, J =
7.2 Hz, 1H), 7.08 (t, J = 7.5 Hz, 1H), 7.26 (d, J = 7.5 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H),
7.46-7.69 (m, 5H), 7.76 (d, J = 7.5 Hz, 2H), 7.87 (d, J = 8.4 Hz, 1H), 8.25 (d, J = 8.4 Hz,
1H), 11.1 (br s, 1H); 13C NMR (75.5 MHz, DMSO-d6) δ 14.7, 112.0, 114.0, 120.5, 122.0,
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122.6, 124.5, 125.1, 126.0, 126.5, 127.4, 128.3, 128.4, 130.5, 131.2, 132.1, 135.5, 140.7,
146.7, 191.3.

O

Br

N

N-Pentyl-3-(4-bromo-1-naphthoyl)indole (39) (JWH-387).
Method A (VJS-178): To a solution of 0.10 g (0.28 mmol) of 3-(4-bromo-1naphthoyl)indole in 5 mL of DMSO was added 0.07 g (1.3 mmol) of crushed KOH and
0.09 g (0.57 mmol) of 1-bromopentane. After heating at 80 °C for 12 h the reaction was
poured into ice and water, extracted with ethyl acetate, dried (MgSO4) and concentrated
in vacuo. Purification by column chromatography (petroleum ether: ether, 8:2) gave
0.022 g (18%) of N-pentyl-3-(4-bromo-1-naphthoyl)indole as an orange oil:

Method B (VJS-569): Dimethylaluminum chloride (0.60 mL, 1M in hexanes, 0.60 mmol)
was added to a solution of 0.08 g (0.44 mmol) of N-pentylindole in 5 mL of dry
dichloromethane under Ar and the mixture was stirred for 1 h at 0 °C. A solution of
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freshly prepared 4-bromo-1-naphthoyl chloride in 3 mL of dry dichloromethane was
added dropwise via syringe. The acid chloride was prepared by the addition of 3 mL (41
mmol) of thionyl chloride to 0.10 g (0.40 mmol) of 4-bromo-1-naphthoic acid under Ar.
The mixture was refluxed for 2 h, cooled to ambient temperature, and the thionyl chloride
was removed in vacuo to give the acid chloride, which was added to the indole mixture
without further purification. The acid chloride and indole mixture was stirred at ambient
temperature for 4 h. The reaction mixture was quenched with water and extracted with
dichloromethane. The organic extract was washed with water, dried (MgSO4) and the
solvent was removed in vacuo. The crude product was purified by column
chromatography (petroleum ether: ethyl acetate, 9:1) to give 0.09 g (53%) of N-pentyl-3(4-bromo-1-naphthoyl)indole as an orange oil:

1

H NMR (300 MHz, CDCl3) δ 0.87 (t, J = 6.6 Hz, 3H), 1.25-1.31 (m, 4H), 1.80-1.85 (m,

2H), 4.09 (t, J = 7.2 Hz, 2H), 7.28 (s, 1H), 7.35-7.41 (m, 4H), 7.50-7.56 (m, 1H), 7.637.68 (m, 1H), 7.87 (d, J = 7.5 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.36 (d, J = 8.4 Hz, 1H),
8.48-8.51 (m, 1H); 13C NMR (75.5 MHz, CDCl3) δ 13.9, 22.2, 28.9, 29.48, 47.2, 110.1,
117.4, 122.9, 123.0, 123.8, 124.8, 125.8, 126.5, 126.9, 127.4, 127.5, 127.8, 128.8, 132.0,
132.2, 137.1, 137.9, 139.1, 191.0; GC/MS (EI) m/z (rel intensity) 419 (64), 402 (31), 362
(42), 340 (11), 334 (61), 283 (9), 269 (13), 254 (16), 245 (11), 233 (16), 214 (100), 207
(16), 186 (7), 170 (2), 154 (2), 144 (59), 126 (36), 116 (18), 102 (5), 89 (7), 76 (2), 63
(2), 50 (1); HRMS (EI+) m/z calcd for C24H22BrNO: 419.0885; found: 419.0086.
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2-Methyl-N-pentyl-3-(4-bromo-1-naphthoyl) (40) (JWH-394).
Method A (VJS-195): A solution of 0.12 g (0.33 mmol) of 2-methyl-3-(4-bromo-1naphthoyl)indole and 0.08 g (1.48 mmol) of crushed KOH in 5 mL of DMSO was stirred
at ambient temperature for 1 h. To this mixture was added 0.10 g (0.66 mmol) of 1bromopentane and stirring at ambient temperature was continued for 4 h. The reaction
was quenched with water and extracted with ethyl acetate. After being dried (MgSO4)
and concentrated in vacuo the product was purified by column chromatography
(petroleum ether: ether, 8:2) to give 0.014 g (10%) of 2-methyl-N-pentyl-3-(4-bromo-1naphthoyl)indole as a green oil:

Method B (VJS-573): The title compound was prepared using the procedure VJS-569.
From 0.11 g (0.57 mmol) of 2-methyl-N-pentylindole and 0.13 g (0.52 mmol) of 4bromo-1-naphthoic acid there was obtained after column chromatography (petroleum
ether: ethyl acetate, 7:3) 0.16 g (73%) of 2-methyl-N-pentyl-3-(4-bromo-1naphthoyl)indole as a green oil:
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1

H NMR (500 MHz, CDCl3) δ 0.96 (t, J = 7.0 Hz, 3H), 1.39-1.42 (m, 4H), 1.83 (p, J =

7.3 Hz, 2H), 2.55 (s, 3H), 4.15 (t, J = 7.8 Hz, 2H), 7.05 (t, J = 7.3 Hz, 1H), 7.19-7.24 (m,
2H), 7.35 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 7.5 Hz, 1H), 7.52 (t, J = 8.3 Hz, 1H), 7.65 (t, J
= 8.0 Hz, 1H), 7.86 (d, J = 7.5 Hz, 1H), 8.16 (d, J = 8.0 Hz, 1H), 8.39 (d, J = 8.5 Hz, 1H);
13

C NMR (125.77 MHz, CDCl3) δ 12.7, 14.0, 22.4, 29.1, 29.4, 43.4, 109.6, 114.7, 121.1,

122.1, 122.4, 124.8, 125.8, 126.2, 127.0, 127.5, 127.7, 127.8, 129.3, 131.6, 132.3, 136.1,
140.7, 145.9, 192.3; GC/MS (EI) m/z (rel intensity) 433 (100), 418 (93), 404 (7), 377
(31), 354 (98), 348 (27), 312 (9), 298 (40), 283 (18), 269 (22), 254 (42), 233 (80), 213
(15), 207 (47), 177 (14), 158 (64), 149 (42), 126 (71), 115 (19), 103 (13), 89 (4), 77 (9),
63 (2), 55 (4), 50 (2); HRMS (EI+) m/z calcd for C25H24BrNO: 433.1041; found:
433.1041.

O

Br

N

2-Methyl-N-propyl-3-(4-bromo-1-naphthoyl)indole (38) (JWH-395).
Method A (VJS-200): The title compound was prepared using the procedure VJS-195.
From 0.22 g (0.60 mmol) of 2-methyl-N-propyl-3-(4-bromo-1-naphthoyl)indole and 0.15
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g (2.72 mmol) of crushed KOH in 5 mL of DMSO followed by addition of 0.21 g (1.21
mmol) of 1-iodopropane to give after column chromatography (petroleum ether: ether,
7:3) 0.12 g (50%) of 2-methyl-N-propyl-3-(4-bromo-1-naphthoyl)indole as a green solid:
m.p. 51-53 °C:

Method B (VJS-562): The title compound was prepared using the procedure VJS-569.
From 0.08 g (0.48 mmol) of 2-methyl-N-propylindole and 0.11 g (0.45 mmol) of 4bromo-1-naphthoic acid there was obtained after column chromatography (petroleum
ether: ethyl acetate, 8:2) 0.11 g (60%) of 2-methyl-N-propyl-3-(4-bromo-1naphthoyl)indole as a green oil:

1

H NMR (300 MHz, CDCl3) δ 1.02 (t, J = 7.5 Hz, 3H), 1.85 (sextet, J = 7.5 Hz, 2H),

2.54 (s, 3H), 4.11 (t, J = 7.5 Hz, 2H), 7.04 (t, J = 7.2 Hz, 1H), 7.14-7.24 (m, 2H), 7.35 (d,
J = 8.4 Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 7.51 (t, J = 7.2 Hz, 1H), 7.64 (t, J = 7.2 Hz,
1H), 7.86 (d, J = 7.5 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H);

13

C

NMR (75.5 MHz, CDCl3) δ 11.5, 12.7, 22.9, 44.9, 109.7, 114.7, 121.1, 122.1, 122.4,
124.8, 125.8, 126.2, 126.9, 127.5, 127.7, 127.8, 129.3, 131.6, 132.3, 136.2, 140.7, 146.0,
192.3; GC/MS (EI) m/z (rel intensity) 405 (82), 390 (31), 376 (4), 348 (22), 326 (100),
309(24), 296 (11), 283 (18), 269 (18), 254 (18), 235 (29), 213 (11), 200 (69), 158 (49),
149 (27), 126 (53), 103 (11), 89 (4), 77 (9), 63 (2), 50 (2); HRMS (ES+) m/z calcd for
C23H20BrNO: 405.0728; found: 405.0721.
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N-Propyl-3-(4-bromo-1-naphthoyl)indole (37) (JWH-386).
Method A (VJS-174): The title compound was prepared using the procedure VJS-195.
From 0.30 g (0.86 mmol) of N-propyl-3-(4-bromo-1-naphthoyl)indole and 0.22 g (3.8
mmol) of crushed KOH in 5 mL of DMSO followed by addition of 0.31 g (1.8 mmol) of
1-iodopropane was obtained after column chromatography (petroleum ether: ether, 9:1)
0.040 g (12%) of N-propyl-3-(4-bromo-1-naphthoyl)indole as a white solid: m.p. 186-188
°C:

Method B (VJS-574): The title compound was prepared using the procedure VJS-569.
From 0.07 g (0.44 mmol) of N-propylindole and 0.10 g (0.40 mmol) of 4-bromo-1naphthoic acid there was obtained after column chromatography (petroleum ether: ethyl
acetate, 9:1) 0.12 g (72%) of N-propyl-3-(4-bromo-1-naphthoyl)indole as a yellow solid:
m.p. 186-187 °C:
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1

H NMR (300 MHz, DMSO-d6) δ 0.77 (t, J = 7.2 Hz, 3H), 1.72 (sextet, J = 7.2 Hz, 2H),

4.15 (t, J = 6.9 Hz, 2H), 7.32-7.36 (m, 2H), 7.58-7.66 (m, 3H), 7.74 (m, 1H), 7.83 (s,
1H), 8.03 (t, J = 9 Hz, 2H), 8.27 (d, J = 8.4 Hz, 1H), 8.32-8.35 (m, 1H); 13C NMR (75.5
MHz, DMSO-d6) δ 11.4, 23.2, 48.1, 111.6, 116.4, 122.2, 123.1, 123.9, 124.0, 126.6,
126.7, 127.2, 128.2, 128.6, 129.8, 131.8, 131.8, 137.4, 139.3, 140.4, 162.3, 190.4;
GC/MS (EI) m/z (rel intensity) 391 (64), 376 (22), 364 (23), 348 (3), 334 (3), 312 (6),
281 (23), 269 (12), 254 (5), 240 (5), 207 (100), 186 (67), 156 (5), 144 (33), 126 (25), 115
(10), 96 (12), 73 (15), 59 (1); HRMS (EI+) m/z calcd for C22H18BrNO: 391.0572; found:
391.0590.

O

Cl

N

2-Methyl-N-pentyl-3-(4-chloro-1-naphthoyl)indole (44) (JWH-397) (VJS-206).
A solution of 0.15 g (0.47 mmol) of 2-methyl-3-(4-chloro-1-naphthoyl)indole and 0.12 g
(2.1 mmol)of crushed KOH in 5 mL of DMSO was stirred at ambient temperature for 1 h.
To this mixture was added 0.14 g (0.94 mmol) of 1-bromopentane and stirring at ambient
temperature was continued for 6 h. The reaction was quenched with H2O and the product
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was extracted with ethyl acetate. After being dried (MgSO4) and concentrated in vacuo
the product was purified by column chromatography (petroleum ether:ether, 8:2)
resulting in 0.05 g (31%) of 2-methyl-N-pentyl-3-(4-chloro-1-naphthoyl)indole as a
yellow oil: 1H NMR (300 MHz, CDCl3) δ 0.97 (t, J = 6.9 Hz, 3H), 1.37-1.42 (m, 4H),
1.80-1.85 (m, 2H), 2.55 (s, 3H), 4.15 (t, J = 7.5 Hz, 2H), 7.01-7.06 (m, 1H), 7.16-7.24
(m, 2H), 7.35 (d, J = 8.1 Hz, 1H), 7.53 (t, J = 7.2 Hz, 2H), 7.63-7.68 (m, 2H), 8.17 (d, J =
8.4 Hz, 1H), 8.41 (d, J = 8.7 Hz, 1H);

13

C NMR (75.5MHz, CDCl3) δ 12.7, 14.0, 22.4,

29.1, 29.3, 43.4, 109.6, 114.7, 121.1, 122.1, 122.4, 124.7, 125.5, 126.2, 127.0, 127.4,
127.7, 131.1, 131.6, 133.7, 136.1, 139.9, 145.9, 192.4; GC/MS (EI) m/z (rel intensity)
389 (100), 374 (81), 354 (43), 332 (30), 304 (27), 269 (9), 154 (13), 228 (32), 189 (88),
172 (7), 161 (39), 149 (9), 126 (22), 103 (7), 77 (5), 55 (3); HRMS (ES+) m/z calc’d for
C25H24ClNO: 389.1546; found: 389.1541.
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N-Pentyl-3-(4-chloro-1-naphthoyl)indole (43) (JWH-398) (VJS-216).
The title compound was prepared using the procedure VJS-206. From 0.10 g (0.33 mmol)
of 3-(4-chloro-1-naphthoyl)indole and 0.08 g (1.5 mmol) of crushed KOH in 5 mL of
DMSO followed by addition of 0.10 g (0.65 mmol) of 1-bromopentane there was
obtained after column chromatography (petroleum ether:ether, 9:1) 0.06 g (48%) of Npentyl-3-(4-chloro-1-naphthoyl)indole as a brown oil: 1H NMR (500 MHz, CDCl3) δ 0.87
(t, J = 6.8 Hz, 3H), 1.28-1.34 (m, 4H), 1.82-1.86 (m, 2H), 4.09 (t, J = 7.0 Hz, 2H), 7.37
(s, 1H), 7.39-7.42 (m, 3H), 7.56 (t, J = 7.5 Hz, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.65-7.68
(m, 2H), 8.25 (d, J = 8.5 Hz, 1H), 8.40 (d, J = 8.5 Hz, 1H), 8.51-8.53 (m, 1H); 13C NMR
(75.5 MHz, CDCl3) δ 13.9, 22.2, 28.9, 29.5, 47.3, 110.1, 117.4, 122.9, 123.0, 123.8,
124.6, 125.0, 125.6, 126.5, 126.9, 127.5, 127.5, 131.0, 132.0, 133.8, 137.1, 138.0, 138.4,
191.0; GC/MS (EI) m/z (rel intensity) 375 (100), 358 (51), 340 (11), 318 (75), 304 (17),
290 (8), 254 (12), 214 (86), 201 (18), 189 (28), 161 (24), 144 (49), 126 (19), 116 (16), 89
(6), 55 (3); HRMS (ES+) m/z calcd for C24H22ClNO: 375.1390; found: 375.1383
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2-Methyl-N-propyl-3-(4-chloro-1-naphthoyl)indole (42) (JWH-399) (VJS-219).
The title compound was prepared using procedure VJS-206. From 0.12 g (0.37 mmol) of
2-methyl-3-(4-chloro-1-naphthoyl)indole and 0.09 g (1.69 mmol) of crushed KOH in 5
mL of DMSO followed by addition of 0.13 g (0.75 mmol)of 1-iodopropane there was
obtained after column chromatography (petroleum ether:ether; 1:1) 0.06 g (46%) of 2methyl-N-propyl-3-(4-chloro-1-naphthoyl)indole as a brown oil: 1H NMR (300 MHz,
CDCl3) δ 1.02 (t, J = 7.2 Hz, 3H), 1.86 (sextet, J = 7.5 Hz, 2H), 2.54 (s, 3H), 4.13 (t, J =
7.2 Hz, 2H), 7.03 (t, J = 7.2 Hz, 1H), 7.16-7.23 (m, 2H), 7.35 (d, J = 8.4 Hz, 1H), 7.52 (t,
J = 7.5 Hz, 2H), 7.63-7.68 (m, 2H), 8.17 (d, J = 8.4 Hz, 1H), 8.41 (d, J = 8.4 Hz, 1H); 13C
NMR (75.5 MHz, CDCl3) δ 11.5, 12.7, 22.9, 44.9, 109.6, 114.7, 121.1, 122.1, 122.4,
124.7, 125.5, 126.1,126.9, 127.5, 127.7, 131.1, 131.6, 133.7, 136.2, 139.8, 145.9, 192.4;
GC/MS (EI) m/z (rel intensity) 361 (100), 346 (26), 326 (56), 304 (29), 283 (7), 269 (8),
254 (11), 200 (38), 189 (35), 158 (31), 149 (6), 126 (19), 103 (8), 89 (3), 77 (5), 63 (2),
50 (1); HRMS (ES+) m/z calcd for C23H20ClNO: 361.1233; found: 361.1232.
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N-Propyl-3-(4-chloro-1-naphthoyl)indole (41) (JWH-400) (VJS-214).
Method A (VJS-214): The title compound was prepared using procedure VJS-206. From
0.16 g (0.52 mmol) of 3-(4-chloro-1-naphthoyl)indole and 0.13 g (2.35 mmol) of crushed
KOH in 5 mL of DMSO followed by addition of 0.18 g (1.05 mmol) of 1-iodpropane was
filtered 0.03 g (15%) of N-propyl-3-(4-chloro-1-naphthoyl)indole as a white solid:

Method B (VJS-575): Dimethylaluminum chloride (1.10 mL, 1M in hexanes, 1.1 mmol)
was added to a solution of 0.13 g (0.80 mmol) of N-propylindole in 5 mL of dry
dichloromethane under Ar and the mixture was stirred for 1 h at 0 °C. A solution of
freshly prepared 4-chloro-1-naphthoyl chloride in 3 mL of dry dichloromethane was
added dropwise via syringe. The acid chloride was prepared by the addition of 3 mL (41
mmol) of thionyl chloride to 0.15 g (0.73 mmol) of 4-chloro-1-naphthoic acid under Ar.
The mixture was refluxed for 2 h, cooled to ambient temperature, and the thionyl chloride
was removed in vacuo to give the acid chloride, which was added to the indole mixture
without further purification. The acid chloride and indole mixture was stirred at ambient
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temperature for 4 h. The reaction mixture was quenched with water and extracted with
dichloromethane. The organic extract was washed with water, dried (MgSO4) and the
solvent was removed in vacuo. The crude product was purified by column
chromatography (petroleum ether: ethyl acetate, 7:3) to give 0.04 g (15%) of N-propyl-3(4-bromo-1-naphthoyl)indole as a tan solid: m.p. 194-195 °C.

1

H NMR (500 MHz, DMSO-d6) δ 0.79 (t, J = 7.3 Hz, 3H), 1.73 (sextet, J = 7.3 Hz, 2H),

4.17 (t, J = 7.0 Hz, 2H), 7.33-7.36 (m, 2H), 7.63-7.69 (m, 3H), 7.76 (t, J = 7.5 Hz, 1H),
7.83-8.84 (m, 2H), 8.07 (d, J = 8.0 Hz, 1H), 8.33 (t, J = 8.5 Hz, 2H); 13C NMR (125.77
MHz, DMSO-d6) 11.4, 23.2, 48.2, 111.6, 116.4, 122.2, 123.1, 123.9, 124.5, 126.1, 126.3,
126.5, 126.8, 128.3, 128.4, 130.6, 131.8, 132.5, 137.4, 138.7, 140.4, 190.4; GC/MS (EI)
m/z (rel intensity) 347 (96), 330 (41), 318 (54), 304 (15), 281 (17), 269 (16), 254 (13),
241 (11), 226 (3), 207 (22), 186 (100), 161 (22), 144 (63), 126 (26), 116 (28), 102 (4), 89
(13), 73 (22), 57 (4), 51 (2); HRMS (EI+) calcd for C22H18ClNO: 347.1077; found:
347.0927.
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N-pentyl-3-(4-iodo-1-naphthoyl)indole (47) (JWH-421) (VJS-254).
Dimethylaluminum chloride (0.73 mL, 1M in hexanes, 0.73 mmol) was added to a
solution of 0.13 g (0.67 mmol) of N-pentylindole in 5 mL of dry dichloromethane under
Ar and the mixture was stirred for 1 h at 0 °C. A solution of freshly prepared 4-iodo-1naphthoyl chloride in 3 mL of dry dichloromethane was added dropwise via syringe. The
acid chloride was prepared by the addition of 3 mL (41 mmol) of thionyl chloride to 0.20
g (0.67 mmol) of 4-iodo-1-naphthoic acid under Ar. The mixture was refluxed for 2 h,
cooled to ambient temperature, and the thionyl chloride was removed in vacuo to give the
acid chloride, which was added to the indole mixture without further purification. The
acid chloride and indole mixture was stirred at ambient temperature overnight. The
reaction mixture was quenched with water and extracted with ether. The ethereal solution
was washed with water, dried (MgSO4) and the solvent was removed in vacuo. The crude
product was purified by column chromatography (petroleum ether: ether, 1:1) to give
0.047 g (15%) of N-pentyl-3-(4-iodo-1-naphthoyl)indole as a peach colored oil: 1H NMR
(500 MHz, CDCl3) δ 0.89 (t, J = 7.5 Hz, 3H), 1.30-1.36 (m, 4H), 1.83-1.86 (m, 2H), 4.08
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(t, J = 7.5 Hz, 2H), 7.35 (s, 1H), 7.36-7.42 (m, 4H), 7.51 (t, J = 8 Hz, 1H), 7.62 (t, J = 8
Hz, 1H), 8.15 (d, J = 8.5 Hz, 1H), 8.19 (d, J = 7 Hz, 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.488.50 (m, 1H);

13

C NMR (75.5 MHz, CDCl3) δ 13.9, 22.2, 28.9, 29.5, 47.3, 101.9, 110.1,

117.5, 122.9, 123.0, 123.8, 126.3, 126.7, 126.9, 127.6, 128.2, 131.4, 132.5, 134.5, 136.4,
137.1, 138.0, 140.1, 191.0; GC/MS (EI) m/z (rel intensity) 467 (33), 450 (14), 410 (21),
380 (2), 340 (7), 324 (1), 281 (36), 240 (15), 214 (100), 191 (8), 170 (5), 144 (53), 126
(43), 89 (9), 73 (5), 55 (3); HRMS (ES+) m/z calcd for C24H22INO: 468.0824; found:
468.0811.
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N

2-Methyl-N-pentyl-3-(4-iodo-1-naphthoyl)indole (48) (JWH-420) (VJS-255).
The title compound was prepared using the procedure VJS-254. From 0.10 g (0.50 mmol)
of 2-methyl-N-pentylindole and 0.15 g (0.50 mmol) of 4-iodo-1-naphthoic acid there was
obtained after column chromatography (petroleum ether: ether, 7:3) 0.065 g (27%) of 2methyl-N-pentyl-3-(4-iodo-1-naphthoyl)indole as a brown oil: 1H NMR (500 MHz,
CDCl3) δ 0.95 (t, J = 6.8 Hz, 3H), 1.39-1.42 (m, 4H), 1.81-1.84 (m, 2H), 2.55 (s, 3H),
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4.15 (t, J = 7.5 Hz, 2H), 7.05 (t, J = 7.5 Hz, 1H), 7.19 (d, J = 8 Hz, 1H), 7.22 (t, J =7.5
Hz, 1H), 7.28-7.29 (m, 1H), 7.35 (d, J = 8 Hz, 1H), 7.50 (t, J = 7.5 Hz, 1H), 7.62 (t, J = 8
Hz, 1H), 8.08 (d, J = 8.5 Hz, 1H), 8.17 (d, J = 7.5 Hz, 1H), 8.23 (d, J = 8.5 Hz, 1H); 13C
NMR (125.77 MHz, CDCl3) δ 12.7, 13.9, 22.4, 29.1, 29.3, 43.4, 101.7, 109.6, 114.7,
121.1, 122.2, 122.4, 126.2, 126.3, 126.9, 127.7, 128.1, 131.0, 132.6, 134.6, 136.1, 136.9,
141.6, 145.9, 192.3; GC/MS (EI) m/z (rel intensity) 481 (100), 466 (62), 425 (17), 396
(12), 354 (48), 337 (7), 312 (2), 298 (17), 281 (41), 269 (8), 254 (16), 228 (30), 213 (9),
177 (7), 158 (27), 126 (46), 115 (6), 103 (4), 77 (3), 63 (1), 50 (1); HRMS (ES+) m/z
calcd for C25H24INO: 482.0981; found: 482.0987.

O
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N

2-methyl-N-propyl-3-(4-iodo-1-naphthoyl)indole (46) (JWH-422) (VJS-256).
The title compound was prepared using procedure VJS-254. From 0.12 g (0.67 mmol) of
2-methyl-N-propylindole and 0.20 g (0.67 mmol) of 4-iodo-1-naphthoic acid there was
obtained after column chromatography (petroleum ether: ether, 7:3) 0.039 g (13%) of 2-
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methyl-N-propyl-3-(4-iodo-1-naphthoyl)indole as a green oil: 1H NMR (500 MHz,
CDCl3) δ 1.03 (t, J = 7.5 Hz, 3H), 1.86 (sextet, J = 7.5 Hz, 2H), 2.55 (s, 3H), 4.14 (t, J =
7.5 Hz, 2H), 7.04 (t, J = 8 Hz, 1H), 7.18 (d, J = 8 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 7.28
(d, J = 7.5 Hz, 1H), 7.35 (d, J = 8.5 Hz, 1H), 7.49 (t, J = 7.8 Hz, 1H), 7.62 (t, J = 7.8 Hz,
1H), 8.07 (d, J = 8.5 Hz, 1H), 8.17 (d, J = 7 Hz, 1H), 8.23 (d, J = 8.5 Hz, 1H); 13C NMR
(125.77 MHz, CDCl3) δ 11.5, 12.7, 22.9, 44.9, 101.7, 109.6, 114.7, 121.1, 122.1, 122.4,
126.1, 126.3, 126.9, 127.7, 128.1, 131.0, 132.5, 134.6, 136.2, 136.9, 141.6, 145.9, 192.3;
GC/MS (EI) m/z (rel intensity) 453 (100), 436 (15), 424 (5), 410 (2), 396 (14), 326 (58),
309 (10), 296 (7), 281 (18), 269 (8), 254 (12), 200 (36), 158 (25), 149 (17), 126 (35), 115
(6), 103 (6), 77 (4), 63 (2), 50 (1); HRMS (ES+) m/z calcd for C23H20INO: 454.0668;
found: 454.0665.
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N-propyl-3-(4-iodo-1-naphthoyl)indole (45) (JWH-423) (VJS-257).
The title compound was prepared using procedure VJS-254. From 0.11 g (0.70 mmol) of
N-propylindole and 0.21 g (0.70 mmol) of 4-iodo-1-naphthoic acid there was obtained
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after column chromatography (petroleum ether:ethyl acetate, 9:1) 0.022 g (7%) of Npropyl-3-(4-iodo-1-naphthoyl)indole as a pale cream powder: m.p. 160-161 °C; 1H NMR
(500 MHz, CDCl3) δ 0.79 (t, J = 7 Hz, 3H), 1.72-1.76 (m, 2H), 4.17 (t, J = 7 Hz, 2H),
7.33-7.35 (m, 2H), 7.43 (d, J = 7 Hz, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.64 (d, J = 7 Hz, 1H),
7.71 (t, J = 7.5 Hz, 1H), 7.81 (s, 1H), 7.98 (d, J = 8 Hz, 1H), 8.15 (d, J = 8.5 Hz, 1H),
8.28 (d, J = 7.5 Hz, 1H), 8.32 (d, J = 6.5 Hz, 1H);

13

C NMR (125.77 MHz, CDCl3) δ

11.3, 23.1, 48.9, 101.9, 110.1, 117.5, 122.9, 123.0, 123.8, 126.3, 126.7, 126.9, 127.6,
128.2, 131.4, 132.5, 134.5, 136.4, 137.1, 138.0, 140.1, 191.0; GC/MS (EI) m/z (rel
intensity) 439 (100), 422 (37), 410 (40), 396 (5), 382 (3), 312 (9), 293 (12), 269 (10), 254
(11), 240 (8), 213 (6), 186 (83), 156 (4), 144 (41), 126 (31), 116 (18), 102 (3), 89 (6), 76
(3), 62 (2), 50 (1); HRMS (ES+) m/z calcd for C22H18INO: 440.0511; found: 440.0526.
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N-pentyl-3-(4-fluoro-1-naphthoyl)indole (51) (JWH-412) (VJS-233).
Dimethylaluminum chloride (0.60 mL, 1M in hexanes, 0.60 mmol) was added to a
solution of 0.07 g (0.38 mmol) of N-pentylindole in 5 mL of dry dichloromethane under
Ar and the mixture was stirred for 30 min at 0 °C. A solution of freshly prepared 4fluoro-1-naphthoyl chloride in 3 mL of dry dichloromethane was added dropwise via
syringe. The acid chloride was prepared by the addition of 3 mL (41 mmol) of thionyl
chloride to 0.11 g (0.58 mmol) of 4-fluoro-1-naphthoic acid under Ar. The mixture was
refluxed for 2 h, cooled to ambient temperature, and the thionyl chloride was removed in
vacuo to give the acid chloride, which was added to the indole mixture without further
purification. This acid chloride and indole mixture was stirred at ambient temperature
overnight. The reaction was quenched with water and extracted with ether. The ethereal
solution was washed with water and 1 M KOH, dried (MgSO4) and the solvent was
removed in vacuo to give the crude product, which was purified by column
chromatography (petroleum ether: ether, 7:3) to give 0.021 g (10%) of N-pentyl-3-(4fluoro-1-naphthoyl)indole as a brown oil: 1H NMR (500 MHz, CDCl3) δ 0.89 (t, J = 7
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Hz, 3H), 1.28-1.35 (m, 4H), 1.85 (p, J = 7 Hz, 2H), 4.11 (t, J = 7 Hz, 2H), 7.22 (dd, J =
8, 10 Hz, 1H), 7.38-7.40 (m, 3H), 7.42-7.43 (m, 1H), 7.56 (t, J = 7 Hz, 1H), 7.61 (t, J = 7
Hz, 1H), 7.66 (dd, J = 5.5, 8 Hz, 1H), 8.21 (d, J = 8 Hz, 1H), 8.28 (d, J = 8.5 Hz, 1H),
8.48-8.50 (m, 1H); 13C NMR (125.77 MHz, CDCl3) δ 13.9, 22.2, 28.9, 29.5, 47.2, 108.1,
108.3, 110.0, 117.5, 120.6, 120.7, 122.9, 122.9, 123.7, 126.0, 126.4, 126.7, 127.0, 127.8,
132.6, 137.1, 137.7, 191.0; GC/MS (EI) m/z (rel intensity) 359 (50), 343 (22), 327 (2),
302 (54), 281 (26), 259 (8), 244 (2), 222 (24), 207 (100), 191 (9), 173 (36), 145 (34), 125
(9), 96 (8), 73 (32), 55 (1); HRMS (ES+) m/z calcd for C24H22FNO: 359.1685; found:
359.1679.
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2-Methyl-N-pentyl-3-(4-fluoro-1-naphthoyl)indole (52) (JWH-413) (VJS-235).
The title compound was prepared using the procedure VJS-233. From 0.10 g (0.48 mmol)
of 2-methyl-N-pentylindole and 0.14 g (0.74 mmol) of 4-fluoro-1-naphthoic acid there
was obtained after column chromatography (petroleum ether: ether, 9:1) 0.022 g (12%) of
2-methyl-N-pentyl-3-(4-fluoro-1-naphthoyl)indole as a green oil: 1H NMR (500 MHz,
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CDCl3) δ 0.95 (t, J = 7 Hz, 3H), 1.41-1.42 (m, 4H), 1.81-1.85 (m, 2H), 2.56 (s, 3H), 4.16
(t, J = 7.5 Hz, 2H), 7.03 (d, J = 8 Hz, 1H), 7.15-7.22 (m, 4H), 7.34 (d, J = 8.5 Hz, 1H),
7.54-7.60 (m, 3H), 8.22 (d, J = 9 Hz, 1H); 13C NMR (125.77 MHz, CDCl3) δ 12.6, 13.9,
22.4, 29.1, 29.4, 43.4, 108.6, 108.8, 109.5, 114.9, 120.7, 120.7, 121.1, 121.9, 122.2,
123.9, 124.1, 125.7, 126.6, 126.7, 127.1, 127.9, 136.1, 145.5, 192.4; GC/MS (EI) m/z (rel
intensity) 373 (74), 358 (45), 341 (9), 316 (44), 300 (10), 281 (35), 259 (8), 228 (12), 207
(49), 173 (100), 145 (55), 125 (11), 103 (4), 73 (59), 55 (2); HRMS (ES+) m/z calcd for
C25H24FNO: 373.1842; found: 373.1850.
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N

2-methyl-N-propyl-3-(4-fluoro-1-naphthoyl)indole (50) (JWH-415) (VJS-239).
The title compound was prepared using procedure VJS-233. From 0.08 g (0.45 mmol) of
2-methyl-N-propylindole and 0.13 g (0.68 mmol) of 4-fluoro-1-naphthoic acid there was
obtained after column chromatography (petroleum ether: ether, 8:2) 0.89 g (56%) of 2methyl-N-propyl-3-(4-fluoro-1-naphthoyl)indole as a yellow oil: 1H NMR (500 MHz,
CDCl3) δ 0.98 (t, J = 7.5 Hz, 3H), 1.82 (sextet, J = 7.5 Hz, 2H), 2.51 (s, 3H), 4.09 (t, J =
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7.5 Hz, 2H), 6.99 (t, J = 7.5 Hz, 1H), 7.16 (q, J =8.3 Hz, 3H), 7.31 (d, J =8.3 Hz, 1H),
7.50 (t, J = 7.4 Hz, 1H), 7.53-7.56 (m, 2H), 8.17-8.20 (m, 2H); 13C NMR (125.77 MHz,
CDCl3) δ 11.5, 12.6, 23.0, 44.9, 108.7, 108.8, 109.6, 114.9, 120.7, 120.8, 121.1, 121.9,
122.3, 125.7, 126.7, 126.7, 127.1, 127.9, 136.1, 136.5, 145.6, 190.5; GC/MS (EI) m/z (rel
intensity) 345 (100), 328 (34), 303 (14), 288 (47), 272 (10), 233 (7), 200 (37), 173 (73),
145 (51), 125 (9), 103 (7), 77 (4), 51 (2); HRMS (ES+) m/z calcd for C23H20FNO:
345.1529; found: 345.1531.
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N-propyl-3-(4-fluoro-1-naphthoyl)indole (49) (JWH-414) (VJS-238).
The title compound was prepared using procedure VJS-233. From 0.07 g (0.44 mmol) of
N-propylindole and 0.12g (0.63 mmol) of 4-fluoro-1-naphthoic acid there was obtained
after column chromatography (petroleum ether: ether, 8:2) 0.076 g (52%) of N-propyl-3(4-fluoro-1-naphthoyl)indole as a tan solid: m.p. 166–167 °C; 1H NMR (500 MHz,
CDCl3) δ 0.94 (t, J =7.3 Hz, 3H), 1.87 (sextet, J = 7.3 Hz, 2H), 4.09 (t, J = 7 Hz, 2H),
7.21 (t, J =8.8 Hz, 1H), 7.40-7.43 (m, 4H), 7.57 (t, J = 7Hz, 1H), 7.62 (t, J = 7 Hz, 1H),
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7.66 (t, J = 6.5 Hz, 1H), 8.22 (d, J = 8 Hz, 1H), 8.29 (d, J = 8 Hz, 1H), 8.51-8.53 (m, 1H);
13

C NMR (125.77 MHz, CDCl3) δ 11.3, 23.1, 48.8, 108.1, 108.3, 110.1, 117.5, 120.7,

120.7, 122.9, 122.9, 123.7, 126.0, 126.4, 126.4, 126.7, 127.0, 127.8, 137.1, 137.8, 191.1;
GC/MS (EI) m/z (rel intensity) 331 (100), 302 (66), 274 (12), 259 (9), 231 (7), 207 (23),
186 (95), 165 (3), 144 (47), 116 (22), 89 (8), 63 (2); HRMS (ES+) m/z calcd for
C22H18FNO: 331.1372; found: 331.1367.

O

O
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Anhydro-8-(hydroxymercuri)-1-naphthoic acid (53) (VJS-240).
To 7.0 g (0.18 mol) of NaOH in 300 mL of water was added 10.0 g (0.05 mol) of 1,8naphthalic anhydride and the suspension was refluxed until dissolution occurred. The
excess NaOH was neutralized with 5 mL of acetic acid and 16.1 g (0.05 mol) of mercuric
acetate and 50 mL of water were added in one portion. The slurry was refluxed for 30
min and 9 mL of acetic acid was added to ensure evolution of CO2. The reaction was
refluxed for 48 h, cooled and filtered to give 18.0 g (96%) of anhydro-8-hydroxymercuri1-naphthoic acid as a cream colored solid, which was used without further purification.
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8-Bromo-1-naphthoic acid (54) (VJS-258).
To a stirring mixture of 3.9 mL (67 mmol) of acetic acid and 0.40 mL (22.2 mmol) of
H2O was added 1.0 g (2.70 mmol) of anhydro-8-hydroxymercuri-1-naphthoic acid and
the suspension was stirred at 0 °C for 10 min. A solution of 0.89 g (8.66 mmol) of NaBr
in 3.2 mL of water and 0.43 g (2.70 mmol) of bromine were added sequentially and the
reaction was slowly heated to 100 °C. After cooling to ambient temperature the mixture
was poured into ice and 0.57 g (84%) of 8-bromo-1-naphthoic acid was filtered out as a
cream colored solid: m.p. 173-174 °C (lit. m.p.58 174-175 °C); 1H NMR (500 MHz,
DMSO-d6) δ 7.49 (t, J = 7.8 Hz, 1H), 7.61 (t, J = 7.3 Hz, 1H), 7.68 (d, J = 7.0 Hz, 1H),
7.96 (d, J = 7.3 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 8.11 (d, J = 8.0 Hz, 1H), 13.32 (s, 1H);
13

C NMR (125.77 MHz, DMSO-d6) δ 119.3, 126.3, 127.6, 128.0, 128.3, 129.4, 131.2,

133.6, 133.9, 135.7, 171.3.
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N-Pentyl-3-(8-bromo-1-naphthoyl)indole (62) (JWH-424) (VJS-259).
Dimethylaluminum chloride (0.90 mL, 1M in hexanes, 0.90 mmol) was added to a
solution of 0.12 g (0.66 mmol) of N-pentylindole in 5 mL of dry dichloromethane under
Ar and the mixture was stirred for 1 h at 0 °C. A solution of freshly prepared 8-bromo-1naphthoyl chloride in 3 mL of dry dichloromethane was added dropwise via syringe. The
acid chloride was prepared by the addition of 3 mL (41 mmol) of thionyl chloride to 0.15
g (0.60 mmol) of 8-bromo-1-naphthoic acid under Ar. The mixture was refluxed for 2 h,
cooled to ambient temperature, and the thionyl chloride was removed in vacuo to give the
acid chloride, which was added to the indole mixture without further purification. The
acid chloride and indole mixture was stirred at ambient temperature overnight. The
reaction mixture was quenched with water and extracted with dichloromethane. The
organic extract was washed with water, dried (MgSO4) and the solvent was removed in
vacuo. The crude product was purified by column chromatography (petroleum ether:ethyl
acetate, 7:3) to give 0.20 g (78%) of N-pentyl-3-(8-bromo-1-naphthoyl)indole as a brown
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oil: GC/MS (EI) m/z (rel intensity) 421 (3), 340 (100), 270 (58), 254 (5), 235 (1), 214 (5),
144 (5), 126 (7), 89 (1), 74 (1), 55 (1); HRMS (ES+) m/z calcd for C24H22BrNO:
420.0963; found: 420.0959.

Ambient Temperature: 1H NMR (500 MHz, DMSO-d6) δ 0.86 (t, J = 7.0 Hz, 3H), 1.221.32 (m, 4H), 1.77-1.81 (m, 2H), 4.00-4.02 (m, 2H), 7.19-7.29 (m, 1H), 7.31-7.43 (m,
4H), 7.53 (t, J = 7.5 Hz, 1H), 7.62 (d, J = 7.0 Hz, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.96 (d, J
= 8.0 Hz, 1H); 13C NMR (75.5 MHz, CDCl3) δ 14.0, 22.2, 28.8, 29.4, 47.1, 110.1, 119.3,
120.2, 122.7, 122.8, 123.5, 125.4, 126.7, 126.9, 128.1, 128.7, 129.5, 130.4, 133.1, 136.0,
137.1, 137.3, 140.1, 192.3.

At 35 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.78 (t, J = 7.0 Hz, 3H), 2.18 (dp, J = 7.5,
36.5 Hz, 4H), 1.69-1.71 (m, 2H), 4.12-4.22 (m, 2H), 7.26 (t, J = 7.5 Hz, 1H), 7.32 (t, J =
7.8 Hz, 1H), 7.49 (t, J = 7.8 Hz, 1H), 7.56 (s, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.67 (t, J =
8.0 Hz, 1H), 7.87 (d, J = 7.5 Hz, 1H), 8.12 (d, J = 8.0 Hz, 1H), 8.16 (d, J = 8.0 Hz, 1H).

At 50 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.79 (t, J = 7.3 Hz, 3H), 1.19 (dp, J = 7.5,
36.5 Hz, 4H), 1.72 (p, J = 7.5 Hz, 2H), 4.17-4.19 (m, 2H), 7.26 (t, J = 7.5 Hz, 1H), 7.31
(t, J = 7.5 Hz, 1H), 7.49 (t, J = 7.8 Hz, 1H), 7.55 (s, 1H), 7.58-7.61 (m, 2H), 7.67 (t, J =
7.0 Hz, 1H), 7.87 (d, J = 7.5 Hz, 1H), 8.11 (d, J = 8.0 Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H),
8.19 (br s, ½H).
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At 75 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.80 (t, J = 7.0 Hz, 3H), 1.17-1.28 (m, 4H),
1.74 (t, J = 7.3 Hz, 2H), 4.18 (t, J = 7.0 Hz, 2H), 7.26 (t, J =7.3 Hz, 1H), 7.31 (t, J = 7.5
Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.51 (s, 1H), 7.57-7.61 (m, 2H), 7.66 (t, J = 7.8 Hz,
1H), 7.86 (d, J = 7.5 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 8.14-8.17 (m, 2H).
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2-Methyl-N-pentyl-3-(8-bromo-1-naphthoyl)indole (63) (JWH-425) (VJS-260).
The title compound was prepared using the procedure VJS-259. From 0.13 g (0.66 mmol)
of 2-methyl-N-pentylindole and 0.15 g (0.60 mmol) of 8-bromo-1-naphthoic acid there
was obtained after column chromatography (petroleum ether: ethyl acetate, 9:1) 0.04 g
(15%) of 2-methyl-N-pentyl-3-(8-bromo-1-naphthoyl)indole as a brown oil: GC/MS (EI)
m/z (rel intensity) 433 (6), 354 (78), 284 (100), 269 (28), 254 (13), 233 (5), 213 (7), 177
(3), 158 (5), 126 (9), 115 (3), 103 (1), 89 (1), 77 (1), 55(1); HRMS (ES+) m/z calcd for
C25H24BrNO: 434.1120; found: 434.1128.
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Ambient Temperature: 1H NMR (500 MHz, DMSO-d6) δ 0.83-0.88 (m, 3H), 1.25-1.34
(m, 4H), 1.64-1.77 (m, 2H), 2.91 (s, 1½H), 4.21-4.27 (m, 2H), 5.89 (br s, ½H), 6.67 (br s,
½H), 7.04 (br s, ½H), 7.27 (br s, 1H), 7.48-7.52 (m, 2 ½H), 7.65 (t, J = 7.5 Hz, 1H), 7.867.91 (m, 1H), 8.13-8.17 (m, 1 ½H), 8.41 (br s, ½H); 13C NMR (125.77 MHz, DMSO-d6)
δ 12.7, 14.0, 22.4, 29.1, 29.4, 43.4, 109.7, 120.1, 121.4, 121.7, 122.7, 125.9, 126.6, 127.4,
127.5, 128.6, 130.1, 132.9, 133.4, 135.4, 136.1, 142.2, 144.3, 146.0, 193.5.

At 35 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.86 (br s, 3H), 1.24-1.34 (m, 4H), 1.67-1.78
(m, 2H), 2.92 (br s, 1½H), 4.16-4.27 (m, 2H), 5.93 (br s, ½H), 6.68 (br s, ½H), 7.04 (br s,
½H), 7.27 (br s, ¾H), 7.46-7.53 (m, 3H), 7.65 (t, J = 7.8 Hz, 1H), 7.88 (br s, 1H), 8.128.17 (m, 2H), 8.44 (br s, ¼H).

At 50 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.86 (br s, 3H), 1.32 (br s, 4H), 2.92 (br s,
1H), 4.22 (br s, 2H), 7.10-7.30 (m, 1½H), 7.46-7.52 (m, 3H), 7.65 (t, J = 7.8 Hz, 1H),
7.87-7.88 (m, 1H), 8.12 (d, J = 8.0 Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H), 8.44 (br s, ¼H).

At 75 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.87 (t, J = 6.8 Hz, 3H), 1.33-1.34 (m, 4H),
1.72-1.74 (m, 2H), 4.21 (t, J = 7.0 Hz, 2H), 7.15 (br s, 1H), 7.46-7.50 (m, 3H), 7.65 (t, J
= 7.8 Hz, 1H), 7.86 (d, J = 7.0 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1H).

At 100 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.88 (t, J = 7.0 Hz, 3H), 1.34-1.36 (m,
4H), 1.75 (p, J = 7.0 Hz, 2H), 4.22 (t, J = 7.5 Hz, 2H), 6.45 (br s, 1H), 7.15 (t, J = 7.3
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Hz, 1H), 7.47 (q, J = 7.3 Hz, 3H), 7.64 (t, J = 7.8 Hz, 1H), 7.86 (d, J = 7.5 Hz, 1H), 8.09
(d, J = 8.0 Hz, 1H), 8.13 (d, J = 7.0 Hz, 1H).

Br
O

N

N-Propyl-3-(8-bromo-1-naphthoyl)indole (60) (JWH-428) (VJS-262).
The title compound was prepared using the procedure VJS-259. From 0.08 g (0.53 mmol)
of N-propylindole and 0.12 g (0.48 mmol) of 8-bromo-1-naphthoic acid there was
obtained after column chromatography (petroleum ether: ethyl acetate, 8:2) 0.09 g (48%)
of N-propyl-3-(8-bromo-1-naphthoyl)indole as an orange solid: m.p. 101-102 °C; GC/MS
(EI) m/z (rel intensity) 391 (10), 312 (100), 296 (2), 282 (19), 270 (99), 254 (26), 241
(25), 226 (10), 213 (15), 207 (6), 186 (31), 156 (16), 144 (42), 126 (38), 116 (29), 101
(7), 89 (14), 75 (6), 63 (4), 50 (1); HRMS (ES+) m/z calcd for C22H18BrNO: 392.0650;
found: 392.0637.

Ambient Temperature: 1H NMR (500 MHz, DMSO-d6) δ 0.74 (t, J = 7.0 Hz, 3H), 1.71
(q, J = 7.0 Hz, 2H), 4.14-4.18 (m, 2H), 7.27-7.33 (m, 2H), 7.49 (t, J = 8.0 Hz, 1H), 7.61
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(t, J = 7.0 Hz, 2H), 7.67 (t, J = 7.5 Hz, 1H), 7.88 (d, J = 7.0 Hz, 1H), 8.12 (d, J = 8.0 Hz,
1H), 8.16 (d, J = 8.0 Hz, 1H);

13

C NMR (125.77 MHz, DMSO-d6) δ 11.3, 23.1, 48.0,

111.4, 118.3, 119.6, 122.1, 122.7, 123.5, 126.2, 126.8, 127.4, 128.4, 129.1, 129.5, 130.7,
133.5, 136.1, 137.3, 139.0, 140.0, 191.5.

At 35 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.77 (t, J = 7.5 Hz, 3H), 1.72 (q, J = 7.0 Hz,
2H), 4.15-4.17 (m, 2H), 7.26-7.32 (m, 2H), 7.48 (t, J = 8.0 Hz, 1H), 7.60-7.62 (m, 3H),
7.66 (t, J = 7.5 Hz, 1H), 7.87 (d, J = 7.5 Hz, 1H), 8.12 (d, J = 8.0 Hz, 1H), 8.16 (d, J =
9.5 Hz, 1H).

At 50 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.78 (t, J = 7.5 Hz, 3H), 1.74 (q, J = 7.0 Hz,
2H), 4.16 (br s, 2H), 7.26 (t, J = 7.5 Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.5 Hz,
1H), 7.56 (s, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.66 (t, J = 8.0 Hz, 1H), 7.87 (d, J = 7.5 Hz,
1H), 8.11 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H).

At 75 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.81 (t, J = 7.5 Hz, 3H), 1.76 (sextet, J = 7.0
Hz, 2H), 4.15 (t, J = 7.0 Hz, 2H), 7.25 (t, J = 7.5 Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 7.47
(t, J = 7.5 Hz, 1H), 7.52 (s, 1H), 7.59 (t, J = 8.5 Hz, 2H), 7.66 (t, J = 7.5 Hz, H), 7.86 (d,
J = 7.0 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 8.13-8.17 (m, 2H).

At 100 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.82 (t, J = 7.3 Hz, 3H), 1.78 (sextet, J =
7.3 Hz, 2H), 4.15 (t, J = 7.5 Hz, 2H), 7.24 (t, J = 7.5 Hz, 1H), 7.29 (t, J = 7.5 Hz, 1H),
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7.45 (d, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.60 (d, J = 7.0 Hz, 1H),
7.65 (t, J = 7.5 Hz, 1H), 7.86 (d, J = 7.5 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 8.13 (t, J = 7.8
Hz, 2H).

Br
O

N

2-Methyl-N-propyl-3-(8-bromo-1-naphthoyl)indole (61) (JWH-429) (VJS-261).
The title compound was prepared using the procedure VJS-259. From 0.13 g (0.66 mmol)
of 2-methyl-N-propylindole and 0.15 g (0.60 mmol) of 8-bromo-1-naphthoic acid there
was obtained after column chromatography (petroleum ether: ethyl acetate, 8:2) 0.04 g
(16%) of 2-methyl-N-propyl-3-(8-bromo-1-naphthoyl)indole as a green oil: GC/MS (EI)
m/z (rel intensity) 405 (10), 326 (100), 311 (1), 284 (79), 269 (31), 254 (16), 226 (4), 200
(9), 158 (9), 142 (2), 126 (13), 103 (3), 77 (2), 51 (1); HRMS (ES+) m/z calcd for
C23H20BrNO: 406.0807; found:406.0788.

Ambient Temperature: 1H NMR (500 MHz, DMSO-d6) δ 0.81-0.90 (m, 3H), 1.65-1.76
(m, 2H), 2.89 (s, 1½H), 4.23-4.24 (m, 2H), 6.63-6.66 (m, ½H), 7.01-7.03 (m, ½H), 7.26-

141

7.27 (m, ½H), 7.43-7.54 (m, 2½H), 7.64 (t, J = 7.5 Hz, 1H), 7.83-7.91 (m, 1H), 8.11-8.17
(m, 2H), 8.39 (br s, ½H);

13

C NMR (75.5 MHz, DMSO-d6) δ 11.5, 14.3, 23.0, 44.7,

109.5, 120.0, 120.2, 121.4, 121.6, 122.7, 125.9, 126.6, 127.4, 127.7, 128.6, 129.2, 130.16,
132.9, 136.1, 142.2, 144.4, 146.0, 193.5.

At 35 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.81-0.90 (m, 3H), 1.65-1.76 (m, 2H), 2.89
(s, 1½H), 4.23-4.24 (m, 2H), 6.63-6.66 (m, ½H), 7.01-7.03 (m, ½H), 7.26-7.27 (m, ½H),
7.43-7.50 (m, 2½H), 7.65 (t, J = 7.5 Hz, 1H), 7.85 (br s, 1H), 8.11 (d, J = 8.0 Hz, 1H),
8.14-8.15 (m, 1H), 8.39 (br s, ½H).

At 50 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.87 (br s, 3H), 1.73 (br s, 2H), 2.89 (br s,
2½H), 4.18 (br s, 2H), 7.44 (t, J = 7.0 H, 1H), 7.47-7.51 (m, 2H), 7.64 (t, J = 7.5 Hz, 1H),
7.84-7.86 (m, 1H), 8.10 (d, J = 8.5 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1H).

At 75 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.88 (t, J = 7.5 Hz, 3H), 1.75 (sextet, J = 7.3
Hz, 2H), 4.17 (t, J = 7.0 Hz, 2H), 7.13 (br s, 1H), 7.43-7.49 (m, 3H), 7.63 (t, J = 7.8 Hz,
1H), 7.84 (d, J = 7.5 Hz, 1H), 8.08 (d, J = 8.0 Hz, 1H), 8.12 (d, J = 8.0 Hz, 1H).

At 100 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.89 (t, J = 7.5 Hz, 3H), 1.76 (sextet, J =
7.3 Hz, 2H), 2.89 (br s, 3H), 4.17 (t, J = 7.0 Hz, 2H), 6.92 (br s, 1H), 7.13 (t, J = 7.5 Hz,
1H), 7.45 (t, J = 7.5 Hz, 3H), 7.63 (t, J = 7.5 Hz, 1H), 7.83 (d, J = 7.5 Hz, 1H), 8.07 (d, J
= 8.0 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H).
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8-Iodo-1-naphthoic acid (55) (VJS-243).
To a round bottom flask containing 5.00 g (13.5 mmol) of anhydro-8-(hydroxymercuri)1-naphthoic acid was added 9.63 g (58.0 mmol) of potassium iodide in 47 mL of H2O.
After dissolution, 3.42 g (13.5 mmol) of iodine was added and the reaction mixture was
refluxed for 15 h. The solution was cooled to ambient temperature and a brown
precipitate was filtered out. The addition of 1.62 g (10 mmol) of sodium thiosulfate in 9
mL of H2O to the filtrate destroyed excess iodine and the solution was acidified by the
dropwise addition of concentrated. HCl. The crude acid was filtered, dissolved in hot
acetone and concentrated in vacuo. Recrystallization with chloroform gave 2.1 g (52%)
of 8-iodo-1-naphthoic acid as a white solid: m.p. 155-156 °C (lit m.p.58 164-165°C); 1H
NMR (500 MHz, CDCl3) δ 7.23 (t, J = 7.8 Hz, 1H), 7.51 (t, J = 7.5 Hz, 1H), 7.90 (d, J =
8.0 Hz, 1H), 7.93 (d, J = 7.5 Hz, 2H), 8.27 (d, J = 7.5 Hz, 1H), 12.63 (br s, 1H);

13

C

NMR (125.77 MHz, CDCl3) δ 93.1, 125.1, 127.5, 129.5, 129.6, 131.4, 132.6, 133.5,
135.4, 141.9, 175.5.
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N-Pentyl-3-(8-iodo-1-naphthoyl)indole (66) (JWH-416) (VJS-244).
Dimethylaluminum chloride (0.79 mL, 1M in hexanes, 0.79 mmol) was added to a
solution of 0.10 g (0.57 mmol) of N-pentylindole in 5 mL of dry dichloromethane under
Ar and the mixture was stirred for 10 min at 0 °C then ambient temperature for 1h. A
solution of freshly prepared 8-iodo-1-naphthoyl chloride in 3 mL of dry dichloromethane
was added dropwise via syringe. The acid chloride was prepared by the addition of 3 mL
(41 mmol) of thionyl chloride to 0.23 g (0.77 mmol) of 8-iodo-1-naphthoic acid under
Ar. The mixture was refluxed for 2 h, cooled to ambient temperature, and the thionyl
chloride was removed in vacuo to give the acid chloride, which was added to the indole
mixture without further purification. The acid chloride and indole mixture was stirred at
ambient temperature overnight. The reaction mixture was quenched with water and
extracted with ether. The ethereal solution was washed with water , dried (MgSO4) and
the solvent was removed in vacuo. The crude product was purified by column
chromatography (petroleum ether: ether, 1:1) to give 0.040 g (11%) of N-pentyl-3-(8iodo-1-naphthoyl)indole as a yellow oil: GC/MS (EI) m/z (rel intensity) 341 (100), 324
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(48), 284 (86), 256 (16), 241 (16), 214 (85), 186 (4), 167 (22), 144 (48), 127 (70), 101
(7), 77 (9), 51 (2); HRMS (EI+) calcd for C24H22INO: 467.0747; found: 467.0742.

Ambient Temperature: 1H NMR (500 MHz, DMSO-d6) δ 0.88 (t, J = 7.0 Hz, 3H), 1.261.32 (m, 4H), 1.81-1.83 (m, 2H), 4.04-4.14 (m, 2H), 7.20 (t, J = 7.0 Hz, 1H), 7.38-7.43
(m, 2½H), 7.54 (t, J = 7.0 Hz, 1H), 7.67 (d, J = 7.0 Hz, 1H), 7.95 (d, J = 8.0 Hz, 2H),
8.22 (d, J = 7.5 Hz, 1H); 13C NMR (125.77 MHz, CDCl3) δ 13.9, 22.2, 28.8, 29.4, 47.1,
93.2, 109.9, 122.7, 123.0, 123.5, 125.1, 126.9, 127.0, 127.3, 128.5, 129.1, 129.5, 130.9,
132.0, 132.2, 135.7, 137.1, 141.6, 191.6.
At 50°C: 1H NMR (500 MHz, DMSO-d6) δ 0.88 (t, J = 7.0 Hz, 3H), 1.26-1.32 (m, 4H),
1.81-1.83 (m, 2H), 4.04 (s, 2H), 7.17 (t, J = 7.0 Hz, 1H), 7.22 (br s, ½H), 7.38-7.43 (m,
2.5H), 7.54 (t, J = 7.0 Hz, 1H), 7.67 (d, J = 7.0 Hz, 1H), 7.95 (d, J = 8.0 Hz, 2H), 8.22 (d,
J = 7.5 Hz, 1H), 8.45 (br s, ½H).

At 75°C: 1H NMR (500 MHz, DMSO-d6) δ 0.88 (t, J = 6.0 Hz, 3H), 1.21-1.28 (m, 4H),
1.74-1.76 (m, 2H), 4.19 (t, J = 7.0 Hz, 2H), 7.25-7.33 (m, 3H), 7.51 (s, 1H), 7.58 (d, J =
8.0 Hz, 1H), 7.62-7.63 (m, 2H), 8.08-8.12 (m, 2H), 8.23 (d, J = 7.0 Hz, 2H).
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2-Methyl-N-pentyl-3-(8-iodo-1-naphthoyl)indole (67) (JWH-417) (VJS-246).
The title compound was prepared using the procedure VJS-244. From 0.17 g (0.84 mmol)
of 2-methyl-N-pentylindole and 0.25 g (0.84 mmol) of 8-iodo-1-naphthoic acid there was
obtained after column chromatography (petroleum ether: ether, 1:1) 0.25 g (64%) of 2methyl-N-pentyl-3-(8-iodo-1-naphthoyl)indole as a brown oil: GC/MS (EI) m/z (rel
intensity) 481 (3), 354 (70), 339 (9), 324 (1), 310 (1), 296 (7), 284 (100), 269 (45), 254
(28), 240 (9), 226 (8), 213 (12), 189 (3), 177 (6), 148 (12), 126 (19), 113 (3), 89 (1), 77
(2), 55 (1); HRMS (ES+) m/z calcd for C25H24INO: 482.0981; found: 482.0961.

Ambient Temperature: 1H NMR (500 MHz, DMSO-d6) δ 0.84-0.89 (m, 3H), 1.24-1.36
(m, 4H), 1.65-1.84 (m, 2H), 2.91 (s, 1½ H), 4.17-4.28 (m, 2H), 5.99-6.01 (m, ½H), 6.696.71 (m, ½H), 7.03-7.06 (m,½ H), 7.28-7.31 (m, 2H), 7.45-7.48 (m, 1H), 7.52-7.61 (m,
2H), 8.13-8.26 (m, 3H), 8.43 (br s, ½H);

13

C NMR (125.77 MHz, DMSO-d6) δ 13.0,

14.3, 22.3, 28.8, 29.4, 43.1, 93.8, 110.7, 119.7, 121.5, 122.0, 122.6, 123.0, 126.4, 127.9,
130.0, 131.1, 131.6, 135.8, 136.2, 141.7, 144.0, 146.3, 191.8.
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At 35 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.88 (br s, 3H), 1.24-1.35 (m, 4H), 1.74-1.92
(m, 2H), 2.92 (br s, 1½H), 4.18-4.28 (m, 2H), 5.99-6.01 (m, ½H), 6.69-6.71 (m, ½H),
7.03-7.06 (m,½ H), 7.30 (t, J = 7.5 Hz, 2H), 7.47-7.54 (m, 2H), 7.60 (t, J = 8.0 Hz, 1H),
8.10-8.17 (m, 2H), 8.23 (br s, 1H), 8.44 (br s, ½H).

At 50 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.88 (s, 3H), 1.34 (s, 4H), 1.73 (s, 2H), 3.21
(s, 3H), 4.23 (br s, 2H), 7.29 (t, J = 7.5 Hz, 1H), 7.47 (d, J = 7.0 Hz, 1H), 7.52 (d, J =
10.0 Hz, 1H), 7.60 (t, J = 8.0 Hz, 1H), 8.11 (t, J = 9.0 Hz, 2H), 8.22-8.24 (m, 1H).

At 75 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.88 (t, J = 7.0 Hz, 3H), 1.35-1.39 (m, 4H),
1.75 (t, J = 7.5 Hz, 2H), 3.07 (br s, 3H), 4.23 (t, J = 7.5 Hz, 2H), 7.16 (br s, 1H), 7.28 (t, J
= 8.0 Hz, 1H), 7.47 (d, J = 7.0 Hz, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.60 (t, J = 7.5 Hz, 1H),
8.10 (t, J = 9.0 Hz, 2H), 8.22 (d, J = 7.5 Hz, 1H).

At 100 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.89 (t, J = 7.0 Hz, 3H), 1.36-1.38 (m, 4H),
1.77 (p, J = 7.5 Hz, 2H), 2.93 (br s, 2½H), 4.23 (t, J = 7.5 Hz, 2H), 6.96 (br s, 1H), 7.15
(t, J = 7.5 Hz, 1H), 7.27 (t, J = 7.5 Hz, 1H), 7.48-7.49 (m, 2H), 7.60 (J = 7.5 Hz, 1H),
8.09 (t, J = 9.0 Hz, 1H), 8.23 (d, J = 7.5 Hz, 1H).
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2-Methyl-N-propyl-3-(8-iodo-1-naphthoyl)indole (65) (JWH-418) (VJS-249).
The title compound was prepared using the procedure VJS-244. From 0.14 g (0.84 mmol)
of 2-methyl-N-propylindole and 0.36 g (1.2 mmol) of 8-iodo-1-naphthoic acid there was
obtained after column chromatography (petroleum ether: ether, 3:7) 0.13 g (35%) of 2methyl-N-propyl-3-(8-iodo-1-naphthoyl)indole as a brown oil: GC/MS (EI) m/z (rel
intensity) 453 (6), 326 (100), 312 (6), 296 (11), 284 (95), 269 (54), 254 (31), 241 (8), 226
(8), 207 (40), 191 (4), 163 (10), 148 (14), 127 (21), 106 (5), 89 (6), 77 (4), 63 (3), 51 (4);
HRMS (ES+) m/z calcd for C23H20INO: 454.0668; found: 454.0662

Ambient Temperature: 1H NMR (500 MHz, DMSO-d6) δ 0.87-0.95 (m, 3H), 1.70-1.86
(m, 2H), 2.91 (s, 1½H), 4.16-4.27 (m, 2H), 5.99-6.00 (m, ½H), 6.69-6.72 (m, ½H), 7.037.06 (m, ½H), 7.28-7.31 (m, 1½H), 7.44-7.46 (m, 1H), 7.54-7.62 (m, 2H), 8.12-8.15 (m,
2H), 8.20-8.28 (m, 1H), 8.42 (br s, ½H);

13

C NMR (125.77 MHz, DMSO-d6) δ 11.5,

13.0, 23.0, 44.9, 92.9, 109.3, 109.7, 116.0, 120.5, 121.4, 121.7, 122.7, 125.7, 127.1,
128.0, 129.5, 130.7, 132.0, 135.9, 141.4, 143.8, 146.2, 192.8.
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At 50 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.93 (s, 3H), 1.76 (br s, 2H), 3.21 (s, 3H),
4.22 (br s, 2H), 7.26 (br s, 1H), 7.30 (t, J = 7.8 Hz, 1H), 7.47 (d, J = 7.0 Hz, 1H), 7.54 (d,
J = 8.5 Hz, 1H), 7.61 (t, J = 7.5 Hz, 1H), 8.12 (t, J = 9.0 Hz, 2H), 8.23-8.24 (m, 1H).

At 75 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.94 (t, J = 7.5 Hz, 3H), 1.78 (sextet, J = 7.5
Hz, 2H), 3.06 (br s, 3H), 4.22 (t, J = 7.0 Hz, 2H), 7.15 (br s, 1H), 7.29 (t, J = 7.5 Hz, 1H),
7.47 (d, J = 7.0 Hz, 1H), 7.51 (d, J = 8.5 Hz, 1H), 7.61 (t, J = 7.5 Hz, 1H), 8.11 (t, J = 9.5
Hz, 2H), 8.23 (d, J = 7.0 Hz, 1H).

At 100 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.94 (t, J = 7.5 Hz, 3H), 1.80 (sextet, J =
7.5 Hz, 2H), 2.93 (br s, 3H), 4.22 (t, J = 7.5 Hz, 2H), 6.95 (br s, 1H), 7.15 (t, J = 8.0 Hz,
1H), 7.28 (t, J = 8.0 Hz, 1H), 7.49 (t, J = 8.0 Hz, 2H), 7.60 (t, J = 7.5 Hz, 1H), 8.09 (t, J =
9.0 Hz, 2H), 8.23 (d, J = 7.5 Hz, 1H).
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N-Propyl-3-(8-iodo-1-naphthoyl)indole (64) (JWH-419) (VJS-250).
The title compound was prepared using the procedure VJS-244. From 0.11 g (0.69 mmol)
of N-propylindole and 0.31 g (1.0 mmol) of 8-iodo-1-naphthoic acid there was obtained
after column chromatography (petroleum ether: ether, 1:1) 0.064 g (21%) of N-propyl-3(8-iodo-1-naphthoyl)indole as a brown oil: GC/MS (EI) m/z (rel intensity) 439 (2), 312
(100), 282 (17), 270 (63), 254 (13), 240 (14), 226 (6), 207 (23), 186 (5), 156 (3), 144
(11), 126 (13), 113 (5), 101 (3), 89 (3), 75 (3), 63 (3), 51 (1); HRMS (ES+) m/z calcd for
C22H18INO: 440.0511; found: 440.0491.

Ambient Temperature: 1H NMR (500 MHz, DMSO-d6) δ 0.78 (t, J = 7.5 Hz, 3H), 1.73
(q, J = 7.0 Hz, 2H), 4.15-4.22 (m, 2H), 7.28-7.33 (m, 3H), 7.62-7.65 (m, 3½H), 8.11-8.14
(m, 2H), 8.23 (d, J = 7.0 Hz, 1H); 13C NMR (125.77 MHz, DMSO-d6) δ 11.3, 23.1, 48.0,
94.1, 111.3, 119.3, 122.3, 122.3, 122.7, 123.5, 125.9, 126.9, 127.8, 128.7, 130.0, 131.2,
131.9, 135.8, 137.3, 141.8, 141.9, 190.9.
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At 50 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.80 (t, J = 7.5 Hz, 3H), 1.75 (sextet, J = 7.0
Hz, 2H), 4.18 (br s, 2H), 7.26-7.33 (m, 3 H), 7.60-7.65 (m, 4H), 8.10-8.13 (m, 2H), 8.24
(d, J = 7.5 Hz, 1H).

At 75 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.82 (t, J = 7.5 Hz, 3H), 1.77 (sextet, J = 7.0
Hz, 2H), 4.17 (t, J = 7.0 Hz, 2H), 7.27-7.32 (m, 3H), 7.54 (s, 1H), 7.58-7.60 (m, 1H),
7.62-7.63 (m, 2H), 8.09-8.12 (m, 2H), 8.23-8.24 (m, 2H).

At 100 °C: 1H NMR (500 MHz, DMSO-d6) δ 0.84 (t, J = 7.5 Hz, 3H), 1.79 (sextet, J =
7.5 Hz, 2H), 4.16 (t, J = 7.0 Hz, 2H), 7.26-7.31 (m, 3H), 7.50 (s, 1H), 7.57 (d, J = 8.5 Hz,
1H), 7.61-7.63 (m, 2H), 8.08-8.11 (m, 2H), 8.19 (d, J = 8.0 Hz, 1H), 8.23 (d, J = 7.5 Hz,
1H).

O
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Cl

8-Chloro-1-naphthoic acid (58).
Method A (VJS-533) To a stirring solution of 1.2 mL (20.2 mmol) of glacial acetic acid
and 0.12 mL (6.7 mmol) of H2O at 0 °C was added 0.18 g (0.48 mmol) of anhydro-8hydroxymercuri-1-naphthoic acid. Vigorous stirring at 0 °C for 15 min was followed by
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the addition of 0.19 g (0.33 mmol) of NaCl in 0.61 mL of H2O and 0.09 g (0.48 mmol)
of 1,3-dichloro-5,5-dimethylhydantoin (DCDMH) over a period of 30 min. The resultant
dense, white precipitate was slowly heated to 100 °C and left at that temperature for 12 h.
The solution was cooled to ambient temperature and poured into ice. A pale yellow
precipitate was filtered out. This precipitate was dissolved in hot 12M NaOH and the
solution was filtered to remove HgCl2. The filtrate was acidified by the dropwise addition
of concentrated HCl and extracted with dichloromethane. After drying (MgSO4) and
concentration in vacuo, 0.04 g (36%) of crude 8-chloro-1-naphthoic acid remained as a
white solid.

Method B (VJS-580) To a round bottom flask containing 0.15 g (0.68 mmol) of methyl8-chloro-1-naphthoate was added 0.38 g (6.8 mmol) of crushed KOH in 10 mL of H2O.
The solution was refluxed overnight and then acidified by the dropwise addition of
concentrated HCl. The mixture was extracted with ether and dried (MgSO4).
Concentration in vacuo gave 0.12 g (88%) of 8-chloro-1-naphthoic acid as a white solid:
m.p. 168-169 °C (lit. m.p.72 171–171.5 °C); 1H NMR (300 MHz, CDCl3) δ 7.49 (t, J =
7.8 Hz, 1H), 7.58 (t, J = 7.8 Hz, 1H), 7.70 (d, J = 7.5 Hz, 1H), 7.81 (d, J = 7.2 Hz, 1H),
7.85 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 13.25 (br s, 1H); 13C NMR (75.5 MHz,
CDCl3) δ 125.3, 126.6, 127.0, 127.9, 128.2, 129.3, 129.8, 130.3, 131.5, 135.4, 176.3.
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O

O

Cl

Methyl-8-chloro-1-naphthoate (59) (VJS-539).
Trimethylsilyldiazomethane (0.25 mL, 2 M in ether, 0.51 mmol) was added to a
suspension of 0.07 g (0.34 mmol) of crude 8-chloro-1-naphthoic acid in 6 mL of MeOH
and the solution was heated at reflux for 1.5 h. After being cooled to ambient temperature
the reaction mixture was quenched with H2O and extracted with dichloromethane. The
organic phase was washed with water, dried (MgSO4), and the solvent was removed in
vacuo. The crude product was purified by column chromatography (petroleum ether:
ether, 8:2) to give 0.03 g (36%) of methyl-8-chloro-1-naphthoate as a peach colored oil:
1

H NMR (500 MHz, CDCl3) δ 4.01 (s, 3H), 7.41 (t, J = 7.5 Hz, 1H), 7.50 (t, J = 7.5 Hz,

1H), 7.62 (d, J = 7.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H);

13

C

NMR (125.77 MHz, CDCl3) δ 52.8, 125.4, 126.4, 127.1, 127.8, 128.0, 129.0, 130.0,
130.6, 131.0, 135.3, 171.2; GC/MS (EI) m/z (rel intensity) 220 (33), 205 (2), 185 (100),
170 (66), 161 (61), 142 (2), 126 (64), 99 (13), 95 (9), 75 (17), 63 (28), 50 (5).
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N

O

N-pentyl-3-(6-methoxy-2-naphthoyl)indole (71) (JWH-408) (VJS-226).
Dimethylaluminum chloride (0.90 mL, 1M in hexanes, 0.90 mmol) was added to a
solution of 0.12 g (0.63 mmol) of N-pentylindole in 5 mL of dry dichloromethane under
Ar and the mixture was stirred for 1 h at 0 °C. A solution of freshly prepared 6-methoxy2-naphthoyl chloride in 3 mL of dry dichloromethane was added dropwise via syringe.
The acid chloride was prepared by the addition of 3 mL (41 mmol) of thionyl chloride to
0.12 g (0.59 mmol) of 6-methoxy-2-naphthoic acid under Ar. The mixture was refluxed
for 1.5 h, cooled to ambient temperature, and the thionyl chloride was removed in vacuo
to give the acid chloride, which was added to the indole mixture without further
purification. The acid chloride and indole mixture was stirred at ambient temperature for
6 h. The reaction mixture was quenched with water and extracted with ether. The ethereal
solution was washed with water, dried (MgSO4) and the solvent was removed in vacuo to
give the crude product, which was purified by column chromatography (petroleum ether:
ether, 7:3) to give 0.13 g (59%) of N-pentyl-3-(6-methoxy-2-naphthoyl)indole as a brown
oil: 1H NMR (300 MHz, CDCl3) δ 0.92 (t, J = 6.6 Hz, 3H), 1.34-1.36 (m, 4H), 1.85-1.91
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(m, 2H), 3.97 (s, 3H), 4.16 (t, J = 7.0 Hz, 2H), 7.24-7.26 (m, 2H), 7.36-7.44 (m, 3H),
7.66 (s, 1H), 7.84 (d, J = 8.4 Hz, 2H), 7.96 (d, J = 8.4 Hz, 1H), 8.28 (s, 1H), 8.49-8.51
(m, 1H); 13C NMR (75.5 MHz, CDCl3) δ 14.0, 22.3, 29.0, 29.6, 47.1, 55.4, 105.8, 110.0,
115.8, 119.6, 122.5, 122.8, 123.5, 126.3, 127.0, 127.5, 127.9, 129.4, 130.6, 136.2, 136.3,
136.8, 136.9, 159.1, 190.7; GC/MS (EI) m/z (rel intensity) 371 (100), 354 (4), 314 (30),
272 (3), 214 (32), 185 (10), 157 (5), 144 (9), 128 (3), 114 (4), 102 (2), 89 (2), 55 (2);
HRMS (ES+) m/z calcd for C25H25NO2: 371.1885; found: 371.1880.

O

N

O

2-Methyl-N-pentyl-3-(6-methoxy-2-naphthoyl)indole (72) (JWH-409) (VJS-230).
The title compound was prepared using procedure VJS-226. From 0.14 g (0.70 mmol) of
2-methyl-N-pentylindole and 0.12 g (0.60 mmol) of 6-methoxy-2-naphthoic acid there
was obtained after column chromatography (petroleum ether: ether, 6:4) 0.026 g (11%) of
2-methyl-N-pentyl-3-(6-methoxy-2-naphthoyl)indole as an orange solid: mp 134-135 °C;
1

H NMR (300 MHz, CDCl3) δ 0.96 (t, J = 6.6 Hz, 3H), 1.41-1.43 (m, 4H), 1.85-1.86 (m,
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2H), 2.66 (s, 3H), 3.98 (s, 3H), 4.18 (t, J = 7.5 Hz, 2H), 7.07 (t, J = 7.8 Hz, 1H), 7.187.24 (m, 3H), 7.36 (t, J = 8.1 Hz, 2H), 7.81 (t, J = 8.7 Hz, 2H), 7.90 (d, J = 8.0 Hz, 1H),
8.26 (s, 1H);

13

C NMR (75.5 MHz, CDCl3) δ 12.5, 14.0, 22.4, 29.2, 29.5, 43.5, 55.4,

105.8, 109.5, 113.9, 119.4, 121.0, 121.2, 121.8, 126.6, 126.7, 127.3, 128.0, 130.3, 130.8,
135.9, 136.5, 136.6, 144.0, 159.2, 192.7; GC/MS (EI) m/z (rel intensity) 385 (100), 370
(25), 342 (7), 328 (28), 315 (7), 281 (11), 270 (3), 254 (4), 228 (11), 207 (46), 185 (57),
158 (26), 142 (11), 128 (6), 114 (8), 96 (5), 73 (8), 55 (5); HRMS (ES+) m/z calcd for
C26H27NO2: 385.2042; found: 385.2028

O

N

O

2-Methyl-N-propyl-3-(6-methoxy-2-naphthoyl)indole (70) (JWH-410) (VJS-231).
The title compound was prepared using procedure VJS-226. From 0.12 g (0.69 mmol) of
2-methyl-N-propylindole and 0.12g (0.58 mmol) of 6-methoxy-2-naphthoic acid there
was obtained after column chromatography (petroleum ether: ether, 7:3) 0.076 g (37%) of
2-methyl-N-propyl-3-(6-methoxy-2-naphthoyl)indole as a brown oil: 1H NMR (300
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MHz, CDCl3) δ 1.05 (t, J = 7.5 Hz, 3H), 1.91 (sextet, J = 7.5 Hz, 2H), 2.66 (s, 3H), 3.98
(s, 3H), 4.16 (t, J = 7.5 Hz, 2H), 7.04 (t, J = 7.2 Hz, 1H), 7.18-7.24 (m, 3H), 7.36 (t, J =
8.1 Hz, 2H), 7.78-7.84 (m, 2H), 7.91 (d, J = 8.4 Hz, 1H), 8.26 (s, 1H); 13C NMR (75.5
MHz, CDCl3) δ 11.5, 12.5, 23.1, 44.9, 55.4, 105.8, 109.5, 113.9, 119.4, 121.0, 121.3,
121.9, 126.6, 126.8, 127.3, 128.0, 130.3, 130.9, 136.0, 136.5, 136.6, 144.1, 159.2, 192.7;
; GC/MS (EI) m/z (rel intensity) 356 (100), 340 (22), 328 (8), 315 (7), 300 (2), 286 (2),
270 (2), 254 (2), 242 (4), 200 (17), 185 (29), 179 (2), 158 (28), 142 (11), 130 (8), 114 (8),
103 (4), 88 (2), 77 (3), 63 (1), 50 (1); HRMS (ES+) m/z calcd for C24H23NO2: 357.1729;
found: 357.1727

O

N

O

N-Propyl-3-(6-methoxy-2-naphthoyl)indole (69) (JWH-411) (VJS-232).
The title compound was prepared using procedure VJS-226. From 0.23 g (1.4 mmol) of
N-propylindole and 0.26 g (1.3 mmol) of 6-methoxy-2-naphthoic acid there was obtained
after column chromatography (petroleum ether: ether, 8:2) 0.016 g (4%) of N-propyl-3(6-methoxy-2-naphthoyl)indole as a white solid: m.p. 139-141 °C; 1H NMR (500 MHz,
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DMSO-d6) δ 0.87 (t, J = 7.3 Hz, 3H), 1.83 (sextet, J = 7.0 Hz, 2H), 3.94 (s, 3H), 4.28 (t, J
= 7.0 Hz, 2H), 7.28-7.33 (m, 3H), 7.44-7.45 (m, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.86 (d, J
= 8.2 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 8.03 (d, J = 9.0 Hz, 1H), 8.15 (s, 1H), 8.31 (d, J
= 7.5 Hz, 1H), 8.35 (s, 1H); 13C NMR (125.77 MHz, DMSO-d6) δ 11.5, 23.3, 48.2, 55.9,
106.4, 111.3, 114.6, 119.7, 122.3, 122.6, 123.6, 126.3, 127.4, 127.5, 128.0, 129.5, 131.4,
136.0, 136.7, 137.1, 138.9, 159.2, 189.8; GC/MS (EI) m/z (rel intensity) 343 (100), 326
(6), 314 (42), 300 (2), 286 (2), 272 (4), 207 (9), 186 (97), 157 (19), 144 (31), 128 (6), 116
(12), 89 (4), 73 (2), 63 (1), 50 (1); HRMS (EI+) m/z calcd for C23H21NO2: 343.1572;
found: 343.1363.

O
NO2

H

H

NO2

O

5-Nitro-1-naphthaldehyde (81) and 8-nitro-1-naphthaldehyde (80) (VJS-442).
To a flamed dried round bottom flask, under Ar containing 20.1 mL (346 mmol) of
glacial acetic acid 14.0 mL (333 mmol) of fuming nitric acid was slowly added followed
by the dropwise addition of 1.0 g (0.64 mmol) of 1-naphthaldehyde. The solution turned
from red to golden yellow over the course of the addition. After the slow addition of 0.68
mL (1.28 mmol) of H2SO4 the reaction mixture was stirred at ambient temperature for 1
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h. The solution was poured into ice and extracted with ether. The ethereal solution was
dried (MgSO4) and concentrated in vacuo. The crude product was purified by column
chromatography (petroleum ether: ether, 7:3) to give 0.39 g (30%) of 5-nitro-1naphthaldehyde as a yellow solid: m.p. 135-137 °C (lit. m.p.119 136-137 °C); 1H NMR
(500 MHz, CDCl3) δ 7.80 (t, J = 8.3 Hz, 1H), 7.92 (t, J = 7.8 Hz, 1H), 8.15 (d, J = 6.5
Hz, 1H), 8.30 (d, J = 7.5 Hz, 1H), 8.79 (d, J = 9.0 Hz, 1H), 9.67 (d, J = 8.5 Hz, 1H),
10.42 (s, 1H);

13

C NMR (125.77 MHz, CDCl3) δ 124.3, 125.3, 127.5, 128.2, 129.6,

131.1, 131.3, 131.4, 137.8, 147.1, 193.1; GC/MS (EI) m/z (rel intensity) 201 (100), 184
(5), 172 (16), 154 (25), 145 (16), 127 (98), 115 (93), 101 (39), 89 (12), 77 (47), 63 (23),
51 (21).

Further elution with the same solvent system (petroleum ether: ether, 7:3) gave 0.77 g
(60%) of 8-nitro-1-naphthaldehyde as a yellow solid: m.p. 120-121 °C (lit. m.p.119 123124 °C); 1H NMR (500 MHz, CDCl3) δ 7.66 (t, J = 8.0 Hz, 1H), 7.76 (t, J = 7.8 Hz, 1H),
8.12-8.18 (m, 4H), 10.15 (s, 1H); 13C NMR (125.77 MHz, CDCl3) δ 120.7, 125.5, 125.9,
126.6, 132.8, 133.9, 134.2, 134.9, 135.0, 147.9, 190.0; GC/MS (EI) m/z (rel intensity)
201 (100), 184 (5), 172 (16), 154 (25), 145 (16), 127 (98), 115 (93), 101 (39), 89 (12), 77
(47), 63 (23), 51 (21).
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HO

O

5-Nitro-1-naphthoic acid (83) (VJS-443).
To a flask containing 3.0 mL of distilled acetone was added 0.12 g (0.60 mmol) of 5nitro-1-naphthaldehyde. Slight heat was applied to the reaction vessel followed by 1.5
mL aliquots of freshly prepared Jones Reagent

89

until the precipitation of a green salt

occurred. The reaction mixture was stirred for 6 h and quenched with water, the
chromium salts were filtered out and the filtrate was extracted with dichloromethane. The
organic layer was dried (MgSO4) and removal of the solvent in vacuo gave 0.07 g (57%)
of 5-nitro-1-naphthoic acid as a white solid: m.p. 239-240 °C (lit. m.p.120 239 °C); 1H
NMR (500 MHz, DMSO-d6) δ 7.82-7.88 (m, 2H), 8.29 (d, J = 7.0 Hz, 1H), 8.33 (d, J =
7.5 Hz, 1H), 8.47 (d, J = 9.0 Hz, 1H), 9.19 (d, J = 8.5 Hz, 1H), 13.59 (br s, 1H);

13

C

NMR (125.77 MHz, DMSO-d6) δ 124.1, 124.9, 126.9, 126.9, 128.9, 129.5, 131.3, 131.6,
132.0, 168.6.
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OH

NO2

8-Nitro-1-naphthoic acid (83) (VJS-452).
The title compound was prepared using procedure VJS-443. From 0.22 g (1.10 mmol) of
8-nitro-1-naphthaldehyde was obtained 0.14 g (60%) of 8-nitro-1-naphthoic acid as a
white solid: m.p. 210-211 °C (lit. m.p.120 215 °C); 1H NMR (500 MHz, DMSO-d6) δ 7.75
(q, J = 7.5 Hz, 2H), 8.12 (d, J = 7.0 Hz, 1H), 8.24 (d, J = 7.5 Hz, 1H), 8.29 (d, J = 8.0 Hz,
1H), 8.38 (d, J = 8.5 Hz, 1H), 13.43 (br s, 1H); 13C NMR (125.77 MHz, DMSO-d6) δ
121.3, 125.6, 126.0, 127.3, 129.1, 131.5, 132.5, 134.8, 135.0, 147.7, 168.7.

NO2

5-Nitroacenaphthene (75) (VJS-301).
To a suspension of 0.20 g (1.3 mmol) of acenaphthene and 1.6 mL (27.4 mmol) of acetic
acid which had been stirring at ambient temperature for 15 min, 0.25 mL (5.6 mmol) of
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nitric acid was added dropwise over 15 min. A yellow precipitate formed and after
cooling in an ice bath 0.23 g (88%) of 5-nitroacenaphthene was filtered off as a yellow
solid: m.p. 98-99 °C (lit m.p.84 100-101 °C); 1H NMR (500 MHz, CDCl3) δ 3.46-3.49 (m,
2H), 3.51-3.53 (m, 2H), 7.36 (d, J = 7.5 Hz, 1H), 7.47 (d, J = 7.0 Hz, 1H), 7.74 (dd, J =
8.5 Hz, 1H), 8.52 (d, J = 7.5 Hz, 1H), 8.59 (d, J = 8.5 Hz, 1H); 13C NMR (125.77 MHz,
CDCl3) δ 30.6, 30.6, 118.0, 120.2, 121.3, 124.4, 127.8, 131.7, 132.0, 140.2, 146.6, 155.8;
GC/MS (EI) m/z (rel intensity) 199 (78), 183 (6), 169 (25), 152 (100), 141 (27), 126 (8),
115 (20), 102 (3), 87 (4), 76 (14), 63 (12), 51 (6).

NO2

O

O

O

4-Nitro-1,8-naphthalic anhydride (76) (VJS-305).
To a solution of 0.12 g (0.60 mmol) of 5-nitroacenaphthene in 1.7 mL (29 mmol) of
acetic acid was slowly added 0.71 g (2.4 mmol) of K2Cr2O7 The mixture was heated at
100 °C for 3 h, cooled to ambient temperature and poured into ice. The product was
extracted using dichloromethane, dried (MgSO4) and concentrated in vacuo to give 0.092
g (63%) of 4-nitro-1,8-naphthalic anhydride as an orange solid: m.p. 226-227 °C (lit
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m.p.85 226-229 °C); 1H NMR (500 MHz, DMSO-d6) δ 8.13 (t, J = 8.3 Hz, 1H), 8.57 (d, J
= 8.0 Hz, 1H), 8.64 (d, J = 8.0 Hz, 1H), 8.67 (d, J = 7.5 Hz, 1H), 8.76 (d, J = 8.5 Hz, 1H);
13

C NMR (125.77 MHz, DMSO-d6) δ 120.5, 123.3, 124.5, 124.8, 130.3, 130.8, 131.1,

131.6, 133.7, 150.0, 159.9, 160.5.

HO

O

NO2

4-Nitro-1-naphthoic acid (78).
Method A (VJS-535): To a solution of 0.35 g (6.2 mmol) of KOH in 9.3 mL of water was
added 0.50 g (2.1 mmol) of 4-nitro-1,8-naphthalic anhydride. Vigorous stirring for 1.5 h
resulted in a homogeneous brown solution. A solution of freshly prepared mercuric
acetate from0.45 g (2.06 mmol) of yellow mercury oxide in 0.37 mL of acetic acid and
1.2 mL of water was added dropwise to the reaction mixture. After addition of the
mercuric acetate a dense, tan colored precipitate formed. The reaction was heated at
reflux for 96 h, cooled to ambient temperature and filtered. The resultant organo-mercuri
intermediate was refluxed in concentrated HCl for 6 h, cooled to ambient temperature,
filtered and washed with water to give crude 4-nitro-1-naphthoic acid as a tan solid.
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Recrystallization from glacial acetic acid gave 0.37 g (82%) of 4-nitro-1-naphthoic acid
as a tan solid:

Method B (VJS-541): To a round bottom flask containing 0.08 g (0.35 mmol) of methyl4-nitro-1-naphthoate was added 0.19 g (3.5 mmol) of crushed KOH in 0.6 mL of water.
The solution was refluxed overnight, acidified by the dropwise addition of concentrated
HCl extracted with ether and dried (MgSO4). Concentration in vacuo gave 0.04 g (50%)
of 4-nitro-1-naphthoic acid as a tan solid: m.p. 220-221 °C (lit. m.p.62 219–220 °C); 1H
NMR (500 MHz, DMSO-d6) δ 7.83-7.86 (m, 2H), 8.17 (d, J = 8.0 Hz, 1H), 8.25-8.28 (m,
2H), 8.82-8.84 (m, 1H), 13.87 (br s, 1H);

13

C NMR (125.77 MHz, DMSO-d6) δ 122.5,

122.9, 124.6, 126.6, 128.1, 129.3, 129.9, 131.6, 134.4, 149.2, 168.1.

NO2

O

O

Methyl-4-nitro-1-naphthoate (79) (VJS-536).
To a solution of 5 mL of MeOH and 1 mL of H2SO4 was added 0.40 g (1.84 mmol) of 4nitro-1-naphthoic acid. The reaction mixture was heated at reflux overnight. The solution
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was cooled to ambient temperature, quenched with water and extracted with
dichloromethane. The organic phase was washed with NaHCO3, dried (MgSO4) and
concentration in vacuo. The crude product was purified by column chromatography
(petroleum ether: ethyl acetate, 7:3) to give 0.06g (14%) of methyl 4-nitro-1-naphthoate
as a reddish orange oil: 1H NMR (500 MHz, CDCl3) δ 4.08 (s, 3H), 7.74-7.79 (m, 2H),
8.09 (d, J = 7.5 Hz, 1H), 8.17 (d, J = 8.0 Hz, 1H), 8.40-8.43 (m, 1H), 8.90-8.92 (m, 1H);
13

C NMR (125.77 MHz, CDCl3) δ 52.9, 121.4, 123.0, 125.1, 126.3, 127.9, 128.9, 129.3,

132.2, 132.7, 149.7, 166.7; GC/MS (EI) m/z (rel intensity) 231 (78), 216 (4), 200 (29),
186 (9), 170 (27), 154 (27), 142 (33), 126 (100), 114 (56), 102 (15), 87 (10), 76 (22), 59
(34), 50 (11).

NO2

O

N
H

3-(4-Nitro-1-naphthoyl)indole (85) (VJS-542).
To a solution of 0.26 mL (0.78 mmol) of MeMgBr [3.17M in diethyl ether] in 2.5 mL of
dry THF was added, at 0 °C under Ar, a solution of 0.06 g (0.52 mmol) of indole in dry
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THF. The mixture was stirred at 0 °C for 1 h. A solution of freshly prepared 4-nitro-1naphthoyl chloride in 3 mL of dry THF was added dropwise via syringe. The acid
chloride was prepared by the addition of 3 mL (41 mmol) of thionyl chloride to 0.11 g
(0.52 mmol) of 4-nitro-1-naphthoic acid under Ar. The mixture was refluxed for 3 hrs,
cooled to ambient temperature, and the thionyl chloride was removed in vacuo to give the
acid chloride, which was added to the indole mixture without further purification. The
acid chloride and indole mixture was stirred at 0 °C for 4 h. After this time the reaction
was quenched with NH4Cl, the organic phase extracted with ethyl acetate and dried
(MgSO4). Concentration in vacuo followed by column chromatography (petroleum
ether;ethyl acetate, 7:3) resulted in 0.02 g (10%) of 3-(4-nitro-1-naphthoyl)indole as a
yellow solid: m.p. 235-236 °C; 1H NMR (500 MHz, DMSO-d6) δ 7.31-7.33 (m, 2H),
7.54-7.55 (m, 1H), 7.72 (t, J = 7.8 Hz, 1H), 7.78-7.79 (m, 1H), 7.84-7.87 (m, 2H), 8.07
(d, J = 8.5 Hz, 1H), 8.32-8.33 (m, 1H), 8.39 (t, J = 9.2 Hz, 2H), 12.24 (s, 1H); 13C NMR
(125.77 MHz, DMSO-d6) δ 113.0, 117.3, 121.9, 123.0, 123.0, 123.5, 124.1, 124.4, 124.9,
126.0, 126.7, 128.7, 130.1, 131.4, 137.5, 138.3, 144.8, 147.3, 190.1.
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2-Methyl-3-(4-nitro-1-naphthoyl)indole (86) (VJS-549).
To a solution of 0.26 mL (0.78 mmol) of MeMgBr [3.17M in diethyl ether] in 2.5 mL of
dry THF was added, at 0 °C under Ar, a solution of 0.07 g (0.55 mmol) of 2-methylindole
in dry THF. The mixture was stirred at 0 °C for 1 h. A solution of freshly prepared 4nitro-1-naphthoyl chloride in 3 mL of dry THF was added dropwise via syringe. The acid
chloride was prepared by the addition of 3 mL (41 mmol) of thionyl chloride to 0.12 g
(0.55 mmol) of 4-nitro-1-naphthoic acid under Ar. The mixture was refluxed for 3 h,
cooled to ambient temperature, and the thionyl chloride was removed in vacuo to give the
acid chloride, which was added to the indole mixture without further purification. The
acid chloride and indole mixture was stirred at 0 °C for 4 h. After this time the reaction
was quenched with NH4Cl, the organic phase extracted with ethyl acetate and dried
(MgSO4). Concentration in vacuo followed by column chromatography (petroleum
ether;ethyl

acetate,

7:3)

resulted

in

0.01

g

(7%)

of

2-methyl-3-(4-nitro-1-

naphthoyl)indole as a yellow solid: m.p. 165-166 °C; 1H NMR (500 MHz, DMSO-d6) δ
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2.41 (s, 3H), 6.73 (t, J = 7.5 Hz, 1H), 6.80 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 8.0 Hz, 1H),
6.95 (t, J = 7.3 Hz, 1H), 7.23 (dd, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 1H), 7.73-7.75 (m,
2H), 10.89 (s, 1H);

13

C NMR (125.77 MHz, DMSO-d6) δ 14.4, 113.0, 117.3, 121.9,

123.0, 123.0, 123.5, 124.1, 124.4, 124.9, 126.0, 126.7, 128.7, 130.1, 131.4, 137.5, 138.3,
144.8, 147.3, 190.1.

N
O

S

O

N-Benzenesulfonyl pyrrole (VJS-454).
To a solution of 0.5 g (7.45 mmol) of pyrrole in 3.0 mL of THF was added 1.45 g (8.20
mmol) of benzenesulfonyl chloride. The mixture was cooled to 0 °C before the addition
of 0.43 g (10.8 mmol) of NaH (60% in mineral oil). The mixture was stirred at ambient
temperature for 16 h and quenched with ice water. The organic product was extracted
with ether and mixed with an equivalent volume of 2M NaOH. The mixture was stirred
for 2 h. The ether layer was extracted, washed with water and dried (MgSO4).
Concentration in vacuo gave 0.19 g (12%) of N-benzenesulfonyl pyrrole as a grey oil.
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1

H NMR (500 MHz, CDCl3) δ 6.27 (t, J = 2.5 Hz, 2H) 7.16 (t, J = 2.3 Hz, 2H), 7.45 (t, J

= 7.8 Hz, 2H), 7.52-7.55 (m, 1H), 7.83 (d, J = 7.5 Hz, 2H) ;

13

C NMR (125.77 MHz,

CDCl3) δ 113.7, 120.8, 126.8, 129.4, 133.9, 139.1; GC/MS (EI) m/z (rel intensity) 207
(83), 141 (55), 115 (14), 104 (1), 97 (3), 77 (100), 67 (7), 51 (36).

N
O

S

O

N-p-Toluenesulfonyl pyrrole (87) (VJS-410).
The title compound was prepared using the procedure VJS-454. From 2.0 g (29.8 mmol)
of pyrrole and 6.25 g (32.8 mmol) of N-p-toluenesulfonyl pyrrole in 23 mL of THF there
was obtained after recrystallization from isopropanol 5.15 g (78%) of N-ptoluenesulfonyl pyrrole as an off-white solid: m.p. 103-104 °C (lit. m.p.121 99-103 °C);
1

H NMR (500 MHz, CDCl3) δ 2.42 (s, 3H), 6.31 (t, J = 2.3 Hz, 2H), 7.18 (t, J = 2.3 Hz,

2H), 7.30 (d, J = 8.0 Hz, 2H), 7.76 (d, J = 8.5 Hz, 2H); 13C NMR (125.77 MHz, CDCl3) δ
21.6, 113.5, 120.7, 126.8, 130.0, 136.2, 145.0; GC/MS (EI) m/z (rel intensity) 221 (33),
155 (29), 128 (2), 115 (2), 91 (100), 77 (1), 65 (23), 51 (2).
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